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Abstract 
ATIC is a dimeric bifunctional protein, with two distinct catalytic domains located on 
each monomer.  These catalyse the penultimate and final steps of the de novo purine 
biosynthetic pathway.  It has been extensively studied as a target for chemotherapeutics 
and anti-viral inhibitors, but the enzyme has not been fully characterized. 
An ordered binding model for AICAR transformylase has been deduced using a new 
two-dimensional high-throughput assay; from this the true KM for substrate and cofactor 
have been measured.  The binding affinities for various ligands and small molecules 
were determined by ITC.  Isolation of the IMPCH domain was achieved to analyse 
binding to a single active site and elucidate the binding parameters observed for both 
ATIC domains. 
The potassium dependence has been defined for the first time as Ka = 796 ± 48μM.  The 
role of the potassium ion has been investigated through the characterization of site 
directed mutants of the potassium binding site. 
The thermal stability of ATIC was investigated with DSC and DSF, which suggest that 
the unfolding landscape of ATIC proceeds initially through the separation of the dimer, 
and then the IMPCH domain or monomer unfolds at a higher temperature.  AICAR, 
PteGlu4 and KCl all enhance protein stability. 
The dimerisation of ATIC was investigated by ITC dilution, dimerisation inhibitors, and 
fluorescent techniques.  Unfortunately, none of these techniques were capable of 
detecting the monomer-dimer equilibrium.  However, the dimerisation of ATIC appears 
to be an entropically-driven event. 
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Abbreviations 
10-f H4F 10-formyl tetrahydrofolate 
10-f-H2F 10-formyl-dihydrofolate 
ADP Adenosine diphosphate 
AICAr 5-amino-4-imidazolecarboxamide riboside 
AICAR Aminoimidazole-4-carboxamide ribonucleotide 
AIR Aminoimidazole ribonucleotide 
ALCL Anaplastic large cell lymphomas 
ALK Anaplastic lymphoma kinase 
AMP Adenosine monophosphate 
AMPK AMP kinase 
ATIC Aminoimidazole-4-carboxamide ribonucleotide 
transformylase inosine monophosphate cyclohydrolase 
ATP Adenosine triphosphate 
AUC Analytical ultracentrifugation 
B. subtilis Bacillus subtilis 
CAIR Carboxyaminoimidazole ribonucleotide 
DDATHF 5,10-Dideazatetrahydrofolate 
DNA Deoxyribonucleic acid 
DSC Differential scanning calorimetry 
DSF Differential scanning fluorimetry 
E. coli Escherichia coli 
FAICAR Formyl AICAR 
FGAM N-formylglycinamidine ribonucleotide 
FGAR N-Formylglycinamide ribonucleotide 
GAR Glycinamide ribonucleotide synthetase 
GDP Guanosine diphosphate 
GMP Guanosine monophosphate 
GTP Guanosine triphosphate 
H4F Tetrahydrofolate 
HGPT Hydroxanthine guanine phosphoribosyl transferase 
IMP Inosine monophosphate 
IMPCH Inosine monophosphate cyclohydrolase 
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ITC Isothermal titration calorimetry 
kbp Kilo base pairs 
kDa Kilo daltons 
M. jannaschii Methanocaldococcus jannaschii 
MTX Methotrexate 
PCR Polymerase chain reaction 
PRA 5-phosphoribosylamine 
PRPP Phosphoribosyl pyrophosphate 
PteGlu4 Pteridine tetraglutamate 
RNA Ribonucleic acid 
SAICAR N-Succinocarboxamide-5-aminoimidazole ribonucleotide 
SDS PAGE Sodium dodecyl sulphate polyacrylamide gel electrophoresis 
TDAF 5,8,10-trideazafolate 
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1 Introduction 
1.1 The de novo purine biosynthetic pathway 
Purine nucleotides are required for the synthesis of DNA and RNA in all organisms
[1]
.  
They are formed by two independent routes, either de novo or via a salvage pathway.  
The de novo biosynthetic pathway (Figure 1-1) provides purines by converting 
phosphoribosyl pyrophosphate (PRPP) to inosine monophosphate (IMP) (Figure 1-2) 
via a ten step enzymatic route,whereas the salvage pathway generates IMP, GMP and 
AMP directly through the reaction of PRPP with the free bases hypoxanthine, xanthine 
and adenine which are obtained through the diet.  Use of this salvage pathway 
economises on the energy balance and nitrogen consumption of the organism.  The 
other building blocks of DNA and RNA, pyrimidines, are also created by either the de 
novo pyrimidine biosynthetic pathway or the pyrimidine salvage pathway
[2]
. 
 
The de novo biosynthesis of purines generates the ‘first purine’ IMP from PRPP 
through ten distinct enzymatic activities which are summarised in Figure 1-1
[3]
.  The 
synthesis of 5-phosphoribosylamine (PRA) is catalysed by PRPP amidotransferase (step 
1) which transfers ammonia, obtained from the hydrolysis of glutamine, to 
phosphoribosylpyrophosphate.  The hydrolysis and the transfer reactions occur in 
separate domains which are linked by a channel for ammonia
[4]
.  Glycinamide 
ribonucleotide synthetase (GAR synthetase, step 2) attaches glycine to the PRA amino 
group to form glycinamide ribonucleotide (GAR).  N-Formylglycinamide 
ribonucleotide (FGAR) is then formed by GAR transformylase (step 3) which uses 10-
formyl tetrahydrofolate to formylate GAR.  N-Formylglycinamidine ribonucleotide 
synthetase (FGAR synthetase, step 4) catalyzes the amidation of FGAR to form N-
formylglycinamidine ribonucleotide (FGAM).  Aminoimidazole ribonucleotide 
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synthase (AIR synthetase, step 5) performs a ring-closing reaction on FGAM to produce 
aminoimidazole ribonucleotide (AIR).  AIR carboxylase (step 6) then catalyzes the 
carboxylation of AIR by CO2 to give carboxyaminoimidazole ribonucleotide (CAIR).  
N-Succinocarboxamide-5-aminoimidazole ribonucleotide synthetase (SAICAR 
synthetase, step 7) catalyzes the ligation of the CAIR carboxylate group to the amino 
group of an aspartate to produce N-succinocarboxamide-5-aminoimidazole 
ribonucleotide (SAICAR) Aminoimidazole-4-carboxamide ribonucleotide (AICAR) is 
formed by the β-elimination of fumarate from SAICAR by Adenylosuccinatelyase (step 
8).  In the penultimate step, AICAR is converted to formyl AICAR (FAICAR) by 
Aminoimidazole-4-carboxamide ribonucleotidetransformylase (AICAR transformylase, 
step 9) which catalyses the transfer of a formyl group from 10-formyl tetrahydrofolate.  
Inosine monophosphate cyclohydrolase (IMP cyclohydrolase, step 10) organises the 
ring-closure reaction of FAICAR with the elimination of water to produce the final 
product of the pathway, IMP.   
12 
 
Figure 1-1:The de novo purine biosynthetic pathway.  The conversion of PRPP to IMP proceeds via 
10 enzymatic steps.  Intermediate in brackets is unique to bacteria.  IMP is then converted to AMP by 
adenylosuccinate synthetase and adenylosuccinate lyase, or GMP by IMP dehydrogenase and GMP 
synthetase. 
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Figure 1-2: R5-P, ribose 5-phosphate.  The numbers indicate the step number in which the highlighted 
atoms are synthesised in the de novo purine biosynthetic pathway.  Steps 1 and 4 incorporate nitrogen 
from glutamine, step 2 incorporates atoms from glycine, steps 3 and 9 incorporate carbon from a folate 
co-factor, step 6 incorporates carbon dioxide and step 7 incorporates nitrogen from an aspartic acid.  
Steps 5 and 10 are cyclisation reactions so no new atoms are incorporated in these steps
[5]
. 
 
1.1.1.1 Discovery of the pathway 
The first studies of the de novo purine biosynthetic pathway investigated the 
incorporation of 
15
N into the ring structure of purines in tissues from rats and pigeons 
through the administration of labelled urea and ammonium citrate
[2]
.  This showed that 
purines could be synthesized by the body, rather than relying on purines absorbed 
through the diet.  A basic characterisation of the biosynthetic pathway was published by 
Buchanan et al. in 1959, who conducted experiments on enzymes extracted from pigeon 
and chicken livers
[6]
, the results showed that purine synthesis de novo consists of 9 
1 
2 
3 
4 
6 
7 
9 
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intermediates that are converted by 10 distinct enzymes.  Since then, the de novo  
pathway has been extensively studied in mammalian
[7]
, avian
[6, 8]
, yeast and bacterial 
systems
[9]
.   
The pathway in Escherichia coli requires an extra enzyme involved in step 6.  Firstly, 
N
5
-carboxyaminoimidazole ribonucleotide synthetase (N
5
-CAIR synthetase) catalyses 
the formation of N
5
-CAIR from AIR, ATP and carbon dioxide, then N
5
-CAIR mutase 
forms CAIR
[10]
 (Figure 1-1).  A significant body of work was conducted by Flaks et al. 
into discerning the enzymes and pathway intermediates from avian liver
[11]
, detailing 
the purification procedures and assay conditions for each of the enzymes in the 
pathway.  Several of the de novo purine pathway enzymes exist as multifunctional 
proteins where activities are combined onto a single polypeptide.  A trifunctional 
protein containing GAR synthetase, GAR transformylase and AIR synthetase activities 
has been isolated from both human and avian sources; and confirmed by functional 
complementation in bacteria and yeast
[12]
.  AIR carboxylase and SAICAR synthetase 
(steps 6 and 7) are located on the same bifunctional protein
[12d]
, and the final two steps 
of the pathway are catalysed by a single protein exhibiting AICAR transformylase and 
IMP cyclohydrolase activities
[13]
.  The gene designations for vertebrates, yeast and 
bacteria are summarised in Table 1.1. 
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 Gene designation 
Step of pathway Enzyme Vertebrates Yeast Bacteria 
1 
PRPP amidotransferase  
EC 2.4.2.17 
PPAT Ade4 PurF 
2 
GAR synthetase 
EC 6.3.4.13 
GART Ade5 PurD 
3 
GAR transformylase 
EC 2.1.2.2 
GART Ade8 PurN 
4 
FGAM synthetase 
EC 6.3.5.3 
PFAS Ade6 PurL 
5 
AIR synthetase 
EC 6.3.3.1 
GART Ade7 PurM 
6 
AIR carboxylase 
EC 4.1.1.21 
PAICS Ade2 - 
6a 
N
5
-CAIR synthetase 
EC 6.3.4.18 
- -  PurK 
6b 
N
5
-CAIR mutase 
EC 5.4.99.18 
- -  PurE 
7 
SAICAR synthetase 
EC 6.3.2.6 
PAICS Ade1 PurC 
8 
Adenylosuccinate lyase 
EC 4.3.2.2 
ADSL Ade13 PurB 
9 
AICAR transformylase 
EC 2.1.2.3 
ATIC Ade16/17 PurH 
10 
IMP cyclohydrolase 
EC 3.5.4.10 
ATIC Ade16/17 PurH 
Table 1.1: Summary of the enzymes of the de novo purine biosynthetic pathway with the gene 
designations found in mammals, yeast and bacteria. 
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De novo purine synthesis is active in a wide range of tissues including the liver
[11, 14]
, 
kidney
[15]
 and skeletal muscle
[16]
, human peripheral blood lymphocytes
[17]
, bone 
marrow
[18]
 and brain
[14]
.  Activity of de novo synthesis is known to change with stages 
of the cell life cycle, there is high activity in the early development of certain tissues
[19]
 
including brain, liver, kidney and spleen, and also during wound healing
[20]
.  Conversely 
there is a dramatic loss of activity (approximately 95%) in G1 phase-arrested 
mammalian cells
[21]
 and no activity in intestinal mucosa that rely completely on the 
salvage pathway for purine synthesis
[22]
. 
 
Plants also use the pathway for purine biosynthesis, for example tropical legumes utilise 
the de novo purine pathway to synthesise ureides, which are major nitrogen-fixation end 
products found in root nodules
[23]
.  The enzymatic activities of the pathway are all 
located on individual proteins, except for AICAR transformylase and IMP 
cyclohydrolase which are located on a bifunctional protein.  The pathway has been 
studied in soybean, mothbean and cowpea nodules and has been found to have similar 
substrate and cofactor requirements to other systems. 
 
More recently, a search of the Integrated Microbial Genome system has started to 
elucidate purine biosynthesis in archaea
[24]
.  Archaea encode several unique enzymes 
for purine biosynthesis, several species are able to form purines despite certain enzyme 
activities found in other organisms being completely absent.  In non-folate containing 
archaea, AICAR transformylase activity is replaced with an archaeal signature PurP 
gene product which uses formate as a cofactor
[25]
.  In M. jannaschii the PurO gene 
product contains IMP cyclohydrolase activity, but has a structure and sequence that is 
completely unrelated to that seen in other organisms
[26]
.  The crystal structure of 
archaeal IMP cyclohydrolase has been solved in complex with IMP (to 2.0 Å 
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resolution) and AICAR (to 2.6 Å resolution).  The PurO gene product has glutamate and 
arginine as the catalytic residues, compared to the tyrosine and aspartate residues found 
in all other organisms.  The mechanism of cyclisation employed by PurO is analogous 
to that of GFP chromophore maturation
[27]
.  There is much variation in the archaeal 
pathway with some species producing a bifunctional enzyme that catalyses steps 9 and 
10, as is found in other organisms, as well as other combinations of PurP, PurO and 
PurH
[24]
.  Several species are purine auxotrophs and rely on exogenous purines for 
growth.  These include the parasitic protozoa
[28]
such as Plamsmodia
[29]
 and 
Toxoplasma
[30]
. 
 
1.2 Aminoimidazole-4-carboxamide ribonucleotide Transformylase/ 
Inosine monophosphate Cyclohydrolase (ATIC) 
Aminoimidazole-4-carboxamide ribonucleotide Transformylase Inosine monophosphate 
Cyclohydrolase (ATIC) is a bifunctional enzyme of the de novo purine biosynthesis 
pathway.  ATIC catalyzes the final two steps of this pathway, with each reaction 
occurring in a specific catalytic domain.  One domain contains the aminoimidazole-4-
carboxamide ribonucleotide transformylase (AICAR transformylase) active site.  This 
domain binds the substrate AICAR and cofactor 10-formyl tetrahydrofolate (10-f H4F), 
and facilitates the transfer of a formyl group from 10-f H4F to the exocyclic amino 
group of AICAR to give the products formyl AICAR (FAICAR) and tetrahydrofolate 
(H4F).  The second step is then catalysed by the inosine monophosphate cyclohydrolase 
(IMPCH) domain which causes a ring-closure reaction in FAICAR to form inosine 
monophosphate (IMP) with the loss of a molecule of water.  The reaction scheme for 
these 2 steps is shown in Figure 1-3. 
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Figure 1-3: A summary of the reactions catalysed by ATIC.  AICAR transformylase transfers a formyl 
group from the 10-f-H4F cofactor to the AICAR substrate before IMP cyclohydrolase catalyses a ring 
closing reaction with the loss of H2O. 
 
1.2.1.1 Identification and purification 
Two isoforms of human ATIC were originally reported, hATIC-a
[31]
 and hATIC-b
[32]
, 
from the sequencing of a cDNA library.  They are almost identical with the exception of 
the N-terminal sequence; hATIC-b contains one extra amino acid at its N-terminus 
(MAPGQL) whereas hATIC-a has the sequence (MSSLS).  Also, position 165 (in 
hATIC-b) has glycine substituted for aspartate.  A BLAST search of the human genome 
performed by Vergis noted that the glycine found in hATIC-a must be the product of a 
point mutation as it is not encoded within the human genome
[33]
.  The N-terminal 
regions of hATIC-a and hATIC-b are both encoded, but it was concluded the second 
isoform (hATIC-b) is the more common form of human ATIC as it is the most 
predominant
[32]
.  Closer inspection of the genome sequence suggests that the hATIC-a 
is an artefact generated as a result of incorrect splicing and will not be expressed in vivo 
(Dr M. E. Webb, personal communication). 
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Early purification procedures for AICAR transformylase noted the co-purification of 
IMP cyclohydrolase activity
[11]
.  Truncation mutation studies conducted by Rayl et al. 
demonstrated that the final 2 steps of the de novo purine synthesis were contained in 
different catalytic domains.  Two amino-terminal mutants containing only the first 223 
and 230 amino acids residues of hATIC-b were found to only exhibit IMPCH activity.  
A carboxyl-terminal mutant consisting of 406 amino acids was subjected to kinetic 
analysis and was found to show only AICAR transformylase catalytic activity.  This 
provided evidence that bifunctional ATIC contains 2 separate functional domains
[31]
. 
 
1.2.1.2 The folate cofactor 
The formyl donor for the formyl transferase reactions catalysed by GAR transformylase 
and AICAR transformylase is N
10
-formyltetrahydrofolic acid (10-f-H4F)
[8]
.  In cells, the 
folate cofactor likely exists as folylpoly--glutamates (10-f-H4PteGlun).  10-f-H4PteGlun 
with n=1, 3, 4, 5, 6 and 7 have been analysed as cofactors for AICAR transformylase at 
physiological [K
+
] of 150 mM; with Vmax/Km of 1, 52, 250, 93, 120 and 59 for n=1, 3, 4, 
5, 6 and 7 respectively
[34]
 demonstrating a preference for the tripolyglutamated form of 
10-f-H4F. 
 
The structure and active site of AICAR transformylase is not consistent with other 10-f-
H4F requiring enzymes
[35]
.  Evidence has been presented that the in vivo substrate 
utilised by AICAR transformylase is not 10-f-H4F, but instead 10-formyl-dihydrofolate 
(10-f-H2F)
[36]
.  This oxidised form was shown to have approximately a 5-fold decrease 
in KM values when compared to the KM measured for 10-f-H4F.  The aforementioned 
kinetic advantage of 10-f-H2F was seen when AICAR transformylase from Jurkat-cell 
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and rat bone marrow was analysed, but the same effect was not significantly 
demonstrated with AICAR transformylase from chicken liver
[36]
.  In contrast, GAR 
transformylase is not able to utilise 10-f-H2F
[36-37]
.  The bioactivity of unnatural (6R)-5-
formyl tetrahydrofolate and (6S)-5,10-methenyltetrahydrofolate can therefore be 
explained by conversion to 10-f-H2F, which proceeds with the loss of the carbon-6 
asymmetric centre
[38]
.  The formation of the multienzyme complex consisting of GAR 
transformylase, serine hydroxylmethyltransferase and the trifunctional folate 
metabolising protein (see section 1.3.1.2) is suggested to channel 10-f-H4F produced by 
the trifunctional folate metabolising protein to the GAR transformylase active site
[3]
.  
As no such complex is seen with ATIC, the 10-f-H4F has to diffuse a greater distance to 
encounter the AICAR transformylase active site, and so has a greater risk of oxidation 
to 10-f-H2F. As micromolar concentrations of iron (Fe
3+
) in solution have been shown 
to oxidise 10-f-H4F in vitro
[39]
, Cytochrome c was suggested to non-enzymatically 
convert 10-f-H4F to 10-f-H2F and was subsequently shown to oxidise both the natural 
(6S)-10-f-H4F and unnatural (6R)-10-f-H4F isomers
[38b]
.  Cytochrome c containing 
complex IV of rat mitochondria has also been shown to oxidise both isomers of 10-f-
H4F
[40]
. The observation of exchange from carbon-2 to carbon-8 in the IMP product is 
seen in vitro but cannot be replicated in vivo
[41]
.  The carbon exchange can only be 
achieved if AICAR transformylase utilises 10-f-H4F as a cofactor (Figure 1-4), 
therefore, as the exchange is not observed in vivo, this lends further support to the 
suggestion that 10-f-H2F, not 10-f-H4F, may be the true cofactor used by AICAR 
transformylase
[42]
. 
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Figure 1-4: The proposed scheme by which carbon-2 can switch to the carbon-8 position in IMP as 
observed in vitro.  The IMP cyclohydrolase and AICAR transformylase reactions are reversible which 
locates carbon-2 onto the tetrahydrofolate to form 10-formyl tetrahydrofolate.  This is then the cofactor 
for the GAR transformylase reaction and positions the former carbon-2 into what will become carbon-8 
after conversion to IMP by the remaining de novo pathway. 
 
The most commonly used method for analysing AICAR transformylase catalytic 
turnover is the rapid assay described by Black et al.
[43]
.  The assay measures the 
production of H4F from the turnover of the 10-f-H4F cofactor (Figure 1-3), calculated 
from the increase in absorbance seen at 298 nm, caused by the difference in the 
absorption spectra of H4F and10-f-H4F.  The difference in the extinction coefficients is 
used to determine the rate.  The alternative cofactor proposed by Baggott and co-
workers, 10-f-H2F, claims a kinetic advantage over 10-f-H4F for certain types of 
AICAR transformylase (Jurkat-cell and rat bone marrow).  For analysing the enzyme 
kinetics of this reaction, the turnover of 10-f-H2F is followed by monitoring the 
absorbance change at 312 nm
[36]
.  A more sensitive, but more complicated radioassay 
has been devised by Szabados et al. involving analysis of radiolabeled substrate by 
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TLC
[44]
.  By using this method the ratio of specific activities of AICAR 
transformylase:IMPCH were measured to be 1:44.   
1.2.1.3 Structure 
Human ATIC consists of a single polypeptide chain of 592 amino acids with a 
molecular mass of 64 kDa.  Avian ATIC is 81% homologous to the human enzyme 
amino acid sequence.  Avian ATIC is 593 amino acids long, and so has human ATIC 
amino acid positions +1, and this needs to be taken into account when comparing 
structures
[31]
.  On evaluating the human and avian ATIC structures they were found to 
be highly conserved
[45]
.   
The active sites of ATIC were identified when the crystal structure of the avian enzyme 
was first determined by the Wilson group
[46]
.  ATIC crystallised as a homodimer with 
an extensive dimer interface of 5000 Å2.  The IMPCH catalytic site is contained in the 
N-terminal domain in residues 4-199, and the C-terminal domain of residues 200-593 
contains the AICAR transformylase activity.  These two domains are linked by a unique 
small substructure that consists of two β-hairpin motifs that form an interlocked 8-
stranded β-sheet.  In the dimer the catalytic domains are approximately 50 Å apart 
(Figure 1-5). 
The IMPCH domain has α-β-α type structure.  The central β-sheet resembles a Rossman 
fold topology, surrounded on one side by 3 α-helices and 7 on the opposite.  One 
monomer was found to have a bound purine nucleotide that was identified as xanthine 
monophosphate (XMP).  This is bound by an extensive hydrogen bonding network with 
high affinity (Ki = 0.12 μM)
[47]
, it is acquired in the bacterial cell used to overexpress 
the protein and remains through the purification process.  The IMPCH active site 
undergoes several conformational changes when a ligand binds.  The most significant 
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change is conducted by residues 103-108 which act to flip Tyr104 and attain its 
substrate from the bulk solvent
[45]
.   
 
Figure 1-5: Crystal structure of homodimeric avian ATIC at 1.93 Å
[47]
.  Monomer chains are shown in 
blue and red.  a) The IMPCH domain is located in the left portion of the structure and is depicted with 
XMP (green) bound in the active site.  The AICAR transformylase domain (right hand portion) has 
AICAR (yellow) bound in the active site and shows the position of the 2 bound potassium ions (purple 
spheres).  b) Close up of the IMPCH active site with XMP (green) bound.  Residues 103 to 108 are 
highlighted in orange, Tyr104 points towards the XMP ligand. 
The AICAR transformylase domain is more complex and consists of 3 sub-domains 
‘domain 2’ (200-374) and ‘domain 3’ (469-532) which is inserted into ‘domain 4’ (375-
a) 
b) 
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593).  Domains 2 and 4 are similar and both contain a core 5-stranded β-sheet 
surrounded by α-helices.  Domain 3 is only 64 residues long and is unique in its 
topology which consists of 4 α–helices and 2 short β–sheets. 
 
The binding mode of AICAR was resolved crystallographically by Wolan et al.
[47]
 who 
observed that AICAR is bound in a 3'-endo sugar pucker conformation with the enzyme 
orientating the carboxamide amino group up away from the imidazole ring.  A 
Multisubstrate Adduct Inhibitor (MAI) β-DADF (6i, Figure 1-9) was used to identify 
the folate binding site as the enzyme crystallises in the absence of bound folate
[48].  β-
DADF (6i Figure 1-9) represents a covalently-linked AICAR and folate co-factor (KM = 
102 μM)[49] and allowed for characterisation of the folate binding site.  The AICAR and 
folate binding sites were found to be located in a cavity at the dimer interface.  AICAR 
was found to interact more with residues from one monomer of the dimer while the 
folate co-factor interacted mainly with residues on the opposite monomer, most notably 
Lys266. 
 
ATIC has previously been shown to participate in a monomer/dimer equilibrium (Kd = 
240 ± 50 nM)
[33]
.  AICAR transformylase requires dimerisation for activity to occur, as 
predicted by the mode of AICAR binding, but IMPCH is still active when the enzyme is 
monomeric (albeit 6 times less active).  The addition of the 10-f-H4F cofactor with the 
AICAR substrate stabilises the enzyme in its dimeric form
[33]
. 
1.2.1.4 Catalytic mechanism 
The first step catalyzed by ATIC is the transfer of a formyl group to an AICAR 
substrate from a folate cofactor.  This reaction is unfavourable (Keq = 0.024 ± 0.001) but 
the reaction is driven forwards due to the second step which involves an entropically 
favourable ring-closing reaction on the unfavourably formed FAICAR.  FAICAR is a 
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product inhibitor (Ki = 0.4 ± 0.1 µM) of AICAR transformylase
[50]
.  The rate limiting 
step is the release of the tetrahydrofolate formed from the turnover of the 10-f-H4F in 
the reaction
[51]
.  Coupling the two catalytic domains on a single polypeptide may aid the 
reaction to go to completion, as the first step is unfavourable and driven forwards by the 
favourable subsequent reaction.  Unexpectedly, there is no substrate channelling within 
the enzyme between the two active sites, and thus the proximity of the two sites and 
local concentration gradient between them is thought to be the reason for their 
coupling
[51-52]
.  AICAR transformylase activity requires ATIC to be in its dimeric form 
to be catalytically active, since the residues which make up the active site are supplied 
by both monomers.  The 4-carboxamide of the AICAR is positioned by the binding 
pocket to increase the nucleophilicity of the C5 amide, ready for nucleophillic attack on 
the formyl group of 10-f-H4F.  Turnover of alternative substrates suggests that the 4-
carboxamide participates in proton transfer.  The catalytic activity of AICAR 
transformylase was found to have virtually no pH dependence in the range 6-10.5.  The 
lack of pH dependence was thought to suggest that the ammonium component of a 
lysine or arginine residue is acting as a general acid catalyst with pKa greater than 
10.5
[53]
.  His267 and Lys266 interact to aid the positioning of the general acid catalyst 
to the N3 of the AICAR imidazole.  His267 is thought to be involved in proton 
abstraction and Lys266 stabilises the oxyanion transition state and facilitates proton 
transfer to the N10 of the tetrahydrofolate leaving group, either directly or through 
His267 or water molecules
[47-48, 50]
.  The crystal structure of avian ATIC determined 
with β-DADF confirms that a buried Lys267 residue (equivalent to Lys266 in human 
ATIC) is protonated during formyl transfer
[48]
.  This causes the stabilization of the 
oxyanion transition state and the following protonation of the tetrahydrofolate leaving 
group
[48]
 (Figure 1-6).   
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Figure 1-6: The catalytic mechanism of AICAR transformylase.  Proton shuffling from the bulk solvent 
proceeds via His592 and His 267. 
 
The catalytic mechanism for IMPCH has been deduced by analysis of ATIC with 
various inhibitors
[54]
, and mutation studies
[45, 55]
.  Loop residues 103-108 and 65-67 
undergo varying degrees of conformational change when substrates or transition state 
analogues bind giving open, half-closed or closed conformations.  Upon substrate 
binding changes twist Tyr104 into the active site, sheilding the substrate from the bulk 
solvent and preventing its diffusion out again.  The enzyme is then in its closed 
conformation with residues positioned optimally for intermolecular nucleophilic attack, 
with Tyr104 and Asp124 residues close to the substrate in an environment that perturbs 
their pKa values ready for catalysis
[45, 55]
.  Tyr104 is stabilised by a hydrogen bonding 
interaction with Lys66.  The negatively charged C2 sp
3
 centre created in the transition 
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state is stabilised by an oxyanion hole formed by the backbone amides of Ile125 and 
Gly126.  The side chains of Tyr104 and Asp124 from one monomer and Lys137 from 
the other, along with bridging water molecules, are important in facilitating catalysis.  
The interactions from opposite monomer residues are consistent with the increased 
efficiency but not dependence of the IMPCH catalytic activity upon dimerisation
[45]
. 
 
 
Figure 1-7: Catalytic mechanism of IMP cyclohydrolase.  Loss of water is proposed to be catalysed by 
either Asp124 or Lys66 and Tyr104. 
 
ATIC has a higher activity in potassium containing buffers
[31]
 and two bound potassium 
ions were identified in the crystal structure
[47]
.  The potassium ion interacts with the 
backbone carbonyls of Val425, Thr428 and Leu589, the hydroxyls of Ser430 and 
Ser432 and the carboxyl side chain of Asp539 in domain 4 (Figure 1-8).  The precise 
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role of these metal ions is not known, but metal cofactors in other enzymes are known 
to have structural or catalytic roles, for example as redox reagents
[56]
.  Potassium is 
essential for maximal activity
[57]
.  Kinetic characterisation of ATIC AICAR tfase with 
polyglutamated tetrahydrofolates at 25 mM K
+
 and physiological 150 mM K
+
 was 
conducted by Baggott and Krumdieck
[34]
.  An inhibitory effect on the rate was seen with 
monoglutamated 10-f-H4F at physiological potassium concentrations.  The KM for 
AICAR increased two fold when measured at 150 mM K
+
.  The phases of colonisation 
of B. subtilis are dependent on potassium levels, as potassium is required for the 
synthesis of purines and pyrimidines so the colonies cannot grow without sufficient 
potassium
[58]
. 
 
 
Figure 1-8: Crystal structure of human ATIC highlighting one of the bound potassium ions and the 
residues surrounding it.  S430, S432 and D539 all make side chain interactions, with V425, T428 and 
L589 interacting through their backbone carbonyl groups. 
V425
D539
S432
S430
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1.2.1.5 Diseases 
There are several diseases associated with aberrations in the de novo purine biosynthetic 
pathway, including autism, muscular dystrophy and lymphoma.  Mutations of enzymes 
within the pathway are associated with various alterations in cell metabolism, and 
therefore the enzymes of the pathway are potential targets for chemotherapeutics and 
inhibitors of viral replication. 
 
Hyperuricema is the condition associated with the overproduction of purines.  A mutant 
cell line displaying hyperuricema was shown to have normal levels of PRPP, and 
instead overproduced purines through an altered sensitivity to the feedback regulation 
of nucleotides inhibiting amidophosphoriboyltransferase
[59]
.  When cells are not under 
energy-limiting conditions a high rate of de novo synthesis leads to purine excretion
[60]
.  
A four fold increase in the de novo purine pathway has, however, been linked to 
patients suffering classic infantile autism, which effects around 20% of the autistic 
population
[61]
. 
 
In contrast, Duchenne muscular dystrophy (DMD) is associated with structural and 
metabolic irregularities at the cellular level, including changes to the plasma membrane 
in erythrocytes
[62]
 and a lack of adenine and guanine nucleotides
[63]
.  The alterations to 
the cell that interfere with the de novo synthesis of IMP in DMD are unknown
[63b]
. 
 
Alteration of a single residue of ATIC has been shown to lead to severe neurological 
defects, dysmorphic features and blindness in the case of a 4-year old girl
[64]
.  The 
mutation K426R completely destroys AICAR transformylase activity which causes the 
build up of AICAR mono-, di-, and tri-phosphates in erythrocytes and the excretion of 
5-amino-4-imidazolecarboxamide riboside (AICAr).  AICAr affects a number of 
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biological processes involved with cell metabolism, such as inhibiting carbohydrate
[65]
 
and lipid
[66]
 metabolism, and promoting glucose uptake
[67]
.  AICAr is toxic and induces 
apoptosis in neuroblastoma cells
[68]
.  The monophosphorylated compound, AICAR, 
accumulates in the erythrocytes of patients suffering from Lesch-Nyhan syndrome
[69]
.  
Lesch-Nyhan syndrome is an inherited disorder that affects the synthesis and 
degradation of purines through the absence or severe lack of hydroxyxanthine guanine 
phosphoribosyl transferase (HGPT).  This causes the build up of atypically high levels 
of uric acid, neurological defects, and behavioural issues
[70]
.  Unusually high 
concentrations of PRPP are found in Lesch-Nyhan patients
[71]
.  The behavioural and 
neurological dysfunctions have been related to abnormalities in the dopamine neuron 
function in the basal ganglia
[72]
, but the relationship to the overproduction of purines is 
still unknown. 
 
ATIC is also implicated in Anaplastic Large Cell Lymphomas (ALCLs), which can be 
separated into two subcatagories, Anaplastic Lymphoma Kinase (ALK)-positive and 
ALK-negative
[73]
.  Once activated ALK-fusion proteins lead to cellular transformation 
through a complex signalling network.  The N-terminus of ATIC fuses to the 
intracytoplasmic region of ALK to form a novel oncogenic dimeric protein
[73-74]
.  The 
ATIC-ALK chimera is found in the cytoplasm
[75]
 and is the product of the chromosomal 
inversion inv(2)(p23;q35)
[76]
.  Detection of ALK-fusion protein allows for further 
analysis of disease progression and outcome; ALK-positive ALCLs have a better 
prognosis than ALK-negative ALCLs
[77]
. 
 
AMP kinase (AMPK) regulates the energy sources within cells.  AMPK is activated 
when the AMP:ATP ratio increases, and responds by phosphorylating a variety of 
substrates which leads to inhibition of ATP consuming processes (such as glucogenesis, 
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protein and lipid synthesis) and activation of ATP generating processes.  Cancer cells 
use glucose at a higher rate compared to that of healthy cells as accelerated cell growth 
is energetically demanding.  Being able to regulate a basic metabolic process that is 
altered only in the cancer cells means AMPK is a potential target for chemotherapeutics 
and cancer prevention
[78]
.  AICAR can activate AMPK by mimicking AMP
[79]
.  
Inhibiting AICAR transformylase (e.g. by disrupting dimerisation) would lead to 
inhibition of the de novo purine biosynthetic pathway and also the activation of AMPK 
(from the build up of AICAR), both of which would have a chemotherapeutic effect.  
AMPK agonists are also known to inhibit viral replication
[80]
. 
1.2.1.6 Inhibition 
Inhibitors of ATIC are not only of interest as potential chemotherapeutic agents, they 
have also been shown to be useful in the treatment of inflammatory diseases.  A wide 
variety of such inhibitors have been synthesized as inhibitors of IMP cyclohydrolase 
and AICAR transformylase activities and to directly interrupt enzyme dimerisation
[81]
. 
1.2.1.7 Folate-based inhibitors of transformylase activity 
The major class of ATIC inhibitors are based on the folate-binding pocket, for example, 
5,10-Dideazatetrahydrofolate (DDATHF, 1i) has inhibitory action in the de novo purine 
synthesis pathway.  DDATHF is a potent inhibitor of GAR transformylase and inhibits 
AICAR transformylase at high concentrations (>10 µM)
[82]
.  Acyclic forms of 
DDATHF bearing a non-transferable formyl (2i)
[83]
 or trifluoroacetyl (3i)
[84]
 group bind 
to the enzymes as gem-diols, which mimic the formyl transfer transition state.  
Sulfonyl-containing antifolates have also been analysed.  BW1540 (4i) (Ki = 8 nM) and 
BW2315 (5i) (Ki = 6 nM) are sulfamido-bridged 5,8-dideazafolate analogues that are 
inhibitors of AICAR transformylase.  These potent inhibitors have been designed to 
occupy the oxyanion hole of AICAR transformylase
[85].  β-DADF (6i) (Kd = 20 µM, 
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IC50 = 125 nM) is a Multisubstrate Adduct Inhibitor (MAI) that was used to probe the 
folate binding site
[48].  β-DADF was designed to incorporate AICAR- and folate-like 
moieties linked by a trans double-bond through 2 methenyls
[50]
.   
 
 
Figure 1-9: A selection of ATIC inhibitors. 
Other inhibitors of the de novo formyl transferase enzymes have been synthesised with 
various different design principles in mind.  A number of functionalised analogues of 
5,8,10-trideazafolate (TDAF) were designed which incorporated different electrophilic 
centres, functionalised with acyl groups that would be incapable of transferring a 
carbonyl group to the substrate
[86]
.  Compound 7i was designed as a competitive 
inhibitor by mimicking the tetrahedral transition state formed during formyl transfer
[86]
.  
Multisubstrate analogue 8i attaches a phosphate group via a flexible linker to the TDAF 
moiety in an attempt to target both cofactor and substrate binding sites
[87]
.  The benzoyl 
and glutamate functions are important to the inhibitory activity of TDAF as compounds 
(9i and 10i) not containing these features are far less potent
[88]
.  Conformationally 
restricted analogue 11i utilises a nitrogen atom incorporated into a 6-membered ring to 
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mimic the electrophilicity of the formyl transfer group of the folate cofactor
[89]
.  
AG2034 (12i) potently inhibited specifically GAR transformylase with Ki = 28 nM, 
which went on to phase 1 trials
[90]
 and through further study was shown to increase 
AMPK phosphorylation
[91]
.   
 
Inhibitors based on the folate cofactors are usually subject to polyglutamation within the 
cell, increasing their retention times.  Compound 13i is an example of an inhibitor 
designed to be non-polyglutamateable by replacing the -carboxylic acid with a 
tetrazole
[92]
.  This would aid in excretion of the drug, ensuring it is not retained in the 
cell for a prolonged period of time. 
 
 
Figure 1-10: A selection of ATIC inhibitors. 
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Methotrexate (MTX, 14i) is a clinically prescribed folate antagonist
[93]
, used to treat 
rheumatoid arthritis, psoriasis
[38a]
, leukemia
[94]
 and breast cancer
[95]
.  MTX inhibits 
dihydrofolate reductase and folate dependent enzymes, including AICAR 
transformylase
[93]
.  AICAr, the nucleoside precursor of AICAR, builds up and promotes 
the release of adenosine
[96]
 which brings about an anti-inflammatory response by 
inducing apoptosis of activated T-lymphocytes
[97]
.  AICAr is also proposed to inhibit 
neutrophil adherence to connective tissue
[98]
.  A single nucleotide polymorphism in the 
ATIC gene, C347G which encodes for the single point mutation Thr116Ser, is being 
monitored to provide a pharmacogenetic biomarker to predict patient response to MTX 
treatment
[99]
 in rheumatoid arthritis
[94, 100]
 and psoriasis
[101]
.  Higher AICAr excretion is 
also associated with better MTX efficacy
[42]
.  Administering folic acid in conjunction 
with MTX treatment has been found to attenuate side effects
[99a]
.  MTX enters the cell 
through the reduced folate carrier protein and is converted by folypolyglutamate 
synthase to MTX polyglutamates, the higher forms of which are retained in the cell 
longer
[93]
.  7-OH MTX is a major metabolite of MTX, catabolised by aldehyde oxidase.  
Comparing the monoglutamated and tetraglutamated forms revealed a 10-fold increase 
in potency
[102]
 showing the importance of cellular processing on administered drugs. 
1.2.1.8 Inhibitors of IMP cyclohydrolase activity 
Only a small number of IMP cyclohydrolase inhibitors have been described.  The 
IMPCH inhibitors 1,5-dihydroimidazol[4,5-c][1,2,6]thiadiazin-4(3H)-one 2,2-dioxide 
(15i) (Ki = 0.13 µM) and the corresponding nucleoside (Ki = 0.23 µM)  and nucleotide 
(Ki = 0.15 µM)  were designed to imitate the tetrahedral transition state formed in the 
cyclisation reaction
[54]
.  The nucleoside and nucleotide were found to mimic XMP 
binding.  The nucleotide inhibitor also binds to the AICAR transformylase domain 
which raises the possibility of designing inhibitors to block both ATIC catalytic sites. 
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1.2.1.9 Inhibitors of ATIC dimerisation 
As the catalytic activity of AICAR transformylase is dependent on the oligomerisation 
state of the enzyme being that of a homodimer, it has been suggested that small 
molecules that could block dimerisation would provide a new mode of selectively 
inhibiting AICAR transformylase.  2 examples of such inhibitors are cyclic peptides
[81b]
 
and a generation of molecules known as cappsins
[81a]
.  The most potent cyclic peptide 
(16i) had Ki =17 ± 4.2 μM and the most potent cappsin, cappsin 1 (17i), had Ki =3.1 ± 
0.3 µM.   
 
 
Figure 1-11: Inhibitors of the IMPCH domain of ATIC (15i) and of ATIC dimerisation (16i and 17i). 
 
  
36 
 
1.3 Regulation of de novo purine biosynthesis 
1.3.1.1 Feedback regulation 
When the salvage pathway is also functioning, de novo purine biosynthesis is 
suppressed by 70%
[103]
.  There are multiple points for feedback regulation found within 
the de novo pathway as summarised in Figure 1-12.  Phosphoribosylpyrophosphate 
synthetase (PRPP synthetase), catalyses the formation of the first substrate of the de 
novo and salvage pathway, PRPP, from ribose 5-phosphate (R 5-P) and ATP
[3]
.  The 
physiological PRPP concentration is rate-limiting for purine synthesis
[104]
.  Cyclic AMP 
decreases the availability of PRPP and thus slows the rate of de novo and salvagepurine 
synthesis
[105]
.  PRPP synthetase is negatively regulated by IMP, AMP, GMP, ADP and 
GDP
[106]
, the products of the purine pathways regulate the activity of their formation.  
PRPP synthetase consists of single polypeptide subunits of 33 kDa.  These are capable 
of self-association to give aggregated forms containing 2, 4, 8, 16 and 32 subunits, of 
which only the 16 and 32 subunit forms were found to be significantly active in 
vitro
[107]
.   
 
PRPP amidotransferase catalyses the first step of de novo purine biosynthesis and is 
also allosterically inhibited by AMP, GMP and IMP ribonucleotide end products
[4, 108]
.  
PRPP amidotransferase exists in two forms, a smaller 133 kDa and larger 270 kDa 
protein.  The presence of the PRPP substrate stabilises the active 133 kDa enzyme 
whilst the regulatory inhibiting purine nucleotides convert the smaller protein into the 
270 kDa inactive form
[109]
.  Synergistic inhibition is seen with mixtures of purine 
nucleotides, for example with AMP + GMP or AMP + IMP the inhibition effect 
measured is far greater than the additive effect expected
[110]
.   
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The fifth step of the pathway, catalysed by AIR synthetase, is inhibited by AMP and 
AIR synthetase is the second slowest step of de novo purine synthesis
[108b]
.  There are 
two other sites of feedback inhibition which occur following the formation of IMP.  
Adenylosuccinate synthetase is inhibited by AMP, and GMP inhibits IMP 
dehydrogenase.  An excess of a triphosphate nucleotide influences the production of its 
monophosphate counterpart, i.e.  GTP stimulates AMP production and ATP stimulates 
GMP production
[108a]
. 
 
Figure 1-12: Feedback regulation of the de novo purine biosynthetic pathway.  Steps also included 
are the synthesis of PRPP from 5-ribose phosphate catalysed by PRPP synthetase, and the conversion of 
IMP to ATP and GTP.  Red dashed lines indicate negative feedback and solid green lines positive 
feedback. 
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1.3.1.2 Regulation via formation of macromolecular complexes 
As previously mentioned, several of the de novo purine pathway enzymes exist as 
multifunctional proteins where activities are combined onto a single polypeptide.  The 
trifunctional ‘GART’ protein containing GAR synthetase, GAR transformylase and AIR 
synthetase (steps 2, 3 and 5) activities, bifunctional ‘PAICS’ with AIR carboxylase and 
SAICAR synthetase (steps 6 and 7) activities, and bifunctional ‘ATIC’ exhibiting 
AICAR transformylase and IMP cyclohydrolase activities catalysing the final two steps 
of the pathway.  ATIC bifunctionality is conserved through bacteria, yeast, vertebrates 
and some species of archaea. 
 
Both folate requiring enzymes GAR transformylase and AICAR transformylase have 
been described as purifiying as a multienzyme complex
[3]
.  The formyltransferases 
extracted from chicken liver each copurify with serine hydroxylmethyltransferase and 
the trifunctional folate metabolising protein containing 10-f-H4F synthetase, 5,10-
methenyl H4F cyclohydrolase and methylene H4F dehydrogenase activities
[111]
.  This 
provides an interesting possibility for substrate channelling of the unstable 10-f-H4F, by 
the close proximity of the trifunctional protein to convert folate species into the required 
10-f-H4F cofactor.  Only the complex containing GAR transformylase has been shown 
to cross-link to the trifunctional protein in solution
[112]
 
All six enzymes of the de novo purine biosynthetic pathway have been postulated to 
cluster together and form a multi-enzyme complex termed the ‘purinosome’ in purine-
depleted conditions (Figure 1-13) by Benkovic et al.
[113]
.  This is intuitive as the de 
novo pathway is essential under purine-depleted conditions, when the salvage pathway 
will have minimal substrates available and purine synthesis must proceed via the de 
novo pathway.  Formation of the purinosome is proposed to be regulated by the 
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activation of endogenous Gi-coupled receptors
[114]
.  The purinosome is punctate 
bodies distributed throughout the cytoplasm by a microtubule network
[115]
. 
Advantages of such multifunctional proteins and multienzyme complexes could include 
channelling of the product of one enzyme to the substrate site of the next and 
preservation of the stoichiometry of the pathway. 
 
 
Figure 1-13: Cellular localisation of GART and FGAMS in HeLa cells grown in purine depleted 
media
[113]
.  A) GART-GFP fusion protein.  B) FGAMS-ORF protein fusion.  C) GART-GFP (green) and 
FGAMS-ORF (red) overlaid.  Scale bar = 10 M. 
However, in a recent publication by Marcotte et al., further investigation into the 
purinosome phenomenon suggests that the formation of these punctate bodies is 
actually the result of protein aggregation
[116]
.  Hydrogen peroxide induces the 
localisation of de novo pathway proteins irrespective of the concentration of purines in 
the growth medium.  This coincides with the co-localisation of endogenous ubiquitin, 
HSP70 (Figure 1-14) and HSP90, which are normally associated with aggregates 
present within the cell
[116]
.  Ubiquitin assigns large aggregates for degradation, whilst 
HSP70 and HSP90 are chaperone proteins.  Analysis of the cells using time-lapse 
microscopy showed that cells containing the punctate bodies died at greater rates than 
those without, suggesting there is an association between the punctate bodies and 
cellular stress; survival rates were largely unaffected by purine availability
[116]
.  
Punctate body construction seems to be either a cause or consequence of stress to the 
cell.  These experiments suggest the aforementioned purinosome is likely to be formed 
A B C 
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from aggregated protein, caused by fusion of the proteins to GFP, excess protein 
expression or compromised protein homeostasis, rather than a functional multienzyme 
complex. 
 
Figure 1-14: Co-localisation of FGAMS-EGFP with endogenous HSP70 and ubiquitin measured by 
immunofluorescence
[116]
. 
 
1.3.1.3 Regulation by post-translational modification 
Post-translational modifications of ATIC that have been identified in humans include 
the phosphorylation of tyrosine 104
[117]
, which is found in the active site of the IMPCH 
domain, and acetylation of lysine 199
[118]
.  K199 is a surface residue and acetylation 
could potentially mediate the interaction with other proteins, such as those of the 
purinosome multienzyme complex.  In E. coli, acetylation at lysine residue 287 occurs.  
K287 is the catalytic lysine residue found in the AICAR transformylase active site and 
would inhibit the enzyme; this could be a means of regulation of de novo activity in 
bacteria.  
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1.3.1.4 Other potential forms of regulation in E. coli 
The gene product of PurR regulates the transcription of the enzymes involved purine 
biosynthesis and the enzymes that convert IMP to AMP or GMP in E. coli
[119]
.  A large-
scale identification of protein-protein interactions in E. coli discovered a putative 
protein-protein interaction between ATIC and YecF, an uncharacterised protein of 
unknown function
[120]
.  This may have a regulatory role by catalysing post-translatory 
modifications to mediate activity, or even the formation of such multienzyme 
complexes as seen in human cells. 
1.4 Objectives 
This thesis aims to further the characterisation of ATIC.  There have been no reports on 
the thermal stability of ATIC within the literature.  The thermal stability of human and 
avian ATIC will be investigated through the use of various biophysical techniques, 
including differential scanning calorimetry and differential scanning fluorimetry. 
The kinetic and physical binding properties of ATIC will be investigated.  The binding 
constants of various small molecules relevant to the de novo pathway will be 
determined for the first time, by isothermal titration calorimetry.  ATIC catalyses two 
successive reactions, from an AICAR substrate and a folate cofactor.  The kinetics of 
these ligands will be investigated using the standard spectroscopic assay described by 
Black
[43]
.  This assay will be developed into a two dimensional, high throughput assay 
to allow for the simultaneous determination of substrate and cofactor KMs, and allude to 
a binding model for the AICAR tfase reaction. 
The crystal structure shows ATIC is a homodimeric protein, with two distinct catalytic 
domains.  The full length ATIC peptide will be cloned into two separate constructs, 
each containing a separate catalytic domain.  These truncation mutants will be used to 
assign kinetic and binding parameters to each of the separate domains.  The 
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dimerisation of ATIC will be investigated through several biophysical techniques 
including isothermal titration calorimetry and analytical ultracentrifugation.  Small 
molecule inhibitors will be synthesised, and deployed to probe ATIC dimerisation.  
Single molecule fluorescence studies with N-terminally fluorescently labelled ATIC 
will be used as a further probe of enzyme dimerisation in the presence of the substrates 
and dimerisation inhibitors.  This may reveal the true dimerisation constant of the 
Michaelis complex which has not previously been determined. 
Within the C-terminal AICAR tfase domain, potassium is always present in the crystal 
structures bound to the ATIC polypeptide.  This thesis presents an investigation into the 
potassium dependence of ATIC.  The Kd of potassium for ATIC has not been reported 
in the literature.  The use of an 18-crown-6 ether complexing agent able to chelate 
endogenous potassium to determine the ATIC Kd for potassium will be investigated.  
The potassium binding site will be probed using site-directed mutagenesis, 
characterising the mutants in an effort to elucidate the role of the potassium ion in 
ATIC. 
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2 Materials and methods 
2.1.1.1 Instrumentation 
Samples and reagents were stored at optimum temperature using a Labcold fridge-
freezer (4 °C/20 °C) or New Brunswick Scientific ultra low temperature freezer U570 
premium (80 °C).  A sterile environment was provided by a Microbiological safety 
cabinet SAFE 2010 Class II (Thermo Electron Corporation).  Solutions and waste were 
sterilised using either a Prestige Medical bench top autoclave, or a LTE Touchclave-R 
autoclave Fisher-brand Hydrus 300.  Bacterial cultures were grown using a Labnet 
311DS shaker incubator, Stuart SI500 orbital shaker, or in a KuhnerSHAKERX shaker 
incubator. Transformations were performed using a Grant SUB14 water bath (heat 
shock method).  Culture plates were grown in a Binder incubator.  Cell disruption was 
performed by using the Bandelin SONOPULS HD2070 or Constant cell disruption 
system (T2/40/AA/AA, Constant Systems Ltd).  Centrifugation was performed using 
the Beckman Coulter
TM
Avanti
TM
 J-30I Centrifuge (with Beckman JLA- 9.1000, 
Beckman JA-10 and Beckman JA- 25.50 rotors) and bench-top centrifuges Heraeus® 
Pico
TM
, Heraeus® Fresco
TM
 and Heraeus® Multifuge® from the Thermo Electron 
corporation.  Size exclusion purification was achieved using a 20/60 Superdex 200 
column or a 10/300 Superdex 200 gel filtration column, run using the Pharmacia AKTÄ 
Purifier FPLC system housed in a Foster Professional Refrigeration cabinet.  Analysis 
of protein samples by SDS-PAGE was performed using the BioRad tetragel system; a 
LabnetAccuBlock™ was used to thermally denature samples.  The molecular weight of 
samples was determined by electrospray ionisation mass spectrometry using a 
BrukerDaltonics® HCT Ultra
TM
 mass spectrometer.  A Varian Cary 50 Bio UV-visible 
spectrophotometer and Varian Cary PCB150 water peltier was used with the Cary 
WinUV software to conduct all UV-Vis studies.  For Isothermal Titration Calorimetry 
44 
 
studies a MicroCal VP-ITC or a MicroCal ITC200 were used and VPViewer and Origin 
software employed to analyse the data.  Analytical UltraCentrifugation studies were 
performed on a Beckman Coulter™ ProteomeLab™ XL-I.  FRET experiments were 
conducted using the JobinYvonHosiba SPEX FluroMax-3®.  Differential Scanning 
Fluorimetry was performed using a Bio-Rad CFX96 touch real-time PCR detection 
system.  Sequencing was carried out by GATC Biotech and analysed with BioEdit 
sequence alignment editor ClustalW
[121]
. 
2.2 Materials 
Analytical grade reagents were obtained from Sigma Aldrich, Fisher Scientific, Alfa 
Aesar and VWR International.  Water was purified using an ELGA PURLAB®
 
Classic.  
DNA samples were purified using the Qiagen QIAquick gel extraction kit and Miniprep 
kit.  Molecular biology reagents (including enzymes, plasmids and buffers) were 
obtained from Promega, Novagen, New England Biolabs, Roche Diagnostics and 
Invitrogen.  Oligonucleotide primers were synthesised by Sigma-Aldrich or IDT.  
Laboratory plasticware and consumables were supplied by Starlab, Fisher Scientific and 
Greiner.  Kanamycin 100 stock at 50 mg/ml was made from kanamycin sulfate 
(BioChemica).  DNA ladder marker Hyperladder I was obtained from New England 
Biolabs (12 bands, 100 bp-1.5 kbp), the Molecular Weight Marker used in SDS-PAGE 
gel electrophoresis was obtained from Fermentas and recombinant DNase 1 from Roche 
Diagnostics.  The resin used in the Ni-NTA column was Qiagen agarose.  5,10-
methylene tetrahydrofolate and (6S)-5-formyl tetrahydrofolate were obtained from 
Schircks laboratories.  Plasmids encoding wild type human ATIC (Pur9) and avian 
ATIC with an N-terminal His-Tag were obtained from Dr M.  E.  Webb.  Plasmids 
encoding some site-directed mutants used were prepared by Dr M. M. Spiering (Penn 
State University). 
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2.3 Solutions 
All solutions were made up to 1 litre with ≥18.2 MΩ purified water and stored at 
ambient temperature unless stated otherwise. 
2.3.1.1 Polymerase Chain Reactions 
Pwo polymerase: purified in house by Dr L Kime. 
Pwo buffer + MgSO4: 100 mM Tris-HCl (pH 8.85), 250 mM KCl, 50 mM (NH4)2SO4, 
20 mM MgCl2. 
2.3.1.2 Bacterial Media 
Auto-Inducing Media (AIM)
[122]
:  Tryptone (10 g/l), Yeast Extract (5 g/l), 50  Salts (20 
ml/l), Magnesium Chloride (407 mg/l), 1000 Metals (200 µl/l), 50% (v/v) Glycerol (10 
ml/l).  The AIM media was autoclaved at 121 °C for 20 minutes as required before the 
remaining components of 50% (w/v) glucose (1 ml/l) and 50% (w/v) lactose (4 ml/l) 
were added.  Kanamycin (50 μg/ml) was added as required.   
50 Salts Stock (500 ml)[122]: Na2HPO4 (88.7 g), KH2PO4 (85 g), NH4Cl (67 g), Na2SO4 
(17.8 g). 
1000 Metals Stock (100 ml)124:FeCl3.6H2O (1.35 g), CaCl2.6H2O (438 mg), 
MnCl2.4H2O (198 mg), ZnSO4.7H2O (288 mg), CoCl2.6H2O (47.6 mg) CuCl2.2H2O 
(34.1 mg), Na2MoO4.2H2O (48.8 mg) Na2SO3 (34.6 mg), H3BO3 (12.4 mg), 
NiSO4.6H2O (52.6 mg), HCl (60µM).  
LB Media: Tryptone (10 g), NaCl (10 g), Yeast Extract (5 g). 
Agar (LBK) Plates: Agar (15 g) was added to 1 l LB media before being autoclaved at 
121 °C for 20 minutes.  When the solution had cooled to 40-60 °C, kanamycin (50 
μg/ml) was added, the plates poured in a sterile environment and left to cool.  Agar 
plates were stored at 4 °C. 
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2.3.1.3 Protein purification buffers 
DNase 1 recombinant, grade 1: (for use and long term storage at 20 °C) 1 tablet 
(10,000 units) was dissolved in 2ml of a buffer consisting of:  20 mM Tris.HCl pH 7.5, 
1 mM MgCl2, Glycerol (50% v/v).  Stored at 20 °C. 
10 PBS (phosphate-buffered saline): 500 mM Potassium phosphate pH 7.0 (0.213 M 
KH2PO4, 0.286 M K2HPO4 at 20 °C), 3 M NaCl. 
Lysis buffer: 1 PBS, 10 mM Imidazole. 
Wash buffer: 1PBS, 50 mM Imidazole. 
Elution buffer: 1 PBS, 250 mM Imidazole. 
ATIC buffer: 50 mM Tris-HCl pH 7.4, 25 mM KCl. 
ATIC low potassium buffer: 50 mM Tris-HCl pH 7.4, 5 mM KCl. 
ATIC zero potassium buffer: 50 mM Tris-HCl pH 7.4. 
TEV cleavage buffer:50 mM Tris-HCl pH 8.0, 0.5 mM EDTA, 1 mM DTT, 100 mM 
KCl. 
Sortase labelling buffer:50 mM HEPES pH 7.5, 150 mM NaCl, 5 mM CaCl2, 50 mM 
KCl. 
AUC ‘HB’ buffer: 20 mM Tris.HCl pH 7.5, 150 mM NaCl, 50 mM KCl. 
2.3.1.4 Buffers for SDS-PAGE 
SDS-PAGE loading buffer: 160 mM Tris.HCl pH 6.8, 4% SDS (w/v), 20% glycerol 
(v/v),  
2 M β-mercaptoethanol, 0.02% (w/v) Bromophenolblue. 
5 SDS-PAGE running buffer: 125 mM Tris base, 960 mM glycine, 0.5% SDS (w/v). 
Coomassie stain: 0.1 % coomassie G250 (w/v), 40% methanol (v/v), 10% acetic 
acid (v/v). 
Coomassie destain: 40% methanol (v/v), 10% Acetic acid (v/v). 
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2.3.1.5 Buffers for Agarose gel electrophoresis 
50 TAE buffer: 2 M Tris base, 1 M acetic acid, 50 mM EDTA. 
6 DNA loading buffer: 6% Orange G (w/v), 80 glycerol (v/v). 
2.3.1.6 Buffers for rubidium chloride chemically competent cells 
Tfb1: 30 mM potassium acetate pH 5.8, 100 mM RbCl2, 50 mM MnCl2, 10 mM CaCl2, 
 15% glycerol (v/v). 
Tfb2: 10 mM MOPS pH 6.6, 10 mM RbCl, 75 mM CaCl2, 15% (v/v) glycerol. 
2.3.1.7 Buffers for protein analysis 
5 M Guanidinium Hydrochloride: for denaturing protein samples to estimate 
concentration using a calculated extinction coefficient 
Bradford reagent: 20% concentrated Bradford reagent (v/v) in water. 
2.3.1.8   Substrate solutions 
AICAR: made up in various concentrations by dilution from a stock of 1-10 mM, in the 
required buffer. 
6(R,S)-10-formyl tetrahydrofolate: 6(R,S)-10-formyl tetrahydrofolate was prepared by 
acid hydrolysis of 5,10-methylene tetrahydrofolate (Schircks). 5,10-
methenyltetrahydrofolate (5 mg) was dissolved in 10 mM HCl (1 ml) to which 1.5 M 
Tris.HCl at pH 8.8 (25 μl) and 0.25 M β-mercaptoethanol (40 μl) were added before 
shaking in the dark for at least 1 hour. The solution (final concentration 10 mM, 
absorbance measured at 253 nm at pH 13) was stored in the dark at −80 °C. The stock 
was diluted into an appropriate buffer and left to equilibrate to the required pH for 1 
hour at room temperature before use. 
6(S)-10-formyl tetrahydrofolate: 5-formyl tetrahydrofolate (5 mg) was dissolved in 0.1 
M H2SO4 (1 ml) at 40 °C before 5,10-methenyl tetrahydrofolate was allowed to 
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precipitate at 4 °C.  The precipitate was collected by centrifugation (17,000 rcf, 10 min), 
dissolved in 10 mM HCl (1 ml) to which 1.5 M Tris.HCl at pH 8.8 (25 μl) and 0.25 M 
β-mercaptoethanol (40 μl) were added before shaking in the dark for at least 1 hour.  
The solution (final concentration 10 mM, absorbance measured at 253 nm at pH 13) 
was stored in the dark at −80 °C.  The stock was diluted into an appropriate buffer and 
left to equilibrate to the required pH for 1 hour at room temperature before use. 
2.4 DNA Primers 
Table 2-1: Primers used in PCR to generate human ATIC site directed mutants F590A (P01) and F590I 
(P02).  Each mutation has a forward primer (f) and a corresponding reverse primer (r).  All sequences are 
written 5 to 3, with the codon site of the mutation underlined. 
Primer code Primer name Sequence 5→3 
P01f F590Af CGA ACC TTC GGC TCG CCC ACC 
P01r F590Ar GGA TCC TCA GTG GTGGGC GAG 
P02f F590If CGA ACC TCC GGC TCA TCC ACC 
P02r F590Ir GGA TCC TCA GTG GTGGAT GAG 
 
Table 2-2: Primers used in PCR to generate truncation mutants of human ATIC, through the introduction 
of restriction sites to the ends of the sequence of interest.  All sequences are written 5 to 3, with the 
restriction site of the mutation underlined. 
Primer code Primer name Restriction site Sequence 5→3 
P03 TFforNco1 Nco1 GAT TCA CCA TGG GCG TAT CTC 
P04 TFforNhe1 Nhe1 GAT TCA GCT AGC GTA TCT CAG 
P05 TFrevBamH1 BamH1 GAT TCA GGA TCC TCA GTG GTG 
P06 IMPCHforNco1 Nco1 GAT TCA CCA TGG CTC CCG GCA 
P07 IMPCHforNde1 Nde1 GAT TCA CAT ATG GCT CCC GGC 
P08 IMPCHrevBamH1 BamH1 GAT TCA GGA TCC TCA TTT GCT 
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Table 2-3: Primers used to synthesise the pET28aTEV plasmid 
Primer code Primer name Sequence 5’→3’ 
P09f Spe1intopET28af 
TCA CAG CAG CGG ACT AGT GCC GCG CGG CAG 
CCA T 
P09r Spe1intopET28ar 
ATG GCT GCC GCG CGG CAC TAG TCC GCT GCT 
GTG A 
P10f TEVinsertf CTA GTT GAG AAC CTG TAC TTC CAA GGT CA 
P10r TEVinsertr TAT GAC CTT GGA AGT ACA GGT TCT CAA 
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2.5 Plasmid maps 
 
 
Figure 2-1: Top:  the pET28a plasmid map containing the gene of interest. Bottom: the pET28a multiple 
cloning site. 
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  M     G     S     S     H     H     H     H     H     H     S     S     G     L     V    P     R     G     S     H     M    A     S     M    T     G     G     Q     Q     M    G   
                                                                                                    
  R     G     S     E     F     E     L     R     R     Q     A     C     G     R     T     R     A     P     P     P     P     P     L     R     S     G     C     *    Q     S     P     K     G  
 C T  A  T T   C T  C T  C C A C C  C T  A  C A A T A A C T A  C A T A A C C C C T T     C C T C T A A A C    T C T T  A     T T T T T T  
  S     *     V     G     C     C     H     R     *     A     I     T     S     I     T     P     W     G     L     *     T     G     L     E     G     F     F   
 
A G A T C T C G A T C C C G C G A A A T T A A T A C G A C T C A C T A T A  G G G A A T T G T G A G C G G A T A A C A A T T C C C C T C T A G A A A T A A T T T T G T T T A A C T T T A A G A A G  A G 
 T  T     T             T   T   T   T   T              T   T                T  T    T     T    T   T           T    T 
  M     G     S     S     H     H     H     H     H     H     S     S     G     L     V    P     R     G     S     H     M    A     S     M    T     G     G     Q     Q     M    G   
            
  R     G     S     E     F     E     L    R     R     Q     A     C     G     R     T     R     A     P     P     P     P     P     L     R     S     G     C     *     Q     S     P     K     G   
                                                                                 
  S     *     V     G     C     C     H     R     *     A     I     T     S     I     T     P     W     G     L     *     T     G     L     E     G     F     F   
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Figure 2-2:  The plasmid map and a multiple cloning site for pET28aTEV.  This vector is an adaption of 
pET28a in which the thrombin cleavage site has been exchanged for a TEV cleavage site.  The TEV 
recognition site is ENLTFQG with cleavage occurring between the glutamine and glycine residues.  
Following cleavage with TEV, the plasmid is designed to leave a glycine-histidine dipeptide, followed by 
the gene of interest. 
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C G A A A G G A A G C T G A G T T G G C T G C T G C C A C C G C T G A G C A A T A A C T A G C A T A A C C C C T T G G G G C C T C T A A A C G G G T C T T G A G G G G T T T T T T G 
  P     K     G     S     *     V     G     C     C     H     R     *     A     I     T     S     I     T     P     W     G     L     *     T     G     L     E     G     F     F   
Bpu1102I
 
A G A T C T C G A T C C C G C G A A A T T A A T A C G A C T C A C T A T A G G G G A A T T G T G A G C G G A T A A C A A T T C C C C T C T A G A A A T A A T T T T G T T T A A C T T T A A G A A G G A G 
A T A T A C C A T G G G C A G C A G C C A T C A T C A T C A T C A T C A C A G C A G C G G C C T G G T G C C G C G C G G C A G C C A T A T G G C T A G C A T G A C T G G T G G A C A G C A A A T G G G T 
M e t G l y S e r S e r H i s H i s H i s H i s H i s H i s S e r S e r G l y L e u V a l P r o A r g G l y S e r H i s M e t A l a S e r M e t T h r G l y G l y G l n G l n M e t G l y 
C G C G G A T C C G A A T T C G A G C T C C G T C G A C A A G C T T G C G G C C G C A C T C G A G C A C C A C C A C C A C C A C C A C T G A G A T C C G G C T G C T A A C A A A G C C C G A A A G G A A 
A r g G l y S e r G l u P h e G l u L e u A r g A r g G l n A l a C y s G l y A r g T h r A r g A l a P r o P r o P r o P r o P r o L e u A r g S e r G l y C y s E n d G l n S e r P r o L y s G l y 
G C T G A G T T G G C T G C T G C C A C C G C T G A G C A A T A A C T A G C A T A A C C C C T T G G G G C C T C T A A A C G G G T C T T G A G G G G T T T T T T G 
S e r E n d V a l G l y C y s C y s H i s A r g E n d A l a I l e T h r S e r I l e T h r P r o T r p G l y L e u E n d T h r G l y L e u G l u G l y P h e P h e 
BgIII T7 promoter lacI Xbal rbs
Nco1 Nhe1
BamH1EcoR1
lacI
Xho1
Eag1
Not1HindIIISal1Sac1
N terminal his6 tag TEV cleavage site
terminal his6 tag
Spe1
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2.6 Genotypes 
Table 2-4: Cell strains and corresponding genotypes used in cloning (DH5, XL10 gold) and protein 
expression (BL21 (DE3), BL21* (DE3), C41 (DE3)). 
Cell Strain Genotype 
DH5 F– Φ80lacZΔM15 Δ(lacZYA-argF) U169 recA1 endA1 hsdR17 (rK–, mK+) 
phoAsupE44 λ– thi-1 gyrA96 relA1 
XL10 gold Tetr ∆(mcrA)183∆(mcrCB-hsdSMR-mrr)173 endA1 supE44 thi-1 recA1 
gyrA96 relA1 lac Hte [F ́ proAB lacIqZ∆M15Tn10 (Tetr) Amy Camr] 
BL21 (DE3) F– ompThsdSB(rB–, mB–) gal dcm(DE3) 
BL21* (DE3) F– ompThsdSB(rB–, mB–) gal dcm rne131 (DE3) 
C41 (DE3) F– ompThsdSB(rB–, mB–) gal dcm(DE3) 
 
2.7 Molecular biology 
2.7.1.1 Polymerase Chain Reactions (PCRs) 
PCR mixtures were made using the recipe from Table 2-5. 
Table 2-5: Recipe for PCR. 
Component Volume/ μl 
H2O 43.2 
10 Polymerase Buffer + MgSO4 5 
DNA template 0.2 
25 mM dNTPs 0.4 
Forward primer 0.5 
Reverse primer 0.5 
PWO enzyme 0.2 
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2.7.1.2   Site-directed mutagenesis 
Site-directed mutants were made following the program settings previously used by 
Shim et al.
[53]
 with the exception of the annealing temperature that was altered from 65 
°C to 55 °C.  The program is shown in Table 2-6.  
 
Table 2-6: PCR program used for site-directed mutagenesis of human ATIC.  Denaturing, annealing and 
extension steps were cycled 16 times. 
Cycle stage Temperature/ °C Time 
Initial denaturing 95 30 s 
Hot start Disabled - 
Denaturing 95 30 s 
Annealing 55 1 min 
Extension 68 14 mins 
Final extension Disabled - 
Final hold 4 ∞ 
 
2.7.1.3   Truncation mutants 
PCR was performed using the general program in Table 2-7.  Variations in primer 
annealing temperatures were used for individual reactions and are stated in the results 
section. 
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Table 2-7: The PCR program used for the truncation mutants of human ATIC.  Denaturing, annealing and 
extension steps were cycled 35 times. 
Cycle stage Temperature (°C) Time 
Initial denaturing 95 30 s 
Hot start Disabled - 
Denaturing 95 30 s 
Annealing Specified in results section 1 min 
Extension 68 2 min 
Final extension Disabled - 
Final hold 4 ∞ 
2.7.1.4 Agarose gel electrophoresis 
Agarose gels between 0.6% and 1.5% (w/v) were used to analyse and purify DNA 
samples.  The following protocol makes 40 ml of 1.2% (w/v) agarose gel solution. 
Agarose (480 mg) was dissolved in 1  TAE buffer (50 ml) by heating at 800 W in a 
microwave for 30 second intervals.  When dissolved, the solution was made up to 40 ml 
with 1  TAE buffer, to which ethidium bromide (1.33 l) was added, mixed and 
poured into gel casting apparatus, adding a comb to create loading wells.  Once set 
(approximately 20 mins), the comb was removed and the gel transferred to the BioRad 
running apparatus.  The gel was covered with 1  TAE buffer and the samples (usually 
5 μl sample mixed with 1 μl 6  DNA loading buffer) and DNA marker added.  The 
apparatus was run at 100 V until the samples had moved to the area indicated by yellow 
tape (approximately 4 cm, taking 20 min).  All waste, gloves and used gels were 
disposed of in the ethidium bromide waste. 
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2.7.1.5 Purification of molecular biology grade DNA 
DNA was purified using QIAGEN QIAprep Spin Miniprep and QIAquick Gel 
Extraction kits following the protocol supplied by the manufacturer. 
2.7.1.6 QIAprep Spin Miniprep 
A pellet of bacterial cells from 5 ml overnight E. coli culture in LB medium was re-
suspended in P1 buffer (250 μl) and transferred to a 1.5 ml microcentrifuge tube.  To 
lyse the cells, P2 buffer (250 μl) was added and mixed 4-6 times by inversion causing 
the solution to go blue.  N3 buffer (350 μl) was added and immediately mixed 4-6 times 
by inversion.  The white precipitate formed was isolated by centrifugation (17,000 rcf, 
10 min) and the supernatant was applied to a QIAprep spin column before further 
centrifugation (17,000 rcf, 1 min).  The flow through was discarded and the column 
washed first with PB buffer (500 μl) followed by PE buffer (750 μl) with centrifugation 
(17,000 rcf, 1 min) after each wash.  The column was centrifuged (17,000 rcf, 1 min) to 
remove any residual buffer before being transferred to a clean microcentrifuge tube.  
Sterile H2O or elution buffer EB (50 μl) was applied to the centre of the column, 
incubated at room temperature for 1 min before the column was centrifuged (17,000 rcf, 
1 min) to elute the purified DNA which was stored at −20 °C. 
2.7.1.7 QIAquick Gel Extraction  
DNA samples were separated by agarose gel electrophoresis at 100 V and visualised by 
irradiation with UV light.  Irradiation was kept to a minimum to preserve the DNA.  Gel 
segments containing the DNA of interest were isolated using a razor blade and weighed 
in 1.5 ml microcentrifuge tubes.  The gel segments were dissolved by adding QG buffer 
(three equivalents to the weight of the gel segment) which was heated at 50 °C with 
intermittent mixing by vortex.  One equivalent of isopropanol was added to the 
dissolved solution, which was then applied to a QIAprep spin column and centrifuged 
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(17,000 rcf, 1 min).  The flow through was discarded and QG buffer (500 μl) was 
applied to the column to remove any remaining agarose and centrifuged (17,000 rcf, 1 
min).  The flow through was discarded and the column washed with PE buffer (750 μl) 
and left at room temperature for 5 mins before centrifugation (17,000 rcf, 1 min).  The 
flow through was discarded and the column centrifuged (17,000 rcf, 1 min) to remove 
any residual buffer.  The column was transferred to a clean 1.5 ml microcentrifuge tube 
and sterile H2O or elution buffer EB (30 μl) added to the centre of the column.  After 
incubating at room temperature for 1 min the column was centrifuged (17,000 rcf, 1 
min) to elute the purified DNA sample which was stored at −20 °C. 
2.7.1.8 Restriction digests 
All buffers and enzymes used for restriction digests were supplied by New England 
Biolabs (NEB).  Single digests were prepared following the recipe in Table 2-9 and 
double digests were prepared following the recipe in Table 2-8.  Reaction mixtures were 
incubated at 37 °C for at least 90 min.  Agarose gel electrophoresis was used to ensure 
the reactions had gone to completion.  The restriction enzymes were deactivated by 
incubation at 80 °C for 20 min. 
 
Table 2-8: Recipe for single restriction digests.  The digest buffer used is that recommended by NEB. 
Component Volume/ μl 
10 digest buffer (+BSA) 2 
DNA sample 2 
H2O 15 
Restriction enzyme 1 
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Table 2-9: Recipe for double restriction digests.  The digest buffer used is that recommended by NEB as 
being compatible with both restriction enzymes 
Component Volume/ μl 
10 digest buffer (+BSA) 2 
DNA sample 10 
H2O 4 
Restriction enzyme 1 2 
Restriction enzyme 2 2 
 
2.7.1.9 Ligation reactions 
The ligation reaction was left to incubate overnight at 4 °C and set up according to the 
recipe in Table 2-10.  Ligation reactions used 1 μl pET28a vector (1-17.5 ng) with insert 
in a 3:1 insert to vector ratio.  2 μl of the ligase mixture was transformed into 10 μl 
XL10-Gold competent cells using the heat shock method. 
Table 2-10: Ligation reaction recipe 
Component Volume/ μl 
5 ligation buffer 2 
pET28a vector 1 
Insert x 
T4 ligase 1 
H2O 10-x 
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2.8 Sequencing and in silico tools 
All DNA was submitted for sequencing to GATC Biotech.  Sequence alignments were 
confirmed using the ClustalW
[121]
 alignment program in BioEdit software.  Molecular 
masses and theoretical extinction coefficients for the expressed protein were calculated 
using ExPASy ProtParam
[123]
.  For human ATIC =54820 M-1 cm-1, and for avian ATIC 
=50350 M-1 cm-1. 
2.9 Protein expression 
2.9.1.1 Rubidium chloride competent cells 
All chemically competent cell preparation was conducted under sterile conditions.  
Starter cultures of LB (5 ml) were inoculated with the competent cell strain required and 
incubated at 37 °C with shaking overnight.  The starter culture (1 ml) was added to LB 
(500 ml) and incubated with shaking at 37 °C until an OD A600 reading of 0.5 was 
reached.  The media was cooled on ice for 15 min before the cells were harvested by 
centrifugation (JLA- 9.1000, 4500 rpm, 10 min, 4 °C).  The pellet was re-suspended in 
Tbf1 (30 ml) and incubated on ice for 15 min before the cells were re-harvested by 
centrifugation (JLA- 9.1000, 4000 rpm, 5 min, 4 °C).  The pellet was re-suspended in 
Tbf2 (6 ml) and the chemically competent cells were flash frozen in liquid nitrogen 
before storage at −80 °C in 100 μl aliquots.  C41 (DE3), BL21 (DE3), BL21* (DE3), 
and DH5 competent cells were prepared. 
2.9.1.2 Transformations 
All transformations were carried out under sterile conditions at 4 °C unless otherwise 
stated.  Plasmids (1 μl) were added to chemically competent E. coli BL21(DE3), 
BL21*(DE3), C41(DE3) or DH5 (50 μl), incubated on ice for 10 minutes and then 
heated at 42 °C for 45-60 seconds before returning to ice for a further 10 minutes.  LB 
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(900 μl) was added and the cells incubated at 37 °C with shaking for 60-90 minutes.  A 
small sample (100 μl) was plated on agar (LBK) plates and incubated overnight at 
37 °C.  The plates were sealed and stored at 4 °C. 
2.9.1.3 Protein overexpression 
Starter cultures of LB (5 ml) inoculated with kanamycin (50 μg/ml) and one colony 
from the plates, under sterile conditions, were incubated at 37 °C with shaking 
overnight.  The starter cultures were added to auto-inducing media (1 l) with kanamycin 
(final concentration 50 μg/ml) and incubated at 30 °C with shaking overnight.  The cells 
were harvested by centrifugation (JLA- 9.1000, 6000 rpm, 30 min, 4 °C) and stored at 
−80 °C. 
2.10 Protein purification protocols 
2.10.1.1 Cell disruption 
The frozen cell pellet was re-suspended in lysis buffer on ice.  Recombinant DNase 1 
(5,000 units/l) was added to the lysis buffer.  The cell suspensions were lysed using the 
Constant cell disruption system (20 psi, 5 ml injections).  Alternatively, the cell 
suspensions were lysed by sonication (40% power, 6 min).  The cell debris was 
sedimented by centrifugation using 50 ml Oak Ridge style centrifuge tubes (JA- 25.50, 
16,000 rpm, 40 min) and the supernatant decanted and stored on ice before purification.   
2.10.1.2 Ni-NTA column 
The Ni-NTA resin (5 ml) was equilibrated with lysis buffer; the protein lysates loaded 
and non-binding fractions collected.  Lysis buffer (40 ml) followed by wash buffer (40 
ml) were applied to the column and wash fractions collected.  Elution buffer was 
applied to the column and fractions containing protein (5 ml) were collected.  Elution 
fractions were analysed by Bradford assay and SDS-PAGE.  The column was 
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regenerated with 0.1% SDS (25 ml), 0.1 M NaOH (25 ml), 10 mM EDTA (25 ml), H2O 
(100 ml), 500 mM NiSO4 (10 ml), H2O (50 ml) and lysis buffer (50 ml).  For storage 
the column was left in 20% EtOH (50 ml) at 4 °C. 
2.10.1.3 Gel filtration 
The fractions containing the ATIC protein obtained from the Nickel-affinity column 
were concentrated to a volume of 1 ml via centrifugal concentration (Vivaspin and 
Amicon) and applied to a 26/60 Superdex 200 gel filtration column using a Pharmacia 
AKTÄ FPLC system.  The purified ATIC was eluted using 50 mM Tris.HCl pH 7.4, 25 
mM KCl buffer (or 50 mM Tris.HCl pH 7.4, 5 mM KCl buffer) at a rate of 1.0 ml/min, 
larger protein fragments being eluted first.  Fractions were identified using UV 
absorbance (280 nm) and SDS-PAGE.  Smaller volumes of protein (100 μl) were 
purified using a 10/300 Superdex 200 gel filtration column eluted at a rate of 0.5 
ml/min.   
2.11 Gel electrophoresis- denaturing SDS-PAGE 
2.11.1.1 Casting the gel 
SDS-polyacrylamide gel electrophoresis was performed using the BioRad tetragel 
apparatus (1 mm plates).   
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Table 2-11: Components and quantities for denaturing SDS-PAGE resolving and stacking gels (casts 2 
gels using 1.0 mm casting plates). 
  10% resolving gel 5% stacking gel 
Component  Volume/ ml Volume/ ml 
    
H2O  4 2.45 
30% (v/v) acrylamide/bisacrylamide mix 
(37.5:1) 
 3.3 0.67 
1.5 M Tris (pH 8.8)  2.5 - 
1 M Tris (pH 6.8)  - 0.75 
10% (w/v) sodium dodecyl sulfate  0.1 0.04 
15% (w/v) ammonium persulfate  0.1 0.04 
Tetramethylethylenediamine 0.005 0.005 
 
10% SDS-PAGE gels were prepared as in Table 2-11 with the addition of APS and 
TEMED just before pouring the gel.  Gels were poured to approximately ¾ the height 
of the plate and water saturated butanol (5 μl) added to the surface.  The gel was left to 
set (10-20 minutes) before the butanol was removed (washed with water and blotted 
with filter paper).  A 5% stacking gel was prepared as in Table 2-11, again with the 
addition of TEMED immediately prior to pouring the gel.  The gels were poured on top 
of the separating gel, the comb inserted and left until set. 
2.11.1.2 Preparing, running and processing the gels 
Protein samples (15μl) were added to an equal volume of SDS loading buffer and 
heated at 95 °C for 10 minutes (Digital Dry Bath-Labnet).  Samples (10 μl) were loaded 
into different lanes of the SDS-PAGE gel using a syringe, along with a Molecular 
Weight Marker (10 μl). 
An appropriate volume of SDS-PAGE running buffer was poured into the apparatus (as 
indicated on the apparatus).  The gel was run at a limiting power of 200 V, until the blue 
stained samples were seen to reach the bottom of the gel (30-50 minutes). 
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The gel was separated from the glass plates and the top stacking gel removed.  
Coomassie Blue stain was added to the gel and heated (20 secs, 800 W) before being 
left to rock at room temperature (1 hour+).  The stain was then removed and Coomassie 
destain added and left again at room temperature (usually overnight) until the bands on 
the gel could be clearly seen.  The gel was imaged using trans-white illumination in the 
Molecular Imager® Gel Doc
TM
 XR. 
2.12 UV-vis spectrometry 
The following experiments were carried out using a Varian Cary 50 Bio UV-visible 
spectrophotometer and a quartz cuvette (1 ml or 600 l). 
2.12.1.1 Determining enzyme concentrations 
The absorbance at 280 nm of 1 ml of protein sample, or a known volume of sample 
made up to 1 ml or 600 μl with potassium buffer, was measured using the ‘scan’ 
program between 300-260 nm.  The baseline was set using a cuvette containing buffer 
without any protein.  The concentration of enzyme was determined via Beers Law. 
 clA   (2-1) 
Where A= absorbance, ε= molar extinction coefficient (M-1cm-1), c= concentration (M) and l= path 
length (cm) 
In this case; A= measured value per ml, l= 1 cm and = 54820 M-1cm-1 for human 
ATIC, and  = 50350 M-1cm-1, as determined from the protein sequence. 
 
2.12.1.2 Determining DNA concentrations 
DNA concentration was determined by measuring UV absorption at 260 nm, 280 nm 
and 320 nm.  Measurements were obtained using a 50 μl quartz cuvette, a blank sample 
of 50 μl H2O was used to zero the readings. 
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𝐶𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛 (𝜇𝑔 ⁄ (𝑚𝑙) = (𝐴260 − 𝐴320) × dilution factor × (ss or ds) (2-2) 
Where ss denotes single stranded DNA (equal to 35), and ds denotes double stranded DNA (equal to 50). 
 
2.12.1.3 Standard ATIC assay 
The absorbance of the tetrahydrofolate at 298 nm was used to measure the turnover of 
the reaction.  Different solutions were prepared, each to a volume of 1 ml or 600 μl 
depending on the size of cuvette used.  For a basic assay potassium buffer was used (25 
mM KCl) along with enzyme, AICAR and 10-formyl tetrahydrofolate.  The conversion 
of 10-formyl tetrahydrofolate to tetrahydrofolate is measured by an increase in 
absorption at 298 nm.  Therefore the rate of AICAR transformylase activity can be 
measured as a change in absorbance at 298 nm.  Scans were conducted using the 
scanning kinetics program operating at 298 nm for 5 minutes.  The rate was measured 
using the ‘ruler least squares’ function in the Cary WinUV software to measure the 
gradient of the change in absorbance. 
The initial scan which measured the solution of buffer, AICAR and enzyme was first 
determined to be flat (no turnover) before 10-formyl tetrahydrofolate was added to 
initiate catalysis, and returned immediately to the beam after a few inversions of the cell 
to mix. 
2.12.1.4 EnVision Plate Reader assay 
A two-dimensional assay was developed to simultaneously determine the substrate and 
cofactor KMs.  A 96-well plate format was designed to contain 48 different assay 
conditions, with increasing cofactor across the columns (left to right) and increasing 
substrate with descending row (A to H).  Table 2-12 summarises the volumes and 
components dispensed into each well. 
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Table 2-12:  Volumes of each solution dispensed into a 96 well plate by a Hamilton Microlab Star robot.  
Each row contains six different assay conditions, in duplicate.  The volume of folate cofactor added 
increases across the columns, left to right.  The total volume of the well decreases with descending row; 
row A is 195 l, B is 190 l, C is 180 l, D is 170 l, E is 160 l, F is 150 l, H is 140 l and I is 120 l.  
AICAR substrate was added to give a total well volume of 200 μl. 
  1 2 3 4 5 6 7 8 9 10 11 12 
A 
Buffer 175 175 165 165 155 155 145 145 125 125 105 105 
Enzyme 10 10 10 10 10 10 10 10 10 10 10 10 
Folate 10 10 20 20 30 30 40 40 60 60 80 80 
B 
Buffer 170 170 160 160 150 150 140 140 120 120 100 100 
Enzyme 10 10 10 10 10 10 10 10 10 10 10 10 
Folate 10 10 20 20 30 30 40 40 60 60 80 80 
C 
Buffer 160 160 150 150 140 140 130 130 110 110 90 90 
Enzyme 10 10 10 10 10 10 10 10 10 10 10 10 
Folate 10 10 20 20 30 30 40 40 60 60 80 80 
D 
Buffer 150 150 140 140 130 130 120 120 100 100 80 80 
Enzyme 10 10 10 10 10 10 10 10 10 10 10 10 
Folate 10 10 20 20 30 30 40 40 60 60 80 80 
E 
Buffer 140 140 130 130 120 120 110 110 90 90 70 70 
Enzyme 10 10 10 10 10 10 10 10 10 10 10 10 
Folate 10 10 20 20 30 30 40 40 60 60 80 80 
F 
Buffer 130 130 120 120 110 110 100 100 80 80 60 60 
Enzyme 10 10 10 10 10 10 10 10 10 10 10 10 
Folate 10 10 20 20 30 30 40 40 60 60 80 80 
G 
Buffer 120 120 110 110 100 100 90 90 70 70 50 50 
Enzyme 10 10 10 10 10 10 10 10 10 10 10 10 
Folate 10 10 20 20 30 30 40 40 60 60 80 80 
H 
Buffer 100 100 90 90 80 80 70 70 50 50 30 30 
Enzyme 10 10 10 10 10 10 10 10 10 10 10 10 
Folate 10 10 20 20 30 30 40 40 60 60 80 80 
 
These studies were based on the standard assay protocol but used a black, clear-
bottomed Greiner bio-one micro assay 96 well plate (transparent to 260 nm) and 
measured absorbance at 296 nm using an EnVision Multilabel Plate Reader.  An 
exclusion filter, ‘Photometric 300’, was used to allow only light of wavelength 300 ± 20 
nm to reach the detector.  A single row of the 96-well plate was processed at a time.  
AICAR substrate was dispensed across the columns (left to right) at a speed of 200 μl/s.  
The volume of AICAR dispensed was different for each row, to ensure a final well 
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volume of 200 l.  The plate was then subjected to a five second shake operation, in an 
orbital motion.  The absorbance at 296 nm was then measured in each well, moving 
from left to right across the columns.  This method of measuring absorbance from left to 
right was then repeated for a minimum of 12 minutes.  Data was exported using 
EnVision Workstation version 1.09 and analysed using Microsoft Excel.   
2.12.1.5 Measuring Potassium dependence 
The assay was conducted as in 2.12.1.3, but this time two buffers were used to vary the 
concentration of potassium in final assay mixture, the potassium buffer (25 mM KCl) 
and the zero potassium buffer (0 mM KCl).  The AICAR and 10-formyl 
tetrahydrofolate substrates were made up using the zero potassium buffer whilst the 
enzyme was stored in the potassium buffer.  Human ATIC was purified in 5 mM KCl 
containing buffer, hence the lowest concentration of KCl in the assay was limited by the 
dilution of the enzyme stock solution into the assay mixture. 
A similar approach was taken to investigate the effect of various metal cations on 
human ATIC.  This experiment was conducted on a single purification batch of human 
ATIC in 5 mM KCl.  This enzyme stock was diluted into the assay mixture to give a 
background concentration of 83 nM KCl.  Metal chloride solutions (KCl, NaCl, LiCl, 
RbCl, CsCl, MgCl2 and CaCl2) were added to the assay mixture to achieve a final 
concentration of 1 mM.  Samples containing human ATIC, AICAR substrate and metal 
chloride were either incubated at 25 °C for 3 minutes, or incubated for 20 minutes on 
ice before 5 minutes at 25 °C.  The reaction was initiated by addition of 10-formyl 
tetrahydrofolate, and the increase in absorbance at 298 nm was measured. 
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2.12.1.6 TEV cleavage reaction 
Protein bearing a TEV cleavage site was incubated with TEV (0.2 molar equivalents) at 
room temperature in TEV buffer until the reaction was complete (2 h), as measured by 
electrospray ionisation mass spectrometry. 
2.12.1.7 Sortase labelling reaction 
Protein bearing an N-terminal glycine was incubated with fluorescently labelled peptide 
(3.5 molar equivalents) and Sortase A (0.2 molar equivalents) in sortase buffer at room 
temperature until the reaction was shown to be complete by electrospray ionisation 
mass spectrometry (approximately 7 h). 
2.13 Isothermal Titration Calorimetry (ITC) studies 
A VP-ITC MicroCalorimeter (MicroCal) and VPViewer and Origin software were used. 
2.13.1.1 ITC theory 
Isothermal Titration Calorimetry (ITC) can be used to measure protein affinities for 
known ligands and other small molecules of interest.  The affinity is related to the 
change in thermal energy that is generated upon ligand binding, as either a release of 
energy (exothermic) or intake of energy (endothermic).  The ITC experimental set-up is 
shown in Figure 2-3; it consists of a reference cell that contains water or buffer, a 
sample cell containing the receptor species of interest and a syringe which is used to 
inject the ligand in to the sample cell in a controlled manner.  The syringe also stirs the 
sample cell contents at a constant rate to ensure thorough mixing during the experiment.  
These cells are held within an adiabatic shield, and have a heater for each cell to allow 
the temperature of each cell to be controlled.  The temperature of both cells is 
maintained by a power supply to the heaters; if a heat change occurs in the sample cell, 
such as that caused by ligand binding, then the power supply is adjusted to ensure the 
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temperature returns to that of the reference cell.  The ligand is injected to the sample 
cell in stages; a normal experiment would involve around 20 injections, during which 
the variations in power supply are recorded.  The magnitude of the change in 
temperature, measured by the change in resulting power supply, corresponds to dilution 
of the ligand into the sample cell and the enthalpy of binding of the ligand to sample.  
The concentrations used in ITC are designed to achieve binding saturation before the 
completion of the experiment.  The initial injections are accompanied by a large heat 
change which requires a large variation in power supply to maintain the temperature 
between sample and reference cells, whereas the final injections cause a smaller heat 
change as the receptor sites are now saturated with ligand which is measured as a 
smaller variation in the power supply.  Analysing the changes in power supply over the 
course of the ligand injections gives information on the rate constant, enthalpy and 
stoichiometry of binding. 
 
When considering a 1:1 ligand:receptor binding model (M + X ↔ MX ), the data 
obtained from the titration experiment is fitted using the Wiseman isotherm
[124]
 
(Equation 2-3). 
dQ
d[X]t
= ∆HV0 [
1
2
+
1-XR-r
2√(1+XR+r)2-4XR
] 
  
(2-3) 
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Where: 
 Q = heat of the system 
 [𝑋]𝑡 = ligand concentration 
 H = change in enthalpy 
 V0 = volume of the sample cell 
 𝑋𝑅 =
[𝑋]𝑡
[𝑀]𝑡
 
[𝑀]𝑡 = receptor concentration 
 𝑟 =
1
𝑐
=
1
𝐾𝑎[𝑀]𝑡
=
𝐾𝑑
[𝑀]𝑡
 
 Ka = association constant 
 Kd = dissociation constant 
 c = Wiseman constant 
 
The Wiseman constant c is the ratio of the receptor concentration to the dissociation 
constant, Kd.  For receptors that have several identical non-interacting binding sites, 
𝑐 = 𝑛𝐾𝑎[𝑀]𝑡, where n is the number of binding sites per receptor molecule.  With low 
c systems, greater equivalents of ligand are needed to reach receptor saturation
[125]
. 
The Gibbs free energy and entropy of binding can be determined by the following 
equations: 
∆𝐺 = −𝑅𝑇 ln𝐾𝑎 
∆𝑆 =
∆𝐻 − ∆𝐺
𝑇
 
Where R = ideal gas constant and T = temperature. 
(2-4) 
(2-5) 
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Figure 2-3: Schematic of the Isothermal Titration Calorimetry (ITC) equipment.  The reference cell is 
filled with water or buffer.  The receptor is loaded into the sample cell.  To this the ligand is injected by 
the syringe, which also continuously stirs the sample cell. 
2.13.1.2     ITC200 experimental 
Matched buffers were used for ligand and cell solutions, which were equilibrated to 25 
°C.  The buffer containing a known concentration of the protein of interest was injected 
into the sample cell (volume ~200μl) using a gas-tight syringe, ensuring no air bubbles 
were left in the cell.  The buffer containing a known concentration of ligand was drawn 
into the injection syringe using the loading syringe.  The injection syringe was then 
placed into the sample cell and suitable parameters entered into the VPViewer program 
along with the concentrations present in each component.  Typically ITC experiments 
were conducted at 25 °C and at a stirring speed of 1000 rpm.  Titrations involved an 
initial 2 μl injection followed by 18 × 10 μl injections with a 180 s delay between each 
injection.  The ‘fast equilibrium’ and ‘auto’ boxes were checked so the injections started 
as soon as the instrument had equilibrated to a steady baseline.  The results were 
analysed using the fitting routines provided in microcal origin 7.0. 
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2.14 Differential Scanning Calorimetry 
Differential scanning calorimetry was used to provide a qualitative analysis of human 
ATIC stability using a MicroCal VP-DSC.  The temperature was cycled between 10 °C 
and 100 °C, at a rate of 90 °C/hour.  The DSC cycling was started the evening before, 
using degassed water to ensure that the thermal history of the cells and between scans 
remains constant.  The Thermovac used to degas samples and the buffer reference was 
set to 10 °C for two cycles of 8 minutes.  Cells were thoroughly rinsed with water (3), 
buffer (2) and degassed buffer (1) before filling with the degassed sample.  Cell 
filling was conducted between 15 °C and 25 °C.  The sample cell contained human 
ATIC at 56 μM, or human ATIC (56 μM) with 1 mM AICAR.  Results were analysed 
using origin 7.0. 
2.15 Differential Scanning Fluorimetry 
Differential Scanning Fluorimetry (DSF) is a method that can be used to monitor the 
stability of proteins in solution
[126]
.  This method does not require a system that can 
reversibly fold and unfold.  Stability is related to the Gibbs free energy of unfolding, 
GU, which is temperature-dependent.  Where the protein is in equilibrium between 
native and unfolded states GU=0.  This is equivalent to the melting temperature of the 
protein, Tm.  The technique utilises certain dyes that are highly fluorescent in 
hydrophobic environments, such as the sites at the core of a protein that are revealed 
upon protein unfolding, but that have their fluorescence quenched in aqueous solution.  
Thus protein unfolding can be monitored as the increase of fluorescence intensity with 
temperature.  When fluorescence intensity is plotted as a function of temperature, this 
gives a sigmoidal curve similar to that shown in Figure 2-4.  Deviation from the curve 
at high temperatures (dotted green line) occurs due to aggregation of the protein sample.  
This aggregation releases some of the dye back into aqueous solution and so quenches 
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fluorescence.  The inflection point of the curve corresponds to the Tm and can be 
calculated using the Boltzman equation, or by determining the maximum of the first 
derivative.  DSF is often used to monitor the effects of ligands and other small 
molecules on Tm. 
 
Figure 2-4: Theoretical sigmoidal curve obtained from Differential Scanning Fluorimetry (DSF).  
Fluorescence intensity increases as a function of temperature upon binding of dye to hydrophobic regions 
of unfolding protein.  Melting temperature (Tm) is determined from where the equilibrium between folded 
and unfolded states is equal (dashed black line), which is when the Gibbs free energy of unfolding (GU) 
is zero.  In reality, Fluorescence intensity decays away as shown by the green dotted line as protein 
aggregates. 
SYPRO orange was chosen as the fluorescent dye due to its favourable properties when 
applied to this technique; it has a high excitation wavelength at 492 nm, so it is unlikely 
any small molecules to be examined will cause interference, high signal to noise ratio, 
and high fluorescence gain upon binding to hydrophobic regions (as demonstrated by a 
~500% gain when measuring the denaturation of lysozyme) 
[126]
.  The fluorescence 
emission was measured at 570 nm. 
DSF experiments were carried out in opaque 96 well plates with a sealed, clear lid to 
prevent evaporation of the samples and to enable visualisation of the SYPRO orange 
dye.  The measurements were taken using a real-time PCR machine to ensure a constant 
increase in temperature, starting at 25 °C and increasing by 1 °C/sec to a final 
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temperature of 100 °C.  The data were differentiated and normalised, to give a tallest 
peak that corresponds to the Tm. 
 
2.16 Analytical UltraCentrifugation (AUC) 
A sample volume of 405 μl and a reference volume of 410 μl were centrifuged in 1.2 
cm pathlength 2-sector aluminium centrepiece cells (sample in right hand sector, 
reference buffer in left hand sector) built with sapphire windows in a 4-place An-50 Ti 
analytical rotor running in an Optima XL-I analytical ultracentrifuge (48,000 rpm, 
20 C).  Different volumes were used to allow differentiation between the reference and 
sample cells.  Changes in solute concentration were detected by interference optics at 
280 nm.  A total of 150 scans per cell were collected.  Data were analysed using Sedfit 
and Sedphat software
[127].  Fitting parameters for the protein and buffer (‘HB’ buffer) 
were calculated using Sednterp from the primary sequence of the protein to give: 
7375.0~   ml/g, 010211.0  and 00736.1  g/ml. 
 
2.17  Mass Spectrometry 
Protein samples were analysed by electrospray ionisation mass spectrometry using a 
Bruker Daltonics® HCT Ultra™ mass spectrometer.  Samples were diluted 1:1 with 
99% acetonitrile, 1% formic acid to achieve a final concentration of between 10 and 50 
μM, and run using the ‘protein best sense method’.  Data were analysed using the 
Compass Open Access software and exported in pdf format. 
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2.18 Protein Crystallisation 
Protein crystallisation trials were conducted using a 2 μl + 2 μl hanging drop method in 
24 well plates.  The precipitating ‘mother liquor’ was dispensed into the well, each well 
contained different precipitating conditions.  2 μl drops of human ATIC at various 
concentrations were pipetted onto a glass cover slip, ensuring enough space between 
drops to prevent bleeding between drops.  2 μl of the mother liquor was then pipetted on 
top of the ATIC-containing drops, and mixed by being drawn back into the pipette tip 
four times.  The cover slip was then inverted over the appropriate well which contained 
the mother liquor mixed into the ATIC-containing drops on the cover slip surface.  
Vacuum grease was used to form a seal between the well and cover slip. 
The plates were left to incubate undisturbed at a constant temperature (a range of 
temperatures were investigated during the optimisation trials).  The drops were 
examined for crystal growth after 1 week, 2 weeks and 1 month. 
 
2.19 Chemistry experimental 
Peptide elongations were performed manually using standard Fmoc solid phase peptide 
synthesis as described by Chan and White
[128]
 using vaculate tubes (Alltech) and a 
vacuum manifold attached to a water aspirator. 
Low-loading Rink Amide resin (500 mg, 0.22 mmole/g) was swollen in DMF for at 
least 30 min.  The resin was separated by filtration. Amino acids used (in order of 
coupling) were: Fmoc- Asp-OAll;  Fmoc- Phe-OH;  Fmoc-Tyr(tBu)-OH;  Fmoc-
Arg(Pbf)-OH; Fmoc-Cys(Trt)-OH;  Fmoc-Val-OH.  The Fmoc-protected amino acid (5 
mmol) and HCTU (5 mmol) were dissolved in DMF (~10 ml). DIPEA (10 mmol) was 
added and the solution was transferred to the dry resin (0.11 mmol).  The mixture was 
gently agitated for 1 h.  The resin was isolated by filtration and washed with DMF (3  
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10 ml for 2 min).  The resin was treated with a solution of 20% piperidine in DMF (5 x 
10 ml x 2 min) to remove Fmoc protecting groups and then washed with DMF (5  10 
ml for 2 min). 
Allyl group removal was carried out under a nitrogen atmosphere. 
Tetrakis(triphenylphosphine)palladium(0) (29.43 mg, 25 mol%) and morpholine 
(200 μl, 2.2 mmole) in DMF (8 ml) were added to the resin and agitated with the 
nitrogen stream until deprotection was complete (22 h).  The resin was then filtered 
from the deprotection solution and washed with DMF (5  10 ml for 2 min).  A small 
sample of the resin was removed for use in the synthesis of the linear peptide. HCTU (5 
mmol) and DIPEA (10 mmol) were dissolved in DMF (~10 ml) and the solution added 
to the remaining resin and gently agitated at room temperature until cyclisation was 
complete (2 h). The resin was washed with DMF (5  10 ml for 2 min), DCM (3  10 
ml for 2 min) and MeOH (3  10 ml for 2 min) before being dried overnight under 
vacuum. 
The dried resin was treated with a cleavage cocktail of TFA/TIS/H2O/EDT 
(94:2.5:2.5:1) (15 ml) and the mixture was gently agitated for 1 h 45.  The resin beads 
were removed by filtration and rinsed with TFA.  The combined filtrates were added 
drop-wise to ice-cold Et2O (2  50 ml).  The orange precipitate was isolated by 
centrifugation (4000 rpm, 5 min) and washed with ice-cold Et2O (5  50 ml).  The crude 
peptide was dried under a stream of N2 to remove the remaining Et2O and lyophilized 
from MeCN.  The crude peptide (10.1 mg, 12%) was purified by preparative reverse 
phase HPLC (gradient elution t=0, MeOH:MeCN 95:5; t=35, 5:95 elution at 12.58 
min), lyophilised and purity confirmed by LCMS (calculated: 782.9, found: 783.6 [M]
+
) 
and analytical HPLC (Figure 2-5).   
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Figure 2-5: Analytical HPLC trace of the cyclic peptide to determine purification conditions. Elution at 
12.58 min 
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3 Characterisation of ATIC 
3.1 Introduction 
Since the discovery of ATIC activity in 1959
[6]
, the enzyme has been extensively 
studied, ultimately leading to the determination of the crystal structure
[46]
, which 
showed ATIC crystallises as a dimer which has a very large interface between 
monomers.  The crystal structure also showed ATIC has two distinct active sites, the 
second of which, AICAR transformylase, is formed by residues from both of the 
monomers.  Hence, AICAR transformylase activity is entirely dependent upon enzyme 
dimerisation.  To date, there have been no reports on the thermal stability of ATIC 
found in the literature. 
The kinetics of various ligands and inhibitors of ATIC have been examined, and a 
selection of results from the literature is presented in  
Table 3-1.  No experiments to determine the binding order or binding constants of the 
substrates and small molecules associated with ATIC have been reported in the 
literature. 
 
Table 3-1: Summary of some of the kinetic properties of various small molecules found in the literature. 
Ligand 
Human ATIC Avian ATIC 
KM/µM Ki/µM KM/µM 
AICAR 1.9 0.4[50], 16.8 1.5[31]
  1.9 0.4[53]
 
10-f-H4F 
39.0  6.0[50],, 60.2 
5.0
[31] 
 7.6 0.6[53]
 
AMP  27 3[50],
  
XMP  1.2 0.4[50],
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Further characterisation of ATIC was undertaken, to fill the gaps in understanding 
found in the literature.   
3.2 Protein purification 
Full length human and avian ATIC bearing N-terminal his tags were overexpressed in 
E. coli BL21(DE3), E. coli BL21*(DE3) and E. coli C41(DE3) strains growth in auto-
induction media for 24 h at 30 °C. Cells containing the overexpressed ATIC were 
harvested by centrifugation and stored at -80 °C.  The cells were resuspended in buffer, 
and lysed by sonication or cell disruption, and the lysates cleared by centrifugation 
before further purification. 
Ni-NTA affinity chromatography under gravity flow was used to purify the protein of 
interest from the crude lysates after cell disruption, as described in Chapter 2.  Crude 
protein lysates were applied to the column to bind the his(6)-tagged proteins before the 
column was washed step-wise with increasing concentrations of imidazole (50 and 150 
mM).  The protein was then eluted with 250 mM imidazole.  Fractions were analysed 
for protein content by using a Bradford dye binding assay, and then for protein purity by 
SDS-PAGE.  Figure 3-1a shows a typical 10% SDS-PAGE analysis of the fractions 
collected during the purification of human ATIC using Ni-NTA affinity 
chromatography.  The elution fractions (lane 7, and onwards) show a high concentration 
of a protein at approximately 66 kDa, consistent with the monomer molecular weight of 
human ATIC (including the his(6)-tag) of 66.8 kDa.  Some trace impurities are present in 
the elution fractions after the affinity purification.  To remove these remaining 
impurities, the fractions containing ATIC were combined and concentrated using 
centrifugal concentrators, prior to further purification by size exclusion 
chromatography. 
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Figure 3-1: a) SDS-PAGE of the purification of human ATIC from E. coli using a gravity flow NTA 
column. Lane 1: molecular weight marker, lane 2: flow through 1, lane 3: flow through 2, lane 4: flow 
through 3, lane 5: wash 1 (10 mM imidazole), lane 6: wash 2 (150 mM imidazole), lanes 7-14: elution 
fractions 1 to 8 (5 ml) 
b) Absorption at 280 nm of size exclusion purification.  Human ATIC is shown in red and has an elution 
volume of 13.79 ml.  Avian ATIC is shown in blue with an elution volume of 14.4 ml. 
c) Mass spectrum of human ATIC reported a mass of 66669.5 kDa, the bottom panel is a expanded view 
of the 700 to 1300 m/z region. 
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The size exclusion chromatography was performed using a Pharmacia AKTA FPLC 
system, using either a 26/60 Superdex 200 column or 10/300 Superdex 200 column 
depending on the scale of protein preparation.  Elution typically yielded a single 
monodisperse peak.  Figure 3-1 shows a typical trace for purification of human (red) 
and avian (blue) ATIC using a 10/300 Superdex 200 column (used for smaller scale 
protein preparations), where pure protein was collected in 1 ml fractions from 13 to 
15 ml elution volume.  Protein purity was reassessed and confirmed by SDS-PAGE 
analysis, and the protein identity was confirmed by electrospray ionisation mass 
spectrometry. 
The approximate size, and therefore the oligomeric state of the samples purified by size 
exclusion can be determined from the retention time.  The analytical Superdex 200 
10/300 gel filtration column was therefore calibrated using molecular weight standards 
(Sigma Aldrich), as shown in Figure 3-2b, to give an appropriate range of data to create 
a calibration curve (Figure 3-2a).  Thyroglobulin (red line), shows a small amount of 
aggregated protein which elutes at the same volume as Blue dextran; this corresponds to 
the void volume of the column. 
To construct the calibration graph, the elution volumes for each of the marker proteins 
were normalised to the void volume, and plotted against the corresponding molecular 
weight (kDa).  This yields a logarithmic relationship that was fitted to an empirical 
equation of the form ln(Mw)= ln c - m (
Ve
V0
)  (Figure 3-2b).  The Molecular weight 
(Mw) was then calculated from the elution volume (Ve) of the species of interest. 
The size estimated by the size exclusion column (Table 3-2), shows human ATIC elutes 
at a volume that corresponds to a molecular weight of 110 kDa, which is larger than a 
monomer (66.8 kDa) but smaller than a dimer (133.6 kDa).  Estimation of molecular 
weight by size exclusion chromatography also depends on the shape of the protein of 
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interest.  Human ATIC is thought to elute at a slightly larger volume than would be 
expected for a dimer, due to its streamlined shape.  Avian ATIC appears to elute at a 
volume that corresponds to a molecular weight larger than a monomer (66.6 kDa), but 
smaller than a dimer (133.2 kDa) at 80 kDa.  This could suggest that the dimeric form 
of avian ATIC is also streamlined, but is more compact than human ATIC, or that it is 
eluting as a monomer. 
Rayl
31
 reports ATIC eluting as a 65.63 kDa species, but this was measured on a 
Superdex 75 column (eluted with 20 mM Tris-Cl pH 7.5, 150 mM NaCl, 50 mM KCl 
and 20% (v/v) glycerol) and was only calibrated using albumin (67 kDa), ovalbumin 
(43 kDa), chymotrypsin (25 kDa) and ribonuclease A (13.7 kDa), which will have 
resulted in a different calibration curve, and may have not calibrated for higher 
molecular weight species as effectively as the molecular weight standards chosen in this 
study. 
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Figure 3-2: Calibration of the GE Healthcare Superdex 200 10/300 gel filtration column with molecular 
weight standards. The elution traces of seven standards of known molecular weight, monitored at 280 nm, 
are reported in (a): blue dextran (2000 kDa), thyroglobulin (669 kDa), apoferritin (443 kDa),  amylase 
(200 kDa), alcohol dehydrogenase (150 kDa), albumin (66 kDa), and carbonic anhydrase (29 kDa).  The 
elution volume of each standard is plotted against molecular weight to give a calibration curve (b) with 
equation  lny = ln13983-4.59x .  Approximate molecular weights were calculated for human and avian 
ATIC by imputing the normalised elution volume (Ve/V0) into this equation. 
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Table 3-2: Estimation of molecular weight from size exclusion chromatography elution volume for 
human and avian ATIC 
Enzyme Ve/ml MW/kDa 
Human ATIC 13.79 110 
Avian ATIC 14.38 80 
 
The mass of human ATIC was determined by LCMS to be 66669.5 kDa, which is 
consistent with the human ATIC monomer after loss of the N-terminal methionine and 
the addition of a potassium ion (see Chapter 6).  The expected mass, as calculated from 
the sequence, of human ATIC including the his(6)-tag is 66779.2 kDa. 
 
3.3 Kinetic analysis 
ATIC catalyses both the formyl transfer reaction, which converts AICAR to FAICAR, 
and the subsequent cyclisation reaction to form IMP.  The formyl transfer reaction 
proceeds by the conversion of the folate cofactor 10-f-H4F to H4F.  Two assays for 
monitoring AICAR transformylase turnover are reported in the literature; a sensitive 
assay that uses radiolabeled substrates for which the products are then analysed by 
TLC
43
 and a spectroscopic assay reported by Black
[43]
.  This assay measures the rate of 
production of H4F from the turnover of 10-f-H4F which is equivalent to the rate of 
formation of FAICAR.  The reaction is monitored by an increase in absorption at 
298 nm.  Both folate compounds absorb at 298 nm but the increase arises from the 
difference in the extinction coefficients.  Figure 3-3 shows the absorption profile of the 
catalytic turnover of ATIC, an increase in absorption at 298 nm is seen as the reaction 
progresses. 
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Figure 3-3: Spectra following the catalytic turnover of AICAR transformylase converting 10-f-H4F to 
H4F.  The arrow indicates the increase in absorption at 298 nm. 
The AICAR Tfase activity in the forwards direction is measured as the aggregate with 
the IMPCH activity, which drives the reaction forward to completion. 
3.3.1.1 Standard spectroscopic assay 
A typical trace from a single assay of the turnover of ATIC is shown in Figure 3-4.  The 
absorption at 298 nm is recorded for a quartz cell containing the initial assay mixture of 
buffer, enzyme and AICAR; this corresponds to the flat line measured for the first 30 
seconds of Figure 3-4.  As there is no increase in absorption, this confirms there is no 
turnover taking place.  Then the cell is removed from the spectrophotometer and the 
cofactor 10-f-H4F is added to initiate the reaction.  The cell is inverted a few times to 
mix, and returned to the spectrophotometer to measure the increase in absorption.  The 
increase in absorption at 298 nm is caused by the conversion of 10-f-H4F to H4F, and is 
therefore a measure of the turnover of the enzyme. 
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Figure 3-4: A typical trace from the Varian Cary 50 Bio UV-visible spectrophotometer monitoring the 
catalytic reaction of ATIC. The turnover over of 10-f-H4F to H4F is measured at 298 nm. 
 
3.3.1.2 Considerations with 10-f-H4F 
10-f-H4F was synthesised either from 5,10-methenyl H4F, or in a two-step process from 
5-f-H4F via 5,10-methenyl H4F (Figure 3-5).  The three folate compounds are 
interconverted through pH driven reactions
[129]
.  10-f-H4F is synthesised by exploiting 
the equilibria of the reactions.  In the first reaction, 5,10-methenyl H4F is the dominant 
species under acidic conditions and is isolated under thermodynamic control.  The pH is 
then adjusted to alkaline (pH 8.8) to afford the 10-f-H4F cofactor.  The reactions are 
performed in the presence of the reducing agent -mercaptoethanol to prevent oxidation 
to the dihydrofolate cofactor.  10-f-H4F slowly reverts back to 5-f-H4F at room 
temperature, and faster at higher temperatures
[130]
.  With this in mind, 10-f-H4F was 
stored at 80 °C and each batch of compound was only used for a couple of days before 
discarding and replacing with a new batch. 
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Figure 3-5: The synthesis of 10-f-H4F from 5-f-H4F via the in situ formation of 5,10-methenyl H4F. 
 
The 10-f-H4F solution must be equilibrated for at least 1 hour before use in UV-visible 
studies. 10-f-H4F has a pH-dependent absorption profile, so if the 10-f-H4F is not 
equilibrated to the assay conditions (pH 7.4) then this will interfere with the rate 
measurements.  Figure 3-6 shows the initial scan (red line) of 10-f-H4F, diluted 1 in 10 
from the synthesis solution which has a pH of 8.8 into an assay buffer of pH 7.4.  Scans 
were then performed every 5 minutes for a total of 70 minutes.  The ATIC assay is 
measured at 298 nm, so if the folate cofactor was not at pH 7.4 before addition to the 
assay mixture an increase in absorption would be measured that corresponds to the pH 
equilibration, not the turnover of ATIC.   As can be seen from Figure 3-6, equilibration 
from pH 8.8 to pH 7.4 at 298 nm takes a minimum of 30 minutes; therefore a 1 hour 
equilibration time was used to ensure complete conversion. 
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Figure 3-6: A scan of the changing absorption profile of 10-f-H4F with pH, where red is the initial scan of 
100 μl of 10-f-H4F synthesis solution (pH 8.8) diluted into 900 μl assay buffer (pH 7.4) at 37 °C. 
Subsequent scans are taken every 5 min.  At 298 nm the absorption of the 10-f-H4F solution increases as 
it equilibrates to pH 7.4 (standard ATIC assay conditions). 
3.3.1.3 Determination of AICAR and 10-f-H4F KM 
Using the standard spectroscopic assay, the KM for AICAR was determined to be 3.75 ± 
0.65 μM at a fixed 10-f-H4F concentration of 66 μM at 37 C.  This value is within the 
range of values found in the literature of 1.9 μM[50] (measured at 25 C) and 16.8 
µM
[31]
.  The KM for the 10-f-H4F cofactor was determined to be 9.05 ± 0.45 µM (Figure 
3-8). 
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Figure 3-7: The effect of AICAR concentration on reaction rate of human ATIC at a fixed concentration 
of (6S)-10-f-H4F (66 μM) 
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Figure 3-8: The effect of (6S)-10-f-H4Fconcentration on reaction rate of human ATIC at a fixed 
concentration of AICAR (20 μM) 
 
3.3.1.4 Determination of a binding model 
To determine the binding model and order of binding of AICAR and 10-f-H4F, a 
method for measuring the kinetics in two dimensions was developed.  This high-
throughput method utilised the EnVision plate reader system, to determine the substrate 
KM and cofactor KM simultaneously, in a two-dimensional, 96 well plate format.  The 
ATIC assay protocol is shown in the methods section (Chapter 2), and involves 
dispensing the AICAR substrate to each well, a shake operation followed by repeated 
UV-visible absorption measurements.  The wavelength was chosen to be comparable 
with the standard ATIC assay (298 nm), and was achieved using a compatible filter of 
296 ± 3 nm.  The protocol was designed to conduct measurements on a single row of 
the plate at a time and to dispense a different amount of substrate for each row, to 
reduce error from a time delay in measurements that would arise from running 96 
assays at one time. 
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Data collected from the high-throughput assay using wild type ATIC were analysed 
using Origin 7.0 and fitted using Equation 3-10.  Figure 3-9 represents how the rate 
changes with varying AICAR and 10-f-H4F concentrations. 
 
 
        
Figure 3-9: a) 3D plot of how the catalytic rate of reaction varies with varying AICAR and 10-f-H4F 
concentrations for human ATIC, measured using the EnVision plate reader system.  b) 3D surface plot 
(shown for clarity). 
 
The data were fitted to a rapid equilibrium sequential ordered binding model, derived 
assuming the binding model shown in Equation 3-1, where E is the enzyme, A and B 
are the substrate and cofactor, EA is the enzyme-substrate or enzyme-cofactor complex, 
EAB is the enzyme-substrate-cofactor complex and P is the resultant product.  The 
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rapid equilibrium binding model assumes that the rate determining step is the chemical 
reaction, not the binding or release of the substrates or products. 
 𝐸 + 𝐴
𝐾1
↔𝐸𝐴 + 𝐵
𝐾2
↔𝐸𝐴𝐵
𝑘𝑐𝑎𝑡
→  𝑃 (3-1) 
 
𝐾1 =
[𝐸][𝐴]
[𝐸𝐴]
 
(3-2) 
 
𝐾2 =
[𝐸𝐴][𝐵]
[𝐸𝐴𝐵]
 
(3-3) 
 
[𝐸𝐴] =
𝐾2[𝐸𝐴𝐵]
[𝐵]
 
(3-4) 
 
[𝐸] =
𝐾1[𝐸𝐴]
[𝐴]
=
𝐾1𝐾2[𝐸𝐴𝐵]
[𝐴][𝐵]
 
(3-5) 
 𝐸0 = [𝐸] + [𝐸𝐴] + [𝐸𝐴𝐵] (3-6) 
 
𝐸0 =
𝐾1𝐾2[𝐸𝐴𝐵]
[𝐴][𝐵]
+
𝐾2[𝐸𝐴𝐵]
[𝐵]
+ [𝐸𝐴𝐵] 
(3-7) 
 
𝐸0 = (
𝐾1𝐾2
[𝐴][𝐵]
+
𝐾2
[𝐵]
+ 1) [𝐸𝐴𝐵] 
(3-8) 
 
𝑣 = 𝑘𝑐𝑎𝑡[𝐸𝐴𝐵] =
𝑘𝑐𝑎𝑡𝐸0
𝐾1𝐾2
[𝐴][𝐵]
+
𝐾2
[𝐵]
+ 1
=
𝑘𝑐𝑎𝑡𝐸0[𝐴][𝐵]
𝐾1𝐾2 + 𝐾2[𝐴] + [𝐴][𝐵]
 
(3-9) 
 
𝑣 =
𝑉𝑀[𝐴][𝐵]
𝐾1𝐾2 + 𝐾2[𝐴] + [𝐴][𝐵]
 (3-10) 
 
When the data obtained for the automated assay were fitted to Equation 3-10, the 
binding order for the ATIC reaction was determined to be A = AICAR and B = 10-f-
H4F.  The cofactor cannot bind before the substrate.  The rate constants were calculated 
as K1 = 14.1 ± 4.5 μM which is the constant at which the enzyme binds AICAR to form 
an enzyme-substrate complex, and K2 = 41.6 ± 11.9 μM which is the constant the  
enzyme–AICAR complex binds the 10-f-H4F cofactor: 
𝐸 + 𝐴𝐼𝐶𝐴𝑅
𝐾1
↔ [𝐸 − 𝐴𝐼𝐶𝐴𝑅] + 10fH4F
𝐾2
↔ [𝐸 − 𝐴𝐼𝐶𝐴𝑅 − 10fH4F]
𝑘𝑐𝑎𝑡
→  𝑃 
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These data therefore suggests that ATIC proceeds by an ordered binding mechanism, in 
which AICAR binds to the enzyme before the 10-f-H4F cofactor can bind.  After the 
enzyme-substrate-cofactor complex has formed ATIC catalyses the formation of 
FAICAR and H4F.  The associated rate constants measured for AICAR and 10-f-H4F 
through this two dimensional analysis are lower than the apparent KMs measured using 
the standard spectroscopic assay. 
 
3.4 Small molecule binding 
Isothermal Titration Calorimetry (ITC) can be used to measure protein affinities for 
known ligands and other small molecules of interest.  The affinity is calculated in terms 
of the change in thermal energy that is generated upon ligand binding, as either a release 
of energy (exothermic) or intake of energy (endothermic).  No binding affinities for any 
ligands of ATIC have been reported in the literature. 
 
The binding affinities of the substrate and cofactor for human and avian ATIC were 
measured by ITC, along with a selection of other small molecules.  AICAR is the 
natural substrate for ATIC, and IMP is the product of the two-step reaction catalysed by 
ATIC.  AMP is structurally analogous to both AICAR and IMP and is one of the 
downstream products of enzymatic reactions that use IMP as a substrate.  AMP is 
almost identical to IMP, having a primary amine in place of a carboxyl group.  XMP is 
structurally similar to IMP, but contains another amide group within its secondary ring 
structure.  In protein crystals of ATIC, electron density that matches XMP has been 
identified within the IMPCH binding site
[46]
.  10-f-H4F is the cofactor for ATIC and 
provides the formyl group that is attached to AICAR in the first catalytic step.  The in 
vivo cofactor is in the polyglutamated form, but this glutamate tail is too readily 
hydrolysed so 10-f-H4F has been used for this kinetic analysis.  PteGlu4 is identical to 
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the in vivo cofactor but crucially does not contain the formyl group required for 
catalysis.  This small molecule was chosen to investigate the role the polyglutamated 
tail plays in cofactor binding.  The results of the binding experiments conducted with 
these molecules with human and avian ATIC are shown in Table 3-3 and discussed 
below.
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Table 3-3: Binding affinities of ligands and small molecules with human and avian ATIC determined by ITC.  Measurements were taken using a MicroCal ITC200 at a constant 
temperature of 25°C.  Ligand:enzyme concentrations were adjusted as required to achieve saturation.  Data were fitted using MicroCal Origin
®
 software to calculate number of 
binding sites, dissociation constant and enthalpy of binding. 
 
 
Ligand 
Human ATIC Avian ATIC 
Ligand 
conc/ 
mM 
Enzyme 
conc/  
μM 
Number of 
sites 
Kd/ μM H/ kcal 
mol
-1 
Ligand 
conc/ 
mM 
Enzyme 
conc/  
μM 
Number of 
sites 
Kd/ μM H/ kcal 
mol
-1 
AICAR 1.2 60 0.78 ± 0.04 6.14 ± 1.37 -7.68 ± 0.38 1 35 1.23 ± 0.07 13.83 ± 2.15 -4.83 ± 0.35 
IMP 1.5 60 0.35 ± 0.06 53.19 ± 4.50 -8.39 ± 0.16      
XMP 1 60 1.67 ± 0.02 4.64 ± 0.37 -3.47 ± 0.06 2 26 2.02 ± 0.16 40.83 ± 4.10 -2.29 ± 0.21 
AMP 0.75 60 0.44 ± 0.03 8.40 ± 2.01 -3.54 ± 0.33 1 70 0.73 ± 0.03 10.96 ± 1.78 -3.14 ± 0.18 
10-f-H4F 1.96 60 1.12 ± 0.16 
120.92 ± 
11.48 
-7.53 ± 1.23 4.9 56 1.26 ± 0.36 
267.95 ± 
23.23 
-4.70 ± 0.32 
PteGlu4 1 60 0.96 ± 0.00 0.22 ± 0.03 -9.43 ± 0.06 0.5 56 0.96 ± 0.00 0.44 ± 0.02 -9.68 ± 0.03 
9
1
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Each monomer of ATIC contains two possible binding domains, IMPCH and AICAR 
tfase.  These are highlighted in Figure 3-10. 
 
Figure 3-10: Crystal structure of human ATIC highlighting the IMPCH (left hand side, bright colours) 
and AICAR tfase (right hand side) binding domains.  XMP is shown in yellow bound in the IMPCH 
active site, and AICAR is shown in green bound to the AICAR tfase active site. 
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Figure 3-11: ITC of AICAR binding to human ATIC (left) and avian ATIC (right) measured at 25 °C. 
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Figure 3-12: ITC of XMP binding to human (left) and avian ATIC (right) measured at 25 °C. 
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Figure 3-13:ITC showing binding of 10-f-H4F (left) and PteGlu4 (right) to avian ATIC measured at 25 °C. 
 
3.4.1.1 Isothermal titration calorimetry of human ATIC 
AICAR binds tightly to human ATIC with a Kd of 6.14 ± 1.37 M to approximately one 
site per monomer (0.78 ± 0.04).  This implies that AICAR does not bind into the 
IMPCH site, and only binds to the AICAR transformylase site.  IMP binds weakly to 
human ATIC (53.19 ± 4.50 M) and with less than half a binding site per monomer 
(0.35 ± 0.06).  It is expected that IMP should bind more weakly than the natural 
substrate AICAR as it is the product of the ATIC catalytic reaction.  It is desirable for 
the product to be released upon its formation.  XMP binds to between one and a half 
and two sites per monomer (1.67 ± 0.02), which suggests XMP can bind to both the 
AICAR transformylase and the IMPCH sites.  XMP would present chemical groups in 
the same orientation as the formyl AICAR product of the first catalytic step, and so 
would be expected to be able to bind to both sites; in AICAR transformylase as a 
product mimic and in IMPCH as a substrate mimic.  The binding constant (4.64 ± 0.37 
M) is tighter than for AICAR, which may explain why XMP has been identified in 
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certain crystal structures over the natural substrate.  As XMP binds more tightly than 
the natural substrate AICAR, it might act as another route for negative feedback within 
the de novo purine biosynthetic pathway (Figure 1-12).  AMP binds to half a binding 
site per monomer (0.44 ± 0.03).  AMP binds with a similar affinity as AICAR, with a 
slightly weaker Kd of 8.40 ± 2.01 M, but within the error of the AICAR Kd.  As 
AICAR and AMP have similar affinities it may imply that the NH2 group of the AICAR 
amide is more important to binding than the carboxyl.  This is consistent with the 
proposed mechanism (Figure 1-6) that has the carboxyl holding the primary amine in 
position ready to attack the formyl group of the folate cofactor.  10-f-H4F binds to one 
site per monomer (1.12 ± 0.16) but very weakly with a Kd of 120.92 ± 11.48 M.  As 
PteGlu4 binds with a much tighter Kd of 0.22 ± 0.03 M it would appear the 
polyglutamated tail of the natural substrate is a major driving force in binding to human 
ATIC. 
3.4.1.2 Isothermal titration calorimetry of avian ATIC 
ITC experiments were conducted on avian ATIC with the same range of ligands 
analysed for binding to human ATIC.  Binding experiments were carried out at a 
constant temperature (25 °C) with ligand and receptor in degassed 25 mM KCl, 25 mM 
Tris pH 7.4 buffer, following the same procedure used for the human ATIC ITC 
experiments.  Avian ATIC (26-70 M) was contained in the sample cell, and the ligand 
was injected to the cell in 2 l portions (with a first injection of 0.5 l).  The ligand 
concentrations were varied for each ligand to ensure saturation was achieved.  Data 
were fitted using MicroCal Origin
®
 software to calculate number of binding sites, 
dissociation constant and enthalpy of binding  (Table 3-3). 
The natural substrate, AICAR, bound to avian ATIC with a Kd of 13.83 ± 2.15 M, to 
approximately one site per monomer (1.23 ± 0.07) which suggests AICAR binds solely 
96 
 
in the AICAR transformylase pocket.  XMP binds fairly weakly to avian ATIC with a 
Kd of 40.83 ± 4.10 µM ,and appears to bind in both the AICAR transformylase and 
IMPCH sites as it binds to 2.02 ± 0.16  sites per monomer.  AMP binds to one site (0.73 
± 0.03) with a similar affinity (10.96 ± 1.78 µM) to the natural substrate AICAR.  IMP 
did not appear to bind to avian ATIC; this might be due to XMP or similar already 
filling the sites from co purification.  If IMP binds very weakly to the apo enzyme, the 
presence of higher affinity molecules bound to avian ATIC would mean IMP could not 
bind.  10-f-H4F binds once per monomer (1.26 ± 0.36) very weakly, with an affinity of 
267.95 ± 23.23 µM.  As for human ATIC the PteGlu4 binds extremely tightly with a Kd 
of 0.44 ± 0.02 µM which implies the lack of a polyglutamated tail will cause the 10-f-
H4F cofactor to bind less tightly than its in vivo equivalent. 
Both human and avian ATIC have AICAR and AMP affinities that are very similar, 
which suggests that they could be binding in the same manner.  Comparing the 
chemical structures, both ligands have two amine groups which, if binding was through 
these groups, would explain the similarity in affinity.  That this can be inferred from 
data across the two organisms gives greater weight to this hypothesis. 
XMP seems to bind in both active sites for human and avian ATIC, but human ATIC 
has a much higher affinity than the avian ATIC.  As would be expected for 10-f-H4F, 
both organisms show one binding site per monomer.  Although both have very weak 
affinity for 10-f-H4F, avian ATIC is two fold weaker than human ATIC.  This weak, 
high micro molar affinity is unexpected for a small molecule cofactor, but 10-f-H4F is 
lacking a polyglutamated tail that is found on the in vivo cofactor.  By comparison with 
the PteGlu4 results, which have extremely high affinities for human and avian ATIC, it 
can be inferred that the glutamate chain that is found on the in vivo substrate would 
cause a greater increase in the binding affinity to ATIC.  The weak binding seen with 
10-f-H4F also supports the ordered binding mechanism; the Kd measured for 10-f-H4F is 
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far larger than the measured KM of 42 µM.  This supports the hypothesis that AICAR 
binds to the enzyme first, and then 10-f-H4F binds.  If AICAR was present in the active 
site, 10-f-H4F would be expected to bind with a higher affinity, but the lack of AICAR 
explains why such a low affinity is seen for 10-f-H4F.  Unfortunately, this cannot be 
measured by ITC, as titrating 10-f-H4F into an AICAR-enzyme mixture would just 
result in a massive enthalpy change associated with catalytic turnover. 
 
3.5 Thermal stability of ATIC 
The thermal stability of ATIC has not been reported in the literature.  Ligand binding 
can enhance the stability of a protein.  The thermal stability of human and avian ATIC 
in the presence of various ligand was investigated to provide an alternative technique 
for investigating ligand binding. 
 
3.5.1.1 Differential Scanning Calorimetry (DSC) 
Differential Scanning Calorimetry (DSC) can be used to monitor the stability of 
proteins by measuring the enthalpy changes that occur during protein unfolding.  DSC 
was used to determine the Tm of human ATIC, with and without AICAR phosphate 
bound. Unfolding occurred between 50 °C and 62 °C.  The Tm of the apoprotein was 55 
°C, which increases to 58 °C upon addition of AICAR (1 mM).  After the protein had 
been subjected to a cycle with a final temperature of 100 °C, no re-folding was seen to 
occur.  Figure 3-14b is a graphical representation of the raw data obtained.  The light 
and dark blue lines show the scan of human ATIC.  The protein scan was repeated to 
show the reproducibility of the experiment.  The red line shows the increase in Tm when 
AICAR is added to the protein.  
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As no refolding occurred during these temperature ranges, a suitable baseline could not 
be fitted to the data set, and so the area under the melting curve could not be estimated. 
 
Figure 3-14: a) The experimental set up for DSC.  b) The sample and reference cells are cycled up and 
down in temperature.  The difference in heat required to the sample and reference cells are measured as a 
function of temperature to calculate the Tm of the sample.  The blue lines show the DSC trace obtained 
for human ATIC (Tm55 °C), and the red line shows the increase in stabilisation upon addition of 1 mM 
AICAR (Tm 58 °C). 
 
This experiment provides qualitative data that addition of the AICAR substrate 
stabilises the human ATIC enzyme.  The stabilisation effect of AICAR (1 mM) is 
shown as a 3 °C increase of the Tm to 58 °C.  This experiment with the addition of 
AICAR should be repeated to determine the error associated with this value. 
 
3.5.1.2 Differential Scanning Fluorimetry (DSF) 
An alternative high-throughput assay of thermal stability is DSF, which monitors the 
unfolding of a protein by a change in fluorescence upon exposure of regions of 
hydrophobicity.  Human and avian ATIC unfolding were measured in the presence of 
varying concentrations of AICAR, 10-f-H4F, PteGlu4 and a fixed concentration of KCl.
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Figure 3-15:Normalised DSF traces for a) human ATIC, and b) avian ATIC at certain concentrations of various small molecules 
Table 3-4: Tm (°C) of human and avian ATIC, as apoproteins (control) and in the presence of various small molecules at specified concentrations, as measured by DSF.  AICAR is 
the substrate for ATIC and 10-f-H4F is representative of the cofactor used in vivo.  PteGlu4 was included in the experiment to monitor the effects of the polygluatmate tail of the in 
vivo cofactor on the thermal stability of the enzymes. 
 Enzyme Control 
0.1 mM 
AICAR 
0.5 mM 
AICAR 
1 mM 
AICAR 
0.5 mM 
10-f-H4F 
1 mM 
10-f-H4F 
0.1 mM 
PteGlu4 
0.5 mM 
PteGlu4 
T
m
/°
C
 Human 
46 50 53 55 46 47 55 55 
Avian 
44 45 52 53 44 45 57 60 

T
m
 /
°C
 
Human 
0 4 7 9 0 1 9 9 
Avian 
0 1 8 9 0 1 13 16 
a) b) 
9
9
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The Tm gives a reasonable interpretation of the data, but the shape of the curves can give 
qualitative information too.  For example, if a curve is comparably broader to another 
then that sample is unfolding over a wider temperature range, or the unfolding process 
could pass through more than one transition.  The peak shape for ATIC suggests that 
there are two transitions to unfolding or two domains unfolding, each occurring at a 
different temperature.  The first peak is the largest which implies this transition 
uncovers a large hydrophobic area.  This occurs at 46 °C in human ATIC and 43 °C in 
avian ATIC (both measured at 25 mM KCl, as apoprotein).  The first peak could be 
attributed to a dimer to monomer transition, which would result in the exposure of a 
very large hydrophobic face.  A second peak, much less intense and broader than the 
first, occurs at 57 °C in human ATIC and 51 °C in avian ATIC.  The height of the 
second peak for human ATIC at 1 mM AICAR gives a second transition Tm of 60 °C, 
which is in agreement with the Tm calculated by DSC of 58 °C.  The increase in 
stabilisation to the second unfolding transition observed in DSF upon addition of 1 mM 
AICAR is 3 °C.  The discrepancy between DSC and DSF calculated values could be 
attributed to the different rate of temperature increase with each technique.  The large 
first unfolding event does not appear to have been measured by DSC, which suggests 
this potential unfolding of dimer to monomer could be an entropically driven event, as it 
is not a transition associated with a thermal change.  The first transition is measured by 
a large increase in fluorescence as a hydrophobic surface is exposed, but is not 
accompanied by a change in enthalpy.  The second transition is characterised by a much 
weaker fluorescence signal, and coincides with the transition measured by the DSC.  
Therefore, the second transition is an enthalpic unfolding which results in the exposure 
of a far smaller area of hydrophobic residues than observed for the first transition.  It 
would be useful to determine the ‘Tm’ associated with the second transition and analyse 
the effect of the various substrates.  However, these are difficult to obtain from the data 
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set as this second transition signal is fairly weak and noisy (especially in human ATIC), 
and becomes buried beneath the first peak as this transition is stabilised. 
The stability for both human and avian ATIC increases with increasing concentration of 
AICAR, implying that the enzyme is more stable upon binding the natural substrate 
(Figure 3-16).  On average, the 10-f-H4F cofactor only causes a small stabilisation at the 
higher concentrations analysed in this study, requiring 1 mM 10-f-H4F to produce 1 °C 
stabilisation.  The in vivo substrate is a polyglutamated form of 10-f-H4F, so PteGlu4 
was included to mimic any stabilisation effects of the glutamate tail.  An increase in 
stabilisation is seen on addition of small amounts of PteGlu4 (0.1 mM). 
 
 
Figure 3-16: Summary of the stabilisation effects of various small ligands 
 
3.6 Discussion and Conclusion 
The true KM for AICAR and 10-f-H4F have been determined for human ATIC using a 
two dimensional assay as 14.1  4.5 µM and 41.6  11.9 µM respectively.  These are 
within the range of previously determined literature values for AICAR of 1.9  
0.4 µM
[50]
 (measured at 25 °C) and 16.8  1.5 µM[31] (temperature of experiment not 
stated), and 10-f-H4F values of 39.0  6.0µM
[50]
 (measured at 25 °C) and 60.2  5.0 
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[31]
 (temperature of experiment not stated). This indicates the automated assay 
method is a suitable means for simultaneous determination of substrate and cofactor 
kinetic parameters.  Analysis of the data obtained from the automated assay suggested 
the sequential binding of substrate and cofactor, where AICAR must bind to the enzyme 
first, followed by 10-f-H4F, before catalysis can take place. 
Section 3.4 provides the first determination of the thermodynamic binding properties of 
AICAR, IMP, AMP, XMP, 10-f-H4F and PteGlu4 to ATIC, measured at 25 °C.  AICAR 
binds fairly tightly to both human and avian ATIC, with a Kd of 6.14 ± 1.37 µM and 
13.83 ± 2.15 µM respectively.  AICAR binds once per monomer unit, which is 
presumed to be the AICAR transformylase site (see Chapter 4 for further analysis of site 
determination).  As expected, the product of the ATIC reaction, IMP, binds more 
weakly than the substrate, with a Kd of 53.19 ± 4.50 µM to human ATIC.  IMP binds to 
only 0.35 ± 0.06 sites per monomer, suggesting that binding to the IMPCH active site 
may be blocked, potentially from a more tightly binding molecule carried through from 
overexpression in E. coli.  Human ATIC binds AMP in a similar number of sites (0.44 ± 
0.03) as IMP, which suggests AMP is also binding to the IMPCH site, and is 
subsequently blocked by the same small molecule inhibiting IMP binding.  AMP binds 
to human ATIC more tightly than IMP, which is unusual as AMP presents opposite 
hydrogen bonding partners to formyl AICAR and IMP.  This suggests AMP must be 
binding in a different orientation to the substrate and product in the IMPCH active site.  
AMP binds with a similar affinity to AICAR in human and avian ATIC (8.40 ± 2.01 
µM and 10.96 ± 1.78 µM respectively).  XMP binds tightly (Kd = 4.64 ± 0.37 µM) to 
1.67 ± 0.02 sites per monomer of human ATIC.  This implies XMP can bind to both the 
AICAR transformylase and IMPCH active sites, which can be explained by the 
similarity in positioning of chemical groups to formyl AICAR.  Hence, XMP can act as 
a product mimic in the AICAR transformylase site, and a substrate mimic in the IMPCH 
103 
site.  As XMP binds more tightly than the natural substrate AICAR, it might act as 
another route for negative feedback within the de novo purine biosynthetic pathway 
(Figure 3-17). 
 
Figure 3-17:Feedback regulation of the de novo purine biosynthetic pathway. Steps also included are the 
synthesis of PRPP from 5-ribose phosphate catalysed by PRPP synthetase, and the conversion of IMP to 
ATP and GTP. Red dashed lines indicate negative feedback and solid green lines positive feedback.  
Potential negative feedback loop of XMP inhibition of AICAR transformylase is shown as a solid red 
arrow indicating the direction of feedback. 
 
Binding of 10-f-H4F to both human and avian ATIC was weak, in the high micro molar 
range (120.92 ± 11.48 µM and 267.95 ± 23.23 µM respectively) to approximately one 
site per monomer.  The dissociation constants for 10-f-H4F may be being observed at a 
weaker value than would be seen if AICAR was bound, since the substrate is known to 
bind prior to cofactor binding.  This supports the ordered binding mechanism where 
AICAR must bind to ATIC before 10-f-H4F.  Also, the in vivo substrate has a 
polyglutamate tail, extending from the single glutamate of 10-f-H4F.  Binding studies on 
PteGlu4 confirm that the glutamate extension has a huge effect on increasing the binding 
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strength of the cofactor for ATIC.  PteGlu4 Kd = 0.22 ± 0.03 µM for human ATIC and 
0.44 ± 0.02 µM for avian ATIC.  The addition of three glutamates increases the binding 
constant by around 500-600 fold; although this does not include the binding 
contribution of the formyl group, it serves to give a good indication of the effect adding 
glutamates to the cofactor would have on binding affinity.  The thermal stability data 
obtained from DSF experiments supports the conclusion that the polyglutamate tail is an 
important aspect of the cofactor.  PteGlu4 (0.5 mM) increases the melting temperature 
of human ATIC by 9 °C and avian ATIC by 16 °C, whereas 10-f-H4F at the same 
concentration has no effect on the Tm for ATIC from either organism.  PteGlu4 would 
not be expected to interfere with AICAR substrate binding as the glutamate tail binding 
pocket sits on the surface of the enzyme and does not obstruct the AICAR binding 
pocket. 
ATIC runs as a monomer by SDS-PAGE, which is due to the denaturing conditions of 
the analysis.  Size exclusion chromatography appears to show a mass of just under that 
for the dimer, but this is thought to be due to the shape of the ATIC dimer.  The large 
dimeric interface that forms from the two monomers allows the ATIC dimer to take up a 
volume that is less than double the volume of the ATIC monomer.  As the ATIC dimer 
has a streamlined shape occupying less than the expected volume area for two 
monomers, the molecular weight is under predicted by the size exclusion calibration.  
Human and avian ATIC both appear to purify as dimers if the streamlined shape of the 
enzymes, observed in the crystal structures, is taken into consideration.  DSC performed 
on human ATIC reported a single melting transition, with a Tm of 55 °C, unfolding over 
a range of 50 to 60 °C.  DSC measures any unfolding processes that occur with a 
change in temperature, so an orthogonal technique, DSF, was also used which measures 
unfolding by the exposure of hydrophobic areas.  Analysis of the data obtained from 
DSF showed two unfolding transitions; the exposure of a large hydrophobic area at 
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46 °C, and a smaller, broader transition at 57 °C.  These data suggest an entropic 
unfolding of the dimeric interface (which has a 5000 Å
2
 area) occurs at 46 °C, followed 
by an enthalpically driven unfolding of the remaining monomer, or the unfolding of the 
two separate domains. 
DSC and DSF show that the enthapically driven unfolding of ATIC is stabilised by 
addition of the native substrate AICAR, both show a 3 °C stabilisation of human ATIC 
on addition of 1 mM.  This shows good reproducibility across orthogonal techniques.  
The differences in Tm measured (58 °C by DSC, 60 °C by DSF) are likely caused by the 
different temperature ramps used by each technique; DSC increases the temperature 
more slowly than DSF. 
A greater stabilisation affect is seen for AICAR compared to 10-f-H4F.  This is 
consistent with the binding affinities measured by ITC that show AICAR binds more 
tightly to ATIC than 10-f-H4F, and therefore also supports the ordered binding model, 
where AICAR binds to ATIC before 10-f-H4F.  AICAR binding may enhance the 
stability and structure of the enzyme in such a way that it enhances the 10-f-H4F 
binding; 10-f-H4F binding is more favourable when AICAR is already bound to ATIC.  
Data obtained from kinetics, DSC, DSF and ITC therefore all support the ordered 
binding reaction: 
𝐸 + 𝐴𝐼𝐶𝐴𝑅
𝐾1=14 𝜇𝑀
↔      [𝐸 − 𝐴𝐼𝐶𝐴𝑅] + 10fH4F
𝐾2=42𝜇𝑀
↔      [𝐸 − 𝐴𝐼𝐶𝐴𝑅 − 10fH4F] → 𝑃𝑟𝑜𝑑𝑢𝑐𝑡 
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4 Isolation of the two domains of ATIC 
ATIC contains two distinct catalytic domains, IMPCH, which is located towards the 
N terminus of the protein, and AICAR transformylase, which is situated towards the 
C terminus.  The characterisation of ATIC contained in Chapter 3 investigated the 
thermal stability and the kinetic and physical binding properties of the full length ATIC.  
To be able to separate out and assign certain properties to each domain would aid in the 
interpretation of some of the results obtained in Chapter 3.  For example, the ITC 
experiments conducted on ATIC suggest that AMP may bind to ATIC in the IMPCH 
site, and ITC analysis shows XMP appears to bind in both the AICAR transforymlase 
and IMPCH active sites.  Truncation mutants were designed to provide a single 
polypeptide encoding IMPCH activity and another incorporating AICAR transformylase 
activity. 
4.1 Truncation mutants of ATIC 
The crystal structure of human ATIC was analysed to design an N-terminal truncation 
mutant of ATIC containing the IMPCH domain, and a C-terminal truncation containing 
the AICAR transformylase domain.  The ATIC protein sequence was chosen to be ‘cut’ 
at residue G200 (Figure 4-1), thus providing an IMPCH containing mutant consisting of 
residues 1-199, and an AICAR transformylase mutant containing residues 201-592.  
The transformylase domain-containing mutant was designed to include the β-sheet 
motif that connects the domains, as this may help the mutant dimerise by providing a 
greater area of interactions  A dimeric C-terminal mutant is desirable as the 
transformylase domain is only active when the enzyme is in its dimeric form. 
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Figure 4-1: The structure of ATIC. The highlighted green residue is G200 and indicates where the protein 
is 'cut' to create two truncation mutants, each containing a separate catalytic domain. 
 
4.1.1.1 Cloning 
The pET28a vector encoding human ATIC was used as the template for amplification 
PCR.  The regions of interest (where bases 1, 2 and 3 code for the first methionine 
residue of the ATIC sequence) bases 1 to 597 were amplified to encode the IMPCH site, 
and bases 598-1776 were amplified encoding ATIC residues 201 to 592.  To clone the 
IMPCH truncation mutant expressed with an N-terminal his6tag, an Nco1 restriction site 
was added to the forward primer P06 and a BamH1 restriction site was added to the 
reverse primer P08.  To clone an IMPCH mutant without a his6 tag an Nde1 restriction 
site was added to the forward primer P07 the same reverse primer was used (P08).  An 
annealing temperature of 50 °C was used and amplification was checked against a 
molecular marker ladder (Figure 4-2, lanes 4 and 5). 
 
To clone the AICAR transformylase truncation mutant into the pET28a vector an Nco1 
restriction site was added to the forward primer P03 and a BamH1 restriction site was 
added to the reverse primer P05.  This encodes for the recombinant protein to be 
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expressed with an N-terminal his6 tag.  To create an AICAR transformylase mutant 
without a his6 tag the same reverse primer was used (P05) but an Nhe1 restriction site 
was added to the forward primer P04.  Initial annealing temperatures of 50 °C were 
used but these resulted in mixed products (Figure 4-2, lanes 2 and 3).  The PCR reaction 
was repeated at 60 °C and the products of this PCR were clean.  Amplification was 
checked against a molecular marker ladder (Figure 4-2, lanes 7-8). 
 
PCR products that contain the Nco1 restriction site were cloned into pET28a upstream 
of the his6 tag coding region, resulting in mutants that do not bear N-terminal his6 tags.  
Nde1 and Nhe1 sites were chosen to ensure the sequences encoding IMPCH and 
AICAR transformylase, respectively, were in the correct frame for expression. 
 
Figure 4-2: 1.2% agarose gel of ATIC truncation mutants. Lane 1 and 6: DNA marker, lane 2: PCR 
product of primers P03 and P05 at an annealing temperature of 50 °C to produce an AICAR 
transformylase mutant with an N-terminal his6 tag, lane 3: PCR product of primers P04 and P05 at an 
annealing temperature of 50 °C to produce an AICAR transformylase mutant without a his6 tag, lane 4: 
PCR product of primers P06 and P08 at an annealing temperature of 50 °C to produce an AICAR 
transformylase mutant with an N-terminal his6 tag, lane 5: PCR product of primers P07 and P08 at an 
annealing temperature of 50 °C to produce an AICAR transformylase mutant without an N-terminal his6 
tag, lane 7: PCR product of primers P03 and P05 at an annealing temperature of 60 °C to produce an 
AICAR transformylase mutant with an N-terminal his6 tag, lane 8: PCR product of primers P04 and P05 
at an annealing temperature of 60 °C to produce an AICAR transformylase mutant without a his6 tag. 
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The PCR products were purified (QIAprep Spin Miniprep, Qiagen) and digested using 
the appropriate restriction enzymes.  The DNA was then fractionated on a 1.2% agarose 
gel and the DNA bands extracted using the QIAquick gel extraction kit (Qiagen).  The 
truncate genes were ligated into the appropriate digested pET28a expression vectors and 
transformed into chemically competent XL10-Gold cells.  The expression vectors 
containing the required genes were then extracted using a QIAprep Spin Miniprep 
(Qiagen) and the plasmid sent for sequencing.  Sequencing data confirmed the 
successful ligation of the truncation mutants into pET28a. 
 
4.1.1.2 Protein expression 
All 4 truncation mutants were first expression tested in E. coli C41 (DE3) cells using 
auto-inducing media and grown at 30 °C.  For each expression test, two cultures were 
grown, the second induced 12 hours after the first to allow for regular sampling.  
Samples of the growth media were taken every hour for 24 hours and frozen at −20 °C. 
These samples were then analysed by SDS-PAGE to monitor protein expression which 
is summarised in Figure 4-3. 
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Figure 4-3:SDS-PAGE analysis of the protein expression of un-tagged AICAR transformylase domain 
and IMPCH domain (left) and his-tagged transformylase domain and IMPCH domain (right) from C41 
(DE3) cells.  Time points of the samples are shown below the relevant lane. 
 
Expression was seen for both tagged and un-tagged IMPCH domain mutants, but there 
was no overexpression for the AICAR transformylase truncation mutant (expected at 
45.4 kDa).  The IMPCH domain of the full length ATIC has a well-defined potential C-
terminal structure, ending in an -helix which implies the IMPCH domain will be stable 
and lead to good overexpression.  The his6 tagged form of IMPCH seems to have 
greater overexpression than the un-tagged form, possibly due to the his6 tag inferring 
extra stability. 
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The lack of overexpression seen for the transformylase mutants may be due to the 
inclusion of the β-sheet motif.  The transformylase truncation mutant expression starts 
with this β-sheet sequence which may not be able to fold correctly without the presence 
of the IMPCH domain to stabilise it.  This expressed but unfolded protein could then be 
targeted for degradation by the cell.  To attempt to overcome this potential problem, 
another set of truncation mutants were designed to include the β-sheet with the IMPCH 
domain containing mutant and not with the transformylase domain.  Figure 4-4 
highlights the G360 residue chosen as the new cleavage point.  There was insufficient 
time to complete the cloning for this system. 
 
Figure 4-4: The structure of ATIC. The green highlighted residue G360 was the point of cleavage used to 
produce different truncation mutants, each containing a separate catalytic domain 
 
The his6tagged IMPCH mutant was overexpressed in C41 (DE3) cells, on a larger scale 
(2  1 l) in auto-inducing media at 37 °C. The cells were harvested after 24 h and stored 
at –80 °C. The IMPCH protein was purified by metal affinity and size-exclusion 
chromatography through a Superdex 200 column (Figure 4-5). 
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Figure 4-5: a) SDS-PAGE analysis of the purification of the IMPCH truncation mutant from E. coli using 
a Ni-NTA gravity flow column. Lane 1: molecular weight marker, lane 2: flow through 1, lane 3: wash 1 
(10 mM imidazole), lane 4: wash 2 (150 mM imidazole), lane 5: elution 1 (250 mM imidazole), lane 6: 
elution 2, lane 7: blank, lanes 8 to 13: samples from the eluent of the Superdex 200 gel filtration column. 
b) Absorption at 280 nm of size exclusion purification.  The IMPCH truncation mutant is shown in red 
and has an elution volume of 15.4 ml.   
The IMPCH domain eluted from the gel filtration column with a peak height at 15.4 ml, 
which corresponds to a molecular weight of 48 kDa, calculated using the calibration 
curve constructed in Chapter 3.  The expected mass of the his6-tagged IMPCH construct 
is 23.70 kDa, calculated from the sequence.  This suggests that the IMPCH truncation 
mutant purifies as a dimer under non-denaturing conditions, which would have an 
expected mass of 47.40 kDa.  IMPCH does not need to be in dimeric form to be 
catalytically active, but it still exists in the dimeric form under the conditions used for 
gel filtration. 
4.1.1.3 ITC of IMPCH 
The binding parameters of small molecules to the IMPCH mutant were sought to help 
elucidate the ITC results obtained for the full length human ATIC.  PteGlu4 was 
analysed, but was not expected to bind to the N-terminal portion of ATIC as it is 
thought to bind to the same site as the 10-f-H4F cofactor.  This experiment was 
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conducted to ensure no binding occurs to a different site within the first 200 residues of 
ATIC.  Figure 4-6 is an example isotherm showing AICAR titrating into IMPCH.  The 
results of small molecule binding to the IMPCH truncation mutant are shown in 
Table 4-1. 
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Figure 4-6: ITC titration of AICAR (1.5 mM) into IMPCH truncation mutant (56 μM) at 25 °C. 
 
Table 4-1: Binding affinities of ligands and small molecules to IMPCH truncation mutant of human ATIC 
determined by ITC.  Measurements were taken using a MicroCal ITC200 at a constant temperature of 
25 °C.  Enzyme concentration was fixed at 56 μM and ligand concentrations were adjusted as required to 
achieve saturation.  Data were fitted using MicroCal Origin
®
 software to calculate number of binding 
sites, dissociation constant and enthalpy of binding. 
Ligand 
IMPCH ATIC 
Ligand concentration/ mM Number of sites Kd/ μM H/ kcal mol
-1 
AICAR 1.5 0.721 ± 0.054 35.8± 3.0 -7.92 ± 0.70 
IMP 1.0 0.639 ± 0.042 26.8 ± 2.4 -7.74 ± 0.62 
XMP 1.0 1.1607 ± 0.033 12.1 ± 1.5 -4.12 ± 0.16 
AMP 1.2 nd nd nd 
PteGlu4 1.0 nd nd nd 
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XMP binds to the IMPCH truncation mutant with the highest affinity of the small 
molecules investigated, but the measured Kd of 12.1 ± 1.5 μM is almost three times 
weaker than the binding seen for XMP to human ATIC (Kd of 4.64 ± 0.37 μM).  This 
implies that XMP binds primarily and most tightly to the AICAR transformylase 
domain. 
Whilst IMP binds weakly to the IMPCH mutant with a Kd of 26.8 ± 2.4 μM, it binds 
twice as tightly as IMP to the protein containing both domains.  The IMPCH mutant 
cannot catalyse the AICAR Tfase activity, which could result in a lower concentration 
of endogenous IMP.  This could potentially lead to the observation of ‘tighter’ binding 
between IMP and the IMPCH mutant. 
AICAR binds to the IMPCH domain with a weak Kd of 35.8 ± 3.0 μM to 0.721 ± 0.054 
sites.  This is much weaker binding than was seen for the full length ATIC chain, 
implying the previously measured AICAR Kd for human ATIC of 6.14 ± 1.37 μM may 
be dominated by a tight binding interaction to the AICAR transformylase domain.  
AICAR can weakly bind to the IMPCH site, but this is most likely due to the structural 
similarity to the natural substrate, FAICAR.  It would be expected for the naturally 
occurring human ATIC that AICAR binds preferentially to the AICAR transformylase 
domain.  Alternatively, as the number of binding sites and enthalpy of binding are 
similar to those measured for full length ATIC, AICAR may only be being measured 
binding to the IMPCH active site.  The affinity may be weaker to the truncation mutant 
due to a loss of stability through a reduction in dimerisation; the IMPCH turnover does 
not require dimerisation, but the monomer shows a 6-fold reduction in activity
[33]
.  If 
AICAR has only been measured binding to the IMPCH site, this implies the AICAR 
transformylase site is already occupied with a higher affinity ligand, potentially XMP, 
which blocks AICAR binding.  If AICAR cannot bind to the AICAR transformylase site 
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then the stability inferred by AICAR binding measured by DSC and DSF may have 
been achieved by stabilising the IMPCH binding domain. 
AMP and PteGlu4 do not bind to the first 200 residues of human ATIC.  The binding 
site for PteGlu4 must be located within residues 200-592.  This was as expected as the 
10-f-H4F is situated within the AICAR transfomylase active site.  This suggests that 
PteGlu4 may be binding in the 10-f-H4F binding pocket.  AMP does not bind within the 
IMPCH active site as previously thought (Section 3.6), so the previously measured Kd 
of 8.4 ± 2.0 μM must have been the affinity of AMP for the AICAR transformylase 
domain. 
 
4.1.1.4 DSF of IMPCH 
The unfolding profile for the apoprotein IMPCH truncation mutant is shown as a black 
curve in Figure 4-7.  There is a single positive peak followed by a negative dip in 
fluorescence.  The single peak confirms IMPCH has a single melting transition, and the 
point of the peak height gives a Tm of 56 °C.  The trough corresponds to the aggregation 
of the protein after it has unfolded.  The Tm of 56 °C is consistent with the second, 
smaller unfolding transition seen with human ATIC at 57 °C, but the IMPCH mutant 
does not have the initial large peak that corresponds to the unfolding dimer.  This 
supports the hypothesis that the large peak at 46 °C is caused by the exposure of the 
large area of hydrophobicity between the AICAR transformylase domains.  Size 
exclusion chromatography predicts that the IMPCH mutant is present in dimeric form, 
but only one unfolding transition is seen, unlike the two transitions seen for the full 
length ATIC thought to correspond to dimer unfolding, then monomer unfolding.  
However, the dimeric interface between the IMPCH monomers is relatively scant, so 
either the dimer separation occurs at the same temperature as the protein unfolding, the 
dimer has fallen apart over the time between size exclusion purification and the DSF 
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experiment (approximately 5 hours), or the dissociation does not correspond to an 
increase in fluorescence. 
 
Table 4-2:Tm (°C) of IMPCH truncation mutant in the presence of various small molecules at specified 
concentrations, as measured by DSF.  Samples were heated from 25°C to 100°C at an increase of 1°C/s.  
Tm was calculated from the peak of the differential of fluorescence intensity.  IMPCH apoprotein had a 
Tm of 56 °C. 
Ligand 
Concentration/ mM 
0.25 0.5 1 1.5 
AICAR 57 58 59 60 
AMP 56 56 56 57 
IMP 58 58 60 61 
 
 
Table 4-3: Tm (°C) of IMPCH truncation mutant in the presence of various small molecules at specified 
concentrations compared to the IMPCH apoprotein.  Values were calculated from Table 4-2. 
Ligand 
Concentration/ mM 
0.25 0.5 1 1.5 
AICAR 1 2 3 4 
AMP 0 0 0 1 
IMP 2 2 4 5 
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The IMPCH truncation mutant was also incubated with increasing concentrations of 
AICAR, AMP and IMP to investigate the stabilising effects of these small molecules by 
DSF.  The addition of AICAR gave a small increase in Tm, and showed a concentration 
dependence with an overall increase in Tm of 4 °C at 1.5 mM AICAR.  AMP had no 
significant effect on the stability of IMPCH, implying that AMP may not have bound to 
the truncation mutant.  IMP conferred the most stability of the ligands analysed, 
increasing the melting temperature by 5 °C at a concentration of 1.5 mM.  In 
comparison to the small molecule stabilisations observed with the full length ATIC, the 
increases in the melting temperature of the IMPCH mutant are small; 1 mM of AICAR 
causes a Tm of 9 °C for the full length protein compared to a Tm of 3 °C for the single 
IMPCH domain. 
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Figure 4-7:Differentiated DSF traces for IMPCH with increasing concentrations of a) AICAR, b) AMP, c)IMP, d) compiled traces at 1.5 mM of each small molecule
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4.2 Discussion and Conclusion 
A truncation mutant consisting of residues 1-200 of human ATIC incorporating the 
IMPCH domain, but not the AICAR transformylase domain was cloned and 
overexpressed in E. coli C41 (DE3) cells.  The remaining residues 200-592 were cloned 
to provide a second truncation mutant containing only the AICAR transformylase 
domain, but this construct did not overexpress. The lack of overexpression was possible 
due to the N-terminal section of the polypeptide chain which encoded the -sheet region 
of the ATIC structure, which may have caused mis-folding without the IMPCH domain 
to act as an anchor, and have been targeted for degradation within the E. coli cells. 
IMPCH purified as a dimer by size exclusion chromatography, but DSF shows the 
domain unfolds by a single transition at 56 °C.  This is either due to the dimer and 
monomers all unfolding at the same temperature, or that the IMPCH dimer is a fairly 
weak interaction that falls apart in the time before the DSF experiment can be 
conducted, hence only the single monomer unfolding transition is seen.  This could be 
easily tested by re-purifing IMPCH samples by gel filtration, at set times points after the 
initial purification, and was merely not completed due to time constraints.  If a second 
elution peak appears at approximately 16.8 ml, this would be representative of the 
monomer IMPCH and support the hypothesis of IMPCH dimer degradation with time.  
As the melting temperature of the IMPCH mutant corresponds with the second peak 
seen in the unfolding profile of human ATIC, this provides further evidence that the 
first unfolding peak of human ATIC (46 °C) is a measure of the falling apart of the 
AICAR transformylase domains to expose a large hydrophobic interface, and that the 
second peak at 57 °C is contributed by the unfolding of the remaining protein (including 
the IMPCH domain). 
The greater the binding constant of a particular small molecule, the greater the increase 
is measured in the Tm of IMPCH when incubated with the molecule of interest.  AMP 
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does not bind to the IMPCH domain and AMP causes no appreciable increase in Tm.  
AICAR and IMP both bind to IMPCH, AICAR slightly more weakly than IMP.  This is 
translated to an increase in stability monitored by DSF when IMPCH is incubated with 
each of the ligands, IMP causes a slightly greater stabilisation effect than AICAR. 
The binding of small molecules to the IMPCH domain was measured by ITC to help 
elucidate the binding data obtained for the full length ATIC in Chapter 3.  The binding 
parameters measured for AICAR titrated into IMPCH are consistent with those obtained 
for the full length ATIC, suggesting the previously measured affinity and stabilisation 
effects were caused by AICAR binding to the IMPCH domain, not to the AICAR 
transformylase domain as would be expected.  This could be due to a higher affinity 
ligand such as XMP blocking the transformylase active site.  In contradiction to this, 
however, is the binding of AMP, which is measured binding to the AICAR 
transformylase site only.  To explain the results of the binding experiments to full length 
ATIC and the IMPCH truncation, a new construct must be created that has the full 
length ATIC structure, but has the IMPCH active site knocked out.  Binding 
experiments would then be performed on the knock-out mutant, the results of which 
would be compared to the data obtained for the IMPCH truncation mutant and the full 
length ATIC to deduce the binding locations. 
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5 Assaying dimerisation of ATIC 
In Chapter 3, the structure of ATIC was analysed by various biophysical techniques.  
The thermal stability as determined by DSC displayed a single unfolding transition 
which corresponded to a melting temperature of 55 °C.  However, when the protein was 
analysed by DSF, an extra unfolding event was seen at 46 °C which was not observable 
using DSC.  As DSC only monitors enthalpic events, this first unfolding transition must 
be entropically driven.  This entropic transition corresponded to a very large increase in 
fluorescence, corresponding to exposure of a large amount of hydrophobic surface area, 
we hypothesised that this large unfolding event is the dissociation of the ATIC dimer, 
which would expose the large, hydrophobic dimeric interface. 
 
Figure 5-1:  Surface representation of a monomer of human ATIC, shaded according to hydrophobicity.  
Bright red indicates Ala, Leu, Val, Ile, Phe, Met and Cys residues, pale red indicates Gly, Ser, Thr and 
Trp residues, and grey indicates hydrophilic residues. 
5.1 Biophysical characterisation 
Analytical UltraCentrifugation (AUC) can analyse a mixture of different species to 
determine the size and shape of the species present.  Here, AUC was employed to 
confirm the oligomeric assemblies present in a sample of human ATIC.  This approach, 
using sedimentation equilibrium has previously been used to identify a monomer-dimer 
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equilibrium in human ATIC
[131]
.  We explored sedimentation velocity, in which the 
sedimentation of the sample with time is analysed to calculate information on the size of 
the species present.  The coloured inset in Figure 5-2 shows the raw data for the 
sedimentation of a sample of human ATIC.  The curves represent the absorbance at 280 
nm in the cell, at different time points during the sedimentation process.  The initial 
sedimentation profile is shown in dark blue and progresses to red over the time course 
of the experiment.  These curves were processed in Sedfit to identify the size of species 
in solution. 
The first small peak corresponds to a species of 32 kDa, the second and dominating 
species has a mass of 132 kDa, and the third hump equates to a species of 225 kDa.  The 
dimer of human ATIC has a molecular weight of 133.6 kDa, as calculated from the 
sequence.  AUC sedimentation velocity confirms human ATIC is primarily present in 
dimeric form, and therefore suggests that at this concentration very little monomer is 
present. 
 
 
Figure 5-2: Sedfit analysis of AUC sedimentation velocity experiment conducted with human ATIC 
(20 μM) at 48,000 g and 20 °C.  The inset shows the absorption at 280 nm over time, as the traces change 
from blue to red. 
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The strength of homodimeric interactions can be measured by ITC dilution experiments.  
In this experiment the protein is highly concentrated in the syringe, and is injected into a 
cell containing only buffer.  As the concentrated protein is injected into the cell it is 
diluted, and dissociates as defined by the dissociation constant Kd, which determines the 
ratio of the monomeric and dimeric species.  With progressive injections the protein 
concentration in the cell increases and the dissociation process becomes less favoured. 
The dissociation constant can be derived from the resulting isotherm 
ITC dilution experiments were performed with human ATIC, over a range of 
concentrations from 300 μM to 1 mM, and conducted between 20 °C and 25 °C.  Figure 
5-3 shows a typical trace for the human ATIC dilution experiment.  A slight weak 
endothermic dilution can be seen, but none of the data collected could be fitted to 
determine Kd of the monomer-dimer equilibrium.  A typical dilution isotherm would be 
expected to show significantly stronger curvature.  This result suggests that the 
dimerisation of ATIC is an entropically driven reaction, as ITC only measures binding 
and dissociations by changes in enthalpy. 
 
Figure 5-3: ITC dilution experiment for human ATIC conducted at 25 °C 
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This also perhaps explains why the large unfolding signal detected by DSF at 46 °C is 
not observed by DSC, since DSF measures unfolding by the exposure of hydrophobic 
sites whilst DSC monitors unfolding through changes in enthalpy. 
5.2 Use of small molecule probes 
Several small molecule inhibitors of ATIC dimerisation have been reported in the 
literature.  It was hoped that direct observation of binding by these inhibitors to ATIC 
would allow them to be used as probes of dimerisation.  Two classes of such inhibitors 
have been reported, the cappsins
105
 and the cyclic peptides
104
.  We focussed on the latter 
class of compounds. 
 
5.2.1.1 Synthesis of the cyclic peptide c[CRYFNV] 
A novel method was developed to synthesise the cyclic hexamer peptide c[CRYFNV], 
utilising SPPS protocol using a Fmoc protecting strategy on a low loading rink amide 
resin (0.22 mmole/g).  The precursor linear peptide was synthesised, Fmoc deprotected 
and then cyclised on-bead before global deprotection and cleavage to yield the cyclic 
peptide.  This new strategy for the synthesis of the cyclic peptide couples the peptide 
through the side chain, which becomes an asparagine residue upon cleavage from the 
resin (Figure 5-4). 
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Figure 5-4: Synthetic route taken to the cyclic peptide c[CRYFNV] (16i), a) coupling of Fmoc-Asp(OAll) 
to a low loading rink amide resin, b) standard SPPS protocol used to couple the amino acids F, Y, N, C 
and V, c) removal of the allyl protecting group; tetrakis(triphenylphosphine)palladium(0) (25 mol%), 
morpholine, DMF, d) cyclisation and cleavage from the resin.  
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The first amino acid to be attached to the rink amide resin was Asp(OAll)-OH, which 
upon cleavage forms the asparagine amino acid of the cyclic peptide (Figure 5-5).  
Subsequent amino acids were added to the N-terminus of the Asp(OAll) residue.  The 
allyl protecting group was removed using a tetrakis(triphenylphosphine)palladium(0) 
catalyst  (25 mol%) with morpholine as a base.  Cyclisation was then achieved with 
standard peptide coupling agents HCTU and DIPEA.  Purification using a LH-20 size 
exclusion column eluted with MeOH was attempted but no material was recovered.  
With no fluorophore present, and no signal from the tyrosine residue at the dilution 
required to solubilise the compound, the fractions containing the purified compound 
could not be identified from the LH-20 purification.  Instead, the compound was 
purified by high performance liquid chromatography. 
 
 
Figure 5-5: Synthesis of the cyclic peptide 16i. The side chain of Fmoc-Asp(OAll)-OH (red) is attached to 
the rink amide resin. Upon cleavage the aspartate side chain is converted into asparagine. 
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5.2.1.2 Analysis of the cyclic peptide inhibitor 
The purified cyclic peptide inhibitor was analysed by a kinetic inhibition assay.  The 
assay was conducted at twice the KM for both AICAR and10-f-H4F substrates, at a range 
of concentrations of the cyclic inhibitor.  The rates measured were plotted against a log 
scale of the concentration of inhibitor and fit using a logistic function.  The IC50 was 
determined to be 3.6 ± 0.8 μM (Figure 5-6).  The Ki reported previously by Tavassoli et 
al. for this cyclic peptide inhibitor was 17.1 μM with respect to 10-f-H4F.  It is believed 
that the actual IC50 of this inhibitor could be lower, but due to its insolubility measuring 
the true value was problematic. 
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Figure 5-6: A log plot showing the inhibitory action of the cyclic peptide inhibitor. IC50 was determined 
to be 3.6 ± 0.8 M. 
 
Preliminary analysis of the binding of the cyclic peptide inhibitor to human ATIC was 
obtained by ITC (Figure 5-7).  The binding constant Kd of the cyclic peptide is 3.61 ± 
0.76 μM with a binding stoichiometry of 0.320 ± 0.016.  This is consistent with the Ki 
measured by Tavassoli et al. of 17 μM.  This was repeated to try and obtain a larger 
signal but all attempts to measure binding failed, either due to precipitation of protein or 
peptide.  The cyclic peptide is only soluble in DMSO-containing buffers so there is a 
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fine balance between the concentration of peptide that can be used and the effect of 
DMSO on the stability and solubility of the protein. 
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Figure 5-7: ITC analysis of the cyclic peptide and human ATIC interaction.  Kd was measured at 3.61 ± 
0.76 μM. 
 
5.2.1.3 c[CRYFNV] inhibition of hepatitis C viral replication 
AMP-activated Kinase (AMPK) regulates energy sources within the cell and AMPK 
agonists have been known to inhibit viral replication
[80]
.  AICAR is a known agonist of 
AMPK
[79]
, so the cyclic peptide dimerisation inhibitor was investigated with respect to 
its potential to inhibit viral replication, as inhibition of ATIC dimerisation will inhibit 
the AICAR transformylase reaction leading to an increase of AICAR in the cell.   
The crude cyclic peptide dimerisation inhibitor underwent preliminary testing (Ana 
Carolina, Harris group, University of Leeds) to observe any effects on viral replication.  
100 μM of c[CRYFNV] was found to inhibit HCV reproduction in Huh-7 cells after 
48 h (Figure 5-8).  The Huh-7 cells are transformed with luciferase-encoding HCV sub-
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genomic replicons.  A reduction in HCV replication is measured as a reduction in 
luminescence in the c[CRYFNV] treated cells compared to the control cells. 
 
Figure 5-8: Effect of c[CRYFNV] on HCV replication. The normalized luciferase is used as a measure of 
HCV replication 
The cyclic peptide was also tested for cell toxicity by the 3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyltetrazolium bromide (MTT) assay, and found not to have any non-specific 
effects.  Unfortunately, when the HPLC purified cyclic peptide was resubmitted for 
testing (Doug Ross, Harris Group, University of Leeds) no inhibition of viral replication 
was observed.  After purification, the compound was even less soluble than it had been 
in the slightly impure state.  Either some impurity was a potent agonist of AMPK, or the 
lowered solubility meant the compound was no longer taken up into the cells. 
5.2.1.4 Crystallisation trials 
Attempts to crystallize human ATIC with and without the cyclic peptide inhibitor have 
been undertaken.  Trials were carried out using 2 μl + 2 μl hanging drop method in 24 
well plates.  We initially attempted to identify crystallization conditions using the 
commercially available Hampton Crystal Screen and Hampton Crystal Screen 2.  These 
screens are based on the original sparse matrix screen and contain 96 crystallization 
buffers covering a wide range of pH, salts, polymers and organics commonly reported 
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to promote crystal growth
[132]
.  Human ATIC was diluted to concentrations of 7.5 mg 
ml
-1
, 10 mg ml
-1
, 12.5 mg ml
-1 
and a drop containing the cyclic peptide inhibitor and 
protein at 10 mg ml
-1
 in the standard ATIC purification buffer.  From this crystallization 
trial the most promising conditions seemed to be 30% (w/v) PEG 1500 or 10% (w/v) 
PEG 8000 with 8% (v/v) ethylene glycol in 0.1 M HEPES pH 7.5, but these results did 
not produce crystals of sufficient quality to obtain X-ray diffraction data.  
The crystal structure for human ATIC was solved in 2001 by Wilson et al.
[46]
.  The 
literature conditions reported for crystallizing human ATIC include 15-17% PEG 3000 
in 0.1 M Tris pH 7.5-8.0 using protein concentrated to 10 mg ml
-1
.  Human ATIC is 
reported to be difficult to crystallize when compared to avian ATIC, with the avian 
homologue crystallizing overnight, but the human form requiring seeding to obtain 
crystals.  Based on these literature conditions a crystal screen to analyse the effects of 
PEG molecular weight and concentration was designed.  The trial included PEGs of 
different molecular weight (and of different ages) varying from left to right across the 
24-well tray and varying concentration of PEG increasing down the tray.  Two trays 
were created with identical compositions of PEG, one at a fixed concentration of 0.05 M 
NaCl and the other at 0.2M NaCl.  Each well contained four drops for crystal growth 
analysis; 7.5 mg ml
-1
, 10 mg ml
-1
, 12.5 mg ml
-1
 and protein and inhibitor at 10 mg ml
-1
.  
After 12 days incubation at 18 °C the drops were analysed for crystal formation with 
photos of each well taken to record the results. 
The quality of the crystals in the multiple drops were graded using a colour scheme.  
Drops which contained no crystals or precipitated protein were annotated red, drops 
which contained tiny crystals which were of very poor quality were given orange 
(Figure 5-9), yellow was assigned to drops which contained larger fern-like crystals (a 
product of the nucleation stage being too fast, Figure 5-10), and green was assigned to 
drops containing larger flat plates and needles (Figure 5-11).  This colour coded scoring 
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system is summarized for each plate (low and medium salt conditions) in 
Figure 5-12. 
 
Figure 5-9: Examples of drops that were assigned ‘orange’. 
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Figure 5-10: examples of drops assigned ‘yellow’. 
 
Figure 5-11: examples of drops assigned ‘green’. 
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Figure 5-12: These tables represent the trays created for the PEG screen trial. Each well is represented by 
a dark border and each drop is represented by a single white outlined square. Each drop is graded by 
colour according to the quality of crystals produced. Red shows drops in which no crystals grew or the 
protein precipitated, whereas green shows the drops which produced the best quality crystals from this 
screen. The conditions are PEG concentration (far left) and PEG molecular weight (and date of stock) 
(top). The top table contains a constant concentration of 0.05 M NaCl and the lower 0.2 M NaCl. 
After comparing the two PEG screen trays it appeared that different concentrations of 
NaCl do not make a noticeable contribution to the quality of the crystals.  To measure 
any affects different cations and anions may have on crystal growth and try and approve 
the appearance of the crystals obtained from the PEG screen, new plates at PEG 3325 
(03/11) and PEG 6000 (07/10) were created.  NaCl, KCl, MgCl2, Na2SO4, K2SO4 and 
MgSO4 were used.  Protein concentrations of 5 mg ml
-1
, 7.5 mg ml
-1
, 10 mg ml
-1
, 12.5 
mg ml
-1
, 7.5 mg ml
-1
 plus inhibitor and 10 mg ml
-1
 plus inhibitor were used.  None of 
the crystals obtained from this salt-type screen showed significant improvement and 
none were deemed suitable to be used for X-ray diffraction data collection. 
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A sample of human ATIC with the inhibitor was taken to the Hauptman-Woodward 
Institute in Buffalo where 1536 conditions were screened for crystallization using the 
High-Throughput liquid handling robot with the microbatch-under-oil method.  This 
technique was carried out in a single plate with each well containing 200 nl of protein 
(at 10 mg ml
-1
) and 200 nl of the crystallization solution.  Digital photographs were 
taken of the wells at regular intervals (After 1 day then weekly for a month).  After 
crystal formation they were analysed under a fluorescence microscope at 280 nm 
(tryptophan fluorescence) to differentiate salt from protein crystals.  Two conditions 
provided promising crystals (Figure 5-13); 0.1 M calcium acetate, 0.1 M HEPES pH 
7.5, 20% (w/v) PEG 8000 produced small cube shaped crystals; 0.1 M Rubidium 
chloride, 0.1 M bis-tris propane pH 7, 20% PEG 4000 produced flat plates with neat 
edges.  The crystals were taken by collaborators at the Hauptman-Woodward Institute to 
be shot at the synchrotron but unfortunately there was not enough time to collect 
diffraction data.  These conditions should be explored and expanded to grow crystals of 
the human ATIC and inhibitor complex which will be shot at the Diamond synchrotron 
source, UK. 
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Figure 5-13: Photos of promising wells from the high-throughput screen taken after 7 days. The left well 
contains 0.1 M calcium acetate, 0.1 M HEPES pH 7.5, 20% (w/v) PEG 8000 and the right well contains 
0.1 M Rubidium chloride, 0.1 M bis-tris propane pH 7, 20% PEG 4000. 
 
5.3 Fluorescently labelled ATIC 
The dimerisation interaction is entropically driven, and so the dimerisation constant 
cannot be measured by ITC dilution experiments.  Therefore, another approach to 
investigate the dimerisation of ATIC was considered.  The monomer-dimer equilibrium 
could be measured as a function of distance, when the monomers are close together they 
would be in the dimeric form, and when they are further apart this would signify the 
monomeric form.  Förster Resonance Energy Transfer (FRET) is a distance dependent 
non-radiative transfer of energy from a donor molecule to an acceptor molecule.  The 
FRET process is initiated as the donor molecule is promoted to an excited state by 
irradiation at a certain wavelength.  The excited donor molecule then loses some of the 
excitation through internal conversion before transferring the remaining energy to the 
acceptor molecule non-radiatively, without the emission of a photon.  The acceptor is 
then promoted to an excited state which decays by internal conversion, and then finally 
by acceptor emission of a photon.  For two molecules to function as a FRET pair they 
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must have different excitation wavelengths and good spectral overlap between the donor 
emission and acceptor absorption spectra.  The distance at which the energy transfer is 
conducted with 50% efficiency is known as the Förster radius; this is different for 
individual donor-acceptor pairs.  The distance between the Gly4 residues of each 
monomer chain is around 40 Å, as measured from the crystal structure
[85]
, so a FRET 
pair with a large Förster radius is required.  Fluorescein and rhodamine were chosen as 
the donor acceptor pair, as they have a Förster radius of 55 Å
[133]
, which will allow for 
the inevitable flexibility of the linker chain from the dye molecule to the N terminus.  
This should mean that when the enzyme is in dimeric form, the dye molecules will be 
positioned to allow FRET to occur, but as the dimer falls apart to two monomers the 
FRET should dramatically decrease as FRET has a distance dependence of  
1
𝑟6
. 
The approach taken was to use Sortase A to label the N terminus of both human and 
avian ATIC with fluorescein and rhodamine dyes.  Sortase is a transpeptidase that 
cleaves the threonine glycine bond of substrate proteins bearing an LPXTG motif, to 
produce a thioacyl intermediate which is subsequently reacted with an N terminal 
glycine to form the new peptide bond
[134]
.  The reaction is reversible as the aminoacetyl 
by-product can react to produce the reactant, so a large excess of nucleophile is required 
to push the reaction to completion.  Sortase can be used to label a protein bearing an N-
terminal oligoglycine with a short peptide containing the LPXTG recognition sequence.  
In 2012, Williamson et al.
 
reported a new method which improved the efficiency of the 
sortase reaction using depsipeptide substrates to label proteins in quantitative yields
[134]
.  
Depsipeptide substrates contain an ester bond in place of the amide bond between the 
theronine and glycine of the recognition motif.  This produces anhydroxyacetyl by-
product which cannot perform the reverse reaction, so an excess of the nucleophile is no 
longer required. 
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The first step was to design a construct that would yield an N-terminal glycine on ATIC.  
The current pET28a construct used to express ATIC contains a thrombin cleavage site 
between the N-terminal his6 tag and the start of the ATIC sequence.  As removal of 
thrombin after cleavage can be inefficient, TEV cleavage was preferred.  The site can be 
added in such a way that a single glycine residue would remain after cleavage with the 
TEV protease.  This approach has the added benefit that the his6 tag can be used to 
purify the protein by metal affinity before cleavage and, if a his6 tagged TEV enzyme is 
used, then the TEV and cleaved ATIC fragment can be pulled from the reaction mixture 
upon completion.  ATIC bearing a single N-terminal glycine residue can then undergo 
the sortase labelling reaction with the fluorescent depsipeptide (Figure 5-14).  This 
approach is summarised in Figure 5-15.  The fluorescently labelled peptides along with 
stocks of TEV and sortase enzymes were kindly provided by D. Williamson. 
 
 
Figure 5-14: The structures of the fluorescent peptides used to label ATIC with sortase.  The fluorescein 
derivative is shown on the right, and the rhodamine containing peptide on the left. 
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Figure 5-15: Scheme showing the methodology behind the approach to labelling ATIC.  TEV cleavage 
exposes a single N terminal glycine which acts as the substrate for the subsequent sortase reaction, 
resulting in fluorescently labelled ATIC. 
 
The first step in exchanging the thrombin cleavage site for a TEV recognition site was 
to mutate an Spe1 restriction site into pET28a as shown in Figure 5-16.  Spe1 was 
chosen as it is not already found in the pET28a sequence and involved the mutation of 
only 2 bases.  The incorporation of Spe1 was achieved by PCR using primers P09f and 
P09r and pET28a as a template.  The product of the reaction was digested to remove the 
methylated template DNA before being transformed into XL-10 gold cells.  The 
resulting colonies were cultured and the DNA was extracted and sent for sequencing.  
The sequencing results confirmed the incorporation of the Spe1 mutation. 
 
Figure 5-16: Mutation of pET28a to include an Spe1 performed by PCR using primers P09f and P09r. 
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Now Spe1 was incorporated into pET28a, the thrombin cleavage site was digested out 
through incubation with Spe1 and Nde1.  The resulting pET28a vector was purified by 
agarose gel extraction, and then ligated with primers P10f and P10r through 
complementary sticky ends.  These primers encode for the TEV recognition sequence.  
Successful ligation reactions were confirmed by sequencing (Figure 5-17, Figure 5-18). 
 
Figure 5-17: Incorporation of the TEV recognition site after the his6 tag which will result in an N terminal 
glycine. 
 
Figure 5-18: Incorporation of the TEV recognition site after the his6 tag which will result in an N terminal 
glycine, followed by a hisitidine then the human ATIC sequence (highlighted in green). 
 
This cloning process was conducted on pET28a encoding human ATIC, pET28a 
encoding avian ATIC, and the empty pET28a vector which may be used to clone any 
other proteins of interest. 
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hATIC TEV site Q L A L F S V S D K T G L V E F A R N L T A L G L N L V A S G G T A K A L R D A
hATIC Q L A L F S V S D K T G L V E F A R N L T A L G L N L V A S G G T A K A L R D A
90 100 110 120
. . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . |
hATIC TEV site G L A V R D V S E L T G F P E M L G G R V K T L H P A V H A G I L A R N I P E D
hATIC G L A V R D V S E L T G F P E M L G G R V K T L H P A V H A G I L A R N I P E D
130 140 150 160
. . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . |
hATIC TEV site N A DM A R L D F N L I R V V A C N L Y P F V K T V A S P G V T V E E A V E Q I
hATIC N A DM A R L D F N L I R V V A C N L Y P F V K T V A S P G V T V E E A V E Q I
170 180 190 200
. . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . |
hATIC TEV site D I G G V T L L R A A A K N H A R V T V V C E P E D Y V V V S T E MQ S S E S K
hATIC D I G G V T L L R A A A K N H A R V T V V C E P E D Y V V V S T E MQ S S E S K
210 220 230 240
. . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . |
hATIC TEV site D T S L E T R R Q L A L K A F T H T A Q Y D E A I S D Y F R K Q Y S X G V S Q M
hATIC D T S L E T R R Q L A L K A F T H T A Q Y D E A I S D Y F R K Q Y S K G V S Q M
250 260 270 280
. . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . |
hATIC TEV site P L R Y GMN P H S D P C P                           
hATIC P L R Y GMN P H Q T P A Q L Y T L Q P K L P I T V L N G A P G F I N L C D A L
290 300 310 320
. . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . |
hATIC TEV site                                         
hATIC N AWQ L V K E L K E A L G I P A A A S F K H V S P A G A A V G I P L S E D E A
330 340 350 360
. . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . |
hATIC TEV site                                         
hATIC K V C M V Y D L Y K T L T P I S A A Y A R A R G A D R M S S F G D F V A L S D V
370 380 390 400
. . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . |
hATIC TEV site                                         
hATIC C D V P T A K I I S R E V S D G I I A P G Y E E E A L T I L S K K K N G N YWV
410 420 430 440
. . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . |
hATIC TEV site                                         
hATIC L Q M D Q S Y K P D E N E V R T L F G L H L S Q K R N N G V L D K S L F S N G V
450 460 470 480
. . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . |
hATIC TEV site                                         
hATIC T K N K D L P E S A L R N L T E A T I G G R Y T E S N S V X N T K ~ X E V X ~ X
10 20 30 40
. . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . |
hATIC TEV site ~ ~ - - - - - L R R R Y T M G S S H H H H H H S S G L V E N L Y F Q G HM A P G
hATIC C E F P Q N I L F T L R R R Y T M G S S H H H H H H S S G L V P R G S HM A P G
50 60 70 80
. . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . |
hATIC TEV site Q L A L F S V S D K T G L V E F A R N L T A L G L N L V A S G G T A K A L R D A
hATIC Q L A L F S V S D K T G L V E F A R N L T A L G L N L V A S G G T A K A L R D A
90 100 110 120
. . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . |
hATIC TEV site G L A V R D V S E L T G F P E M L G G R V K T L H P A V H A G I L A R N I P E D
hATIC G L A V R D V S E L T G F P E M L G G R V K T L H P A V H A G I L A R N I P E D
130 140 150 160
. . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . |
hATIC TEV site N A DM A R L D F N L I R V V A C N L Y P F V K T V A S P G V T V E E A V E Q I
hATIC N A DM A R L D F N L I R V V A C N L Y P F V K T V A S P G V T V E E A V E Q I
170 180 190 200
. . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . |
hATIC TEV site D I G G V T L L R A A A K N H A R V T V V C E P E D Y V V V S T E MQ S S E S K
hATIC D I G G V T L L R A A A K N H A R V T V V C E P E D Y V V V S T E MQ S S E S K
210 220 230 240
. . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . |
hATIC TEV site D T S L E T R R Q L A L K A F T H T A Q Y D E A I S D Y F R K Q Y S X G V S Q M
hATIC D T S L E T R R Q L A L K A F T H T A Q Y D E A I S D Y F R K Q Y S K G V S Q M
250 260 270 280
. . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . |
hATIC TEV site P L R Y GMN P H S D P C P                           
hATIC P L R Y GMN P H Q T P A Q L Y T L Q P K L P I T V L N G A P G F I N L C D A L
290 300 310 320
. . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . |
hATIC TEV site                                         
hATIC N AWQ L V K E L K E A L G I P A A A S F K H V S P A G A A V G I P L S E D E A
330 340 350 360
. . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . |
hATIC TEV site                                         
hATIC K V C M V Y D L Y K T L T P I S A A Y A R A R G A D R M S S F G D F V A L S D V
370 380 390 400
. . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . |
hATIC TEV site                                         
hATIC C D V P T A K I I S R E V S D G I I A P G Y E E E A L T I L S K K K N G N YWV
410 420 430 440
. . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . |
hATIC TEV site                                         
hATIC L Q M D Q S Y K P D E N E V R T L F G L H L S Q K R N N G V L D K S L F S N G V
450 460 470 480
. . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . |
hATIC TEV site                                         
hATIC T K N K D L P E S A L R N L T E A T I G G R Y T E S N S V X N T K ~ X E V X ~ X
his6 tag TEV site
human ATIC
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5.3.1.1 Labelling of ATIC using sortase 
Human and avian ATIC bearing N-terminal his6 tags, linked to the protein through a TEV recognition 
site, were overexpressed in E. coli C41 (DE3) cells grown in auto-inducing media at 30 °C.  Cells 
containing the overexpressed protein were harvested by centrifugation and stored at 80 °C.  Cell pellets 
were resuspended in buffer and lysed by sonication.  Cell debris was cleared by centrifugation, and the 
protein of interest was purified from the crude cell lysate by metal affinity chromatography (Figure 5-18. 
lanes 1 to 6).  Further purification was achieved through size exclusion chromatography, which was also 
used to buffer exchange into the TEV reaction buffer.  Protein concentrations were measured by 
absorption at 280 nm, with the molar extinction coefficients calculated from the sequence (including the 
his tag with TEV cleavage site). 
The his tag was then removed via a TEV cleavage reaction to leave an N-terminal glycine.  This reaction 
was monitored using electrospray ionisation mass spectrometry.  Small scale test cleavage reactions 
showed the reaction was complete in 2 hours, using 20% TEV in the reaction mixture (Table 5-1).  The 
measured mass is the calculated mass plus the addition of a potassium ion, as the N-terminus has been 
cleaved to leave a glycine residue so there was no loss in mass for potential cleaved methoinine, as 
observed for the his tagged human and avian ATIC.  Small scale metal affinity chromatography was used 
to pull out the his tagged TEV protease and the cleaved ATIC his tags.  The flowthrough was 
concentrated and purified by size exclusion chromatography to exchange the enzyme into the sortase 
reaction buffer (Figure 5-18, lanes 7 to 15). 
The sortase labelling reaction was performed on the purified, cleaved protein using 3.5 
molar equivalents of peptide and 0.2 molar equivalents of his tagged sortase incubated 
at room temperature.  An initial labelling reaction conducted at the recommended 
literature temperature of 37 °C
[134]
 resulted in the formation of a precipitate in the 
reaction vessel, however when the reaction was repeated at a room temperature, no 
precipitation was observed.  The labelling reaction was monitored by electrospray 
ionisation mass spectrometry and was typically completed after 7 hours.  Upon 
completion, his tagged sortase was removed using small scale metal affinity 
chromatography, and the flowthrough mixture of labelled ATIC and excess fluorescent 
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peptide were separated by size exclusion chromatography (Figure 5-20).  The labelled 
protein eluted at around 14 ml, whilst the excess peptide eluted after 20 ml. 
 
 
 
Figure 5-19: SDS-PAGE analysis of the metal affinity purification of human ATIC containing the TEV 
cleavage site and the subsequent TEV cleavage of human ATIC after gel filtration.  Lane 1: flowthrough, 
lane 2: molecular weight marker, lane 3: wash 1, lane 4: wash 2, lane 5: elution 1, lane 6: elution 2, lane 
7-15: fractions collected from the gel filtration purification. 
 
 
Figure 5-20: Purification of the sortase labelling reaction by size exclusion. a) absorption peak at 14 ml 
corresponds to fluorescein labelled human ATIC, with excess fluorescein peptide eluting at 20 ml, b) 
absorption peak at 14 ml corresponds to rhodamine labelled avian ATIC, with excess rhodamine peptide 
eluting from 20 ml onwards. 
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Table 5-1: Calculated and observed masses (Da) for the different protein species used in the process of 
fluorescently labelling ATIC. 
Protein Human ATIC Avian ATIC 
Calculated TEV cleaved 64810 64609 
Measured TEV cleaved (2 h) 64849 64650 
Calculated fluorescein labelled 65859 65658 
Measured fluorescein labelled 65843 65666 
Calculated rhodamine labelled 65969 65768 
Measured rhodamine labelled 65947 65781 
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Figure 5-21: Size exclusion purification of avian ATIC after labelling with sortase and both fluorescein 
and rhodamine peptides  in 1:1 ratio. 
 
To enable the determination of labelled protein concentrations, extinction coefficients 
were calculated for each of the fluorescently labelled peptides.  These were then added 
to the molar extinction coefficients calculated for each protein from the sequence 
(Table 5-2). 
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Table 5-2: Molar extinction coefficients calculated for each of the fluorescent labels (M
-1 
cm
-1
). 
Compound Fluorescein Rhodamine 
Free peptide 18000 16800 
Labelled human ATIC 72820 71620 
Labelled avian ATIC 68350 67150 
 
5.3.1.2 FRET  
Different mixtures of the labelled proteins were investigated using fluorimetry to 
observe FRET between the dye pairs.  Optimisation studies showed the best wavelength 
to monitor rhodamine emission was 580nm.  Each experiment was repeated at 
excitation wavelengths of 460 nm, 480 nm, and 494 nm, although 480 nm was the 
optimal excitation wavelength, the others were monitored to record a lower (460 nm) 
and higher (494 nm) excitation of fluorescein.  The differently labelled proteins were 
mixed and incubated at room temperature for at least 30 mins, to allow the monomers to 
redistribute through monomer-dimer equilibrium.  Different ratios of the FRET pairs 
were investigated, fluorescein:rhodamine, 1:1, 1:2, 1:3, 1:4 and 1:5.  The fluorescence 
observed at 580 nm was recorded for the excitation of fluorescein (5 M) without the 
presence of rhodamine to measure the background emission of fluorescein.  Background 
scans of rhodamine emission when subjected to the excitation wavelength without the 
presence of fluorescein showed a slight emission at 580 nm, for example at 5 M 
rhodamine-labelled protein excitation at 480 nm caused an emission at 580 nm of 6650 
fluorescence units. 
No detectable FRET signal was ever observed between the fluorescein and rhodamine 
dyes even when incubated at 4 °C (temperature chosen for stability reasons) for 2 days.  
The fluorescence emission measured at 580 nm was equal to the sum of the background 
144 
 
emissions for each dye.  To investigate if no FRET was seen due to a lack of dynamic 
behaviour between the monomeric and dimeric forms, the sortase labelling reaction was 
repeated with a 1:1 mixture of fluorescein and rhodamine peptides to generate dimeric 
protein containing both labels, but still no FRET was observed. 
This system was designed to have the shortest practical linker between the dye and the 
protein, but inevitably this is still very flexible.  The dyes cannot be fixed into a known 
position.  The hydrophobic dyes may potentially have flexed around to bind to a 
hydrophobic pocket on the surface of the protein, or the peptide linker may have formed 
favourable interactions with some part of the protein that prevents the dyes from 
interacting within a preferential distance. 
 
Figure 5-22: Fluorescence emission profile from rhodamine dye after fluorescein excitation and 
subsequent FRET. 
5.3.1.3 Fluorescence correlation spectroscopy 
As the attempts to monitor ATIC dimerisation through a FRET interaction between dyes 
located at the N-terminus of each monomer were unsuccessful, different concentrations 
of labelled protein were investigated using fluorescence correlation spectroscopy.  This 
technique can determine the size of particles by monitoring the diffusion times through 
an aqueous solution.  The diffusion of individual molecules is tracked using a 
fluorescent label.  Each of the labelled proteins was measured at a fixed concentration 
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(60 nM), unlabelled protein was then added incrementally to increase the overall 
enzyme concentration up to 10 M.  If the dimerisation constant was with the range of 
these concentrations, fluorescence correlation spectroscopy should be able to measure 
the diffusion of the monomer at the low concentrations, increasing in size to form the 
dimer with increasing the enzyme concentration.  However, no diffusion constant or 
changes in diffusion time were measured, suggesting that ATIC dimerisation cannot be 
monitored by this technique either.  Potentially the size difference between monomer 
and dimer is too small to be analysed by this technique. 
5.4 Conclusion 
The lack of enthalpic signal measured during the ITC dilution experiments supports the 
previous hypothesis that the dimerisation is entropically driven, supporting the results 
shown with DSC and DSF experiments.  To further characterise the monomer/dimer 
equilibrium, a new vector construct was created based on pET28a that incorporates a 
TEV recognition site after the N-terminal his tag, designed to leave an N-terminal 
glycine residue as a substrate for a sortase catalysed labelling reaction. 
Two techniques have been investigated to be able to measure ATIC dimerisation using 
fluorescently labelled monomers.  Fluorescence measurements to observe FRET 
between dimers containing one fluorescein-labelled monomer and one rhodamine-
labelled monomer showed no FRET emission from the rhodamine acceptor molecule.  
This is thought to be due to the position of the dye molecules relative to each other, the 
flexible linker between the dye and the monomer may allow the dye to flex around and 
interact with the surface of the protein in some way that destroys any possibility of 
FRET between the donor and acceptor molecules.  No change in particle size could be 
detected by fluorescence correlation spectroscopy over a 60 nM to 10 M concentration 
range. 
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6 Potassium dependence of human ATIC 
6.1 Metal dependence of ATIC 
In 1957, Flaks et al. reported that AICAR transformylase has an absolute requirement 
for potassium ions, with an optimal activity being shown over a concentration range of 
3 to 30mM
56
.  The Ka for potassium has not been published, but all experiments have 
been conducted in potassium containing buffers.  Crystal structures of ATIC from 
different organisms all show the presence of two bound potassium ions, one per 
monomer
[47]
. 
Kryptofix 222 has a high affinity for potassium cations.  The determination of the 
potassium Ka for human and avian ATIC was attempted using ITC.  Kryptofix 222 was 
titrated into the sample cell which contained ATIC, and ATIC was also titrated into 
kryptofix 222.  These experiments resulted in highly precipitated protein, suggesting 
that once the potassium is removed from ATIC the protein is no longer stable in 
solution. 
To be certain that this dependence upon a metal ion for activity was unique to 
potassium, a metal dependence screen was undertaken.  The standard spectroscopic 
assay (monitoring the absorbance at 298 nm) was used to quantify catalytic turnover.  
The enzyme was added last to the buffer, AICAR and metal solution contained in the 
cuvette, and was incubated at 25 °C for 3 min before the change in absorbance at 298 
nm was monitored.  A ‘standard’ activity was measured at a concentration of 83 nM 
KCl, as the ITC experiment titrating kryptofix 222 into human ATIC suggested that 
removal of endogenous potassium would result in protein precipitation.  To this 
‘background’ amount of potassium, various monovalent and divalent metal chlorides 
were added, to achieve a final concentration of 1 mM.  The results of this experiment, 
Figure 6-1, show a unique dependence upon potassium ions for maximal activity but, 
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substantial activity is still seen in the presence of the other metal cations.  This was 
thought to be due to the 83 nM K
+
 present in each sample.  The activities recorded for 
all other metal ions except potassium have similar activities to the control sample.  
Addition of 1 mM K
+
 only seems to have a small effect on increasing the catalytic 
activity.  This was thought to result from the short incubation time the enzyme was left 
to incubate with the metal ion solution, as the enzyme was added to the assay mixture 
just prior to measurement. 
Control K
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+
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+
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Figure 6-1: The effects of various metal cations on human ATIC activity.  The control sample contains 
human ATIC, AICAR, 10-f-H4F and 83 nM KCl.  All other samples contain an additional metal chloride 
at a final concentration of 1 mM.  Sample were prepared without 10-f-H4F and incubated at 25°C for 3 
min prior to initiation of the catalytic reaction by the addition of 10-f-H4F. 
Therefore, the enzyme was incubated with the buffer, AICAR and metal solution on ice 
for 20 min and then incubated in the cuvette at 25 °C for 5 min before the change in 
absorbance at 298 nm was measured. Figure 6-2 confirms that the metal dependence 
exhibited by human ATIC is unique for potassium; the presence of other monovalent 
cations or magnesium or calcium divalent cations does not increase activity. 
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Figure 6-2: The effects of the addition of different monovalent metal chlorides upon rate of catalysis of 
human ATIC.  The control sample contains human ATIC, AICAR, 10-f-H4F and 83 nM KCl.  All other 
samples contain an additional metal chloride at a final concentration of 1 mM.  Samples were prepared 
without 10-f-H4Fand incubated on ice for 20 min, and then at 25°C for 5 min before 10-f-H4F was added 
to initiate the reaction. 
 
The potassium dependence of the wild type ATIC was measured by changing the 
concentration of KCl present in the assay cell.  The Kd for potassium was found to be 
796 ± 48 μM (Figure 6-3) when AICAR is at a final concentration of 66.7 μM and 10-f-
H4F is present at 230 μM.  This is consistent with the potassium concentration required 
for maximal activity, as described by Flaks, et al.
 
of 3 to 30 mM
[57]
, and confirms that 
working at a standard buffer concentration of 25 mM will ensure maximal ATIC 
activity. 
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Figure 6-3: The potassium dependence of human ATIC at 25°C 
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6.2 Cloning, overexpression and purification of site-directed mutants 
of human ATIC 
The crystal structure of human ATIC has been used to identify the residues that form 
the potassium binding site, Figure 1-8.  The potassium ion is held in an octahedral 
geometry; S430, S432 and D539 all make interactions through their side chains and 
V425, T428 and L589 interact with the potassium ion through backbone carbonyls.  
Residues suitable for site directed mutation were identified using PyMOL software, 
shown in Figure 6-4. Serine residues S430 and S432 were both mutated to alanine, as 
this will remove any polar interactions between the hydroxyl and the positively charged 
potassium ion.  D539 makes an ionic interaction to the potassium ion, so D539A was 
chosen to remove this interaction, and D539N was chosen to preserve potential 
hydrogen bonding.  Due to the close proximity of the potassium ion to the bound 
AICAR substrate, residue N431 was chosen as the residue sits between the S430 and 
S432 sites, and is oriented towards bound AICAR and potentially forms hydrogen 
bonds with the amino group of the imidazole ring and the carbonyl of the carboxamide 
group.  N431A will disrupt any potential hydrogen bonds that could form through the 
side chain, and N431D will introduce a negative charge and eliminate the capability for 
the side chain to participate as a hydrogen bond donor.  F590 was chosen as the 
phenylalanine ring has the correct orientation for a favourable T-shaped -stacking 
interaction with the imidazole ring of the AICAR substrate.  F590A and F590I both 
remove the phenylalanine ring, and F590I was chosen to retain a similar steric bulk to 
the phenylalanine.  These mutations will be analysed to investigate whether the 
potassium ion performs a structural role which supports the nearby AICAR binding site, 
either by stabilising the structure of the AICAR transformylase domain, or by stabilising 
the dimeric form of the enzyme, which is required for maximum catalytic activity. 
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The site-directed mutants S430A, N431A, N431D, S432A, D539A and D539N were 
kindly provided by Dr M. M. Spiering (Penn State University).  These mutants were 
each cloned into a pET28a plasmid, designed to produce N-terminal his(6)-tagged 
proteins overexpressed under the control of a T7 lac promoter.  This same design 
approach was taken in creating mutants F590A and F590I. 
 
 
Figure 6-4: Schematic of the human ATIC, highlighting the residues surrounding the potassium binding 
site.  a) Cartoon representation of the human ATIC crystal structure.  Potassium is represented by purple 
spheres, AICAR is yellow and coloured by element, and residues selected for site directed mutation are 
black and coloured by element.  b) Residues surrounding the potassium binding site.  c) Residues directed 
towards the AICAR binding pocket. 
F590
N431
S430
S432
D539
AICAR
F590
N431
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b) c) 
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6.2.1.1 Cloning of F590A and F590I 
All cloning was performed using primers specified in the appendix, using the PCR 
programs stated in 2.7.1.  The additional site-directed mutants of human ATIC were 
generated via the Quikchange site-directed mutagenesis protocol.  Site-directed 
mutagenesis was performed on the pET28a plasmid containing the gene encoding for 
wild type human ATIC.  Primers were designed to incorporate a single mutation at 
residue F590.  Mutant F590A used the forward primer P01f and reverse primer P01r, 
mutant F590I used the forward primer P02f and used the reverse primer P02r with an 
annealing temperature of 55 °C.  To digest the methylated template DNA the PCR 
product was digested using the restriction endonuclease Dpn1.  The digested DNA was 
then transformed into XL10-Gold competent cells.  Single colonies were selected and 
the plasmids containing the required mutations were extracted using a QIAprep Spin 
Miniprep (Qiagen).  Conformation of the presence of the mutated ATIC gene was 
confirmed by agarose gel electrophoresis and sequencing (Appendix). 
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Proteins bearing N-terminal his(6)-tags were expressed in E. coli BL21 (DE3), E. coli 
BL21* (DE3) and E. coli C41 (DE3) strains in auto-inducing media at 30 °C.  After 24 
h, the protein-containing cells were harvested by centrifugation and stored at -80 °C.  
The cells were lysed by sonication or cell disruption, and the lysates cleared by 
centrifugation before further purification.  The his(6)-tagged ATIC mutants were 
separated from other cellular proteins by Immobilized Metal ion Affinity 
Chromatography (IMAC).  The crude cell lysates were applied to a Ni-NTA agarose 
resin under gravity flow. The column was washed step-wise with increasing 
concentrations of imidazole, to compete off weakly bound proteins.  The ATIC mutant 
was eluted with a high concentration of imidazole (250 mM).  Column fractions were 
analysed by a simple Bradford assay which detects the presence of proteins by a colour 
change from brown to blue, and by SDS-PAGE to assess the purity of the elution 
fractions obtained.  An example SDS-polyacrylamide gel (Figure 6-5) shows some trace 
impurities that remained after the IMAC purification; these are likely to be E. coli 
proteins that contain a high number of sequential histidine amino acids that also have a 
high affinity for the Ni-NTA resin, or proteins that co-purified with human ATIC.  The 
elution fractions containing the protein of interest were combined and concentrated 
(Amicon
®
 Ultra-15 Centrifugal Filter, 10 kDa NMWL), before further purification on a 
Superdex 200 gel filtration column using the Pharmacia AKTÄPurifier FPLC system.  
The absorption of the eluent from the gel filtration column is monitored at 280 nm; an 
example trace is shown in Figure 6-5.  The first peak, observed at approximately 8 ml 
volume is thought to be due to aggregated species caused by the concentration of the 
sample, prior to loading onto the gel filtration system.  The peak obtained at 14 ml is the 
pure ATIC mutant of interest. 
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Figure 6-5: The purification of N431A site-directed mutant of human ATIC. 
a) SDS-PAGE 10% of the purification of N431A ATIC from E. coli using a gravity flow column: lane 1: 
molecular weight marker, lane 2: flow through, lane 3: wash 1 (10 mM imidazole),, lane 4: wash 2 (150 
mM imidazole),, lane 5: elution 1 (250mM imidazole), lane 6: elution 2. 
b) Gel filtration using Superdex 200 10/300 column. Elution is monitored by absorption at 280 nm.  
Aggregates formed during concentration are eluted in the void volume of the column, 8 ml, with the pure 
N431A ATIC eluting at 14 ml. 
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Figure 6-6: Normalised absorption traces at 280 nm for each of the potassium mutants.  The first elution 
peak at approximately 8 ml is due to aggregates that form during the concentration process.  The elution 
volume for each mutant is taken as the highest peak; this is then used to calculate the molecular mass 
using the equation 𝑦 = 13983𝑒−4.59𝑥  which was obtained from the calibration curve shown in Figure 2-
2. 
a) b) 
MW/kDa 
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Table 6-1: Molecular mass for each mutant was determined by high resolution mass spectrometry and 
from the absorption traces obtained from size exclusion purification.  The calculated mass was 
determined from the protein sequence. 
Mutant 
Calculated mass 
/Da 
Mass determined 
by mass 
spectrometry /Da 
Calculated mass 
with the loss of 
methionine/ Da 
Mass determined 
by gel filtration 
/kDa 
S430A 66763.2 66640.3 66631.0 129 
N431A 66736.1 66608.0 66603.9 99 
N431D 66780.1 nd 66647.9 120 
S432A 66763.2 66646.1 66631.0 115 
D539A 66735.1 66625.6 66632.9 132 
D539N 66778.2 nd 66646.0 106 
F590A 66703.1 66597.4 66570.9 122 
F590I 66745.1 66643 66612.9 127 
 
The calculated mass for each of the mutants was determined from the protein sequence.  
Under the denaturing conditions of SDS-PAGE analysis, all mutants displayed a band at 
approximately 66 kDa, which is comparable to the calculated masses.  As the SDS-
PAGE technique is also dependent on charge and size, the observed bands were deemed 
to be the species of interest.  High resolution mass spectroscopy was used to confirm the 
mass of the mutants.  These measured masses are presented in Table 6-1, and are 
consistent with the expected mass when the sample is considered to have lost the N-
terminal methionine and gained a potassium ion. 
Mass spectrometry confirmed the monomeric mass of all the mutants, except N431D 
and D539N which could not be observed by mass spectrometry.  These two mutants 
were potentially unstable in the acetonitrile/formic acid solution used to prepare mass 
spectrometry samples.  The apparent mass determined from the absorption traces at 
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280 nm, obtained from the size exclusion purification stage, suggests that all of the 
potassium mutants are present in their dimeric form under non-denaturing conditions, 
the same oligomeric form that is seen for wild-type human ATIC. 
6.3 Characterisation of potassium binding site mutants 
6.3.1.1 Thermal stability 
The DSF studies performed on human and avian ATIC in Chapter 3, which studied the 
effects of various small molecules at different concentrations on protein stability, were 
repeated at a lower overall concentration of potassium, 5 mM in comparison with 25 
mM, to investigate any effect potassium may have on the melting temperature of the 
proteins.  The melting temperature of both proteins was also measured in the presence 
of 1 M KCl. 
Interpretation of the DSF plots of ATIC show that the enzyme unfolds through two 
separate transitions (Chapter 3).  For human ATIC, the largest of these transitions 
occurs at 46 °C, and a second transition characterised by a small broader peak at 57 °C.  
Avian ATIC has a large peak corresponding to a Tm of 43 °C and, similar to human 
ATIC, a small broad second hump at 51 °C.   
The Tm is calculated from the peak of the curve, but the shape can also give information 
about the protein unfolding.  When the potassium concentration is reduced to 5 mM, the 
larger unfolding peak is destabilised slightly, and a greater proportion of the area 
underneath the curves are occupying a lower temperature range, implying at the lower 
potassium concentration a greater proportion of the enzyme is unfolded below the Tm.  
The increase in Tm with increased K
+
 ion concentration hints that the essential nature of 
potassium may have a structural role, as increasing the potassium concentration appears 
to increase the Tm of the first unfolding transition.  Increasing the potassium does not 
eliminate the first transition and leave the second transition, as the intensity of the 
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fluorescence emission is comparable between the assays conducted at the different 
potassium concentrations, indicating a similar area of hydrophobicity has been exposed.  
As discussed in Chapter 3, the intense first peak is thought to be attributed to the dimer 
unfolding to the monomer.  This process unveils an expansive hydrophobic region of 
approximately 5000 Å
2
, which would account for the magnitude of the peak.  Hence, 
this data suggests that the potassium ion, which is essential for maximal catalytic 
activity, could play a role in stabilising the dimeric form of the enzyme.  The AICAR 
transformylase domain catalytic activity is dependent on dimerisation of the enzyme, so 
if potassium is required to stabilise the dimer, this would link to the essential nature of 
the potassium ion. 
 
Figure 6-7: Summary of the fluorescence traces obtained by DSF for the experiments investigating the 
stabilising effects of potassium.  a) human ATIC, b) avian ATIC. 
 
Stabilisation is also seen with the addition of the various ligands and small 
molecules.For the human protein, there is a greater Tm between the AICAR-containing 
experiments at the different potassium levels than seen with the apoprotein.  At the 
higher concentration of potassium, AICAR has a greater stabilising effect than under 
low potassium conditions; the presence of more potassium allows the AICAR to impart 
more stability by holding the dimer together.  This suggests that AICAR may play a part 
in maintaining the dimeric structure, or may bind more strongly to the dimeric form of 
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human ATIC.  However, with 10-f-H4F, there is no change in Tm between low and 
high potassium, with the absolute Tm value between sets of experiments only varying by 
1 °C which can be attributed to the stabilisation provided by the potassium, as shown by 
the control.  This implies that the stabilisation added by 10-f-H4F is not affected by 
potassium concentration, so the binding is either not dependent on having an effect on 
dimerisation, or the effects are too small to be measured by this technique.  The greatest 
Tm seen across the conditions examined was upon the addition of 1 M KCl to the 
apoprotein in 5 mM KCl, but the addition of 1 M KCl brings both high and low 
potassium experiments to the same Tm of 55 °C.  1 M KCl was chosen as this is an 
extremely high concentration, hence would represent the maximum stability that can be 
provided by potassium.  It has been considered unlikely that this high concentration may 
be conferring stability simply through a crowding effect; performing DSF experiments 
solely examining the effects of increasing KCl concentration would investigate any 
crowding effects. 
 
The ligands and other small molecules investigated have a greater stabilisation effect 
(Tm) on avian ATIC than compared to the same conditions human ATIC.  Larger 
stabilisation by AICAR and 10-f-H4F is seen at the lower potassium concentration.  The 
absolute values of the Tm are higher in the higher potassium containing buffer, as with 
human ATIC, but AICAR has a greater effect on stabilising the melting temperature in 
the lower potassium experiments.  At low potassium, PteGlu4 seems to show a 
concentration dependence, however, if the shape of the curves is taken into 
consideration, rather than just the maximum peak, the vast majority of the area below 
both curves overlap, suggesting a very similar unfolding profile, hence both 
concentrations of PteGlu4 provide a very similar stabilisation.  As with human ATIC, 
the addition of 1 M KCl brings the maximum stabilisation, corresponding to 55 °C. 
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Figure 6-8:Normalised DSF traces for a) human ATIC in high potassium (25 mM) buffer, b) avian ATIC in high potassium buffer, c)human ATIC in low potassium  
(5 mM) buffer, d) avian ATIC in low potassium buffer, at certain concentrations of various small molecules 
a) b) 
c)
a) 
d) 
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Table 6-2: Tm (°C) of human and avian ATIC, as apoproteins (control) and in the presence of various small molecules at specified concentrations, as measured by DSF.  AICAR is 
the substrate for ATIC and 10-f-H4F is representative of the cofactor used in vivo.  PteGlu4 was included in the experiment to monitor the effects of the polygluatmate tail of the in 
vivo cofactor on the thermal stability of the enzymes.  The presence of potassium was also investigated, by addition of 1 M KCl and purification of each enzyme in both low 
potassium (5 mM KCl) and high potassium (25 mM) buffer to monitor any effects potassium may have on stability. 
 Enzyme 
Control 
0.1 mM 
AICAR 
0.5 mM 
AICAR 
1 mM 
AICAR 
0.5 mM 
10-f-H4F 
1 mM 
10-f-H4F 
0.1 mM 
PteGlu4 
0.5 mM 
PteGlu4 
1 M 
K
+ 
H
ig
h
 K
+
 
Human 46 50 53 55 46 47 55 55 55 
Avian 44 45 52 53 44 45 57 60 55 
L
o
w
 K
+
 
Human 45 46 49 52 45 46 50 51 55 
Avian 40 44 47 48 42 43 55 55 55 
 
Table 6-3:Changes in Tm (°C) on addition of various small molecules, as compared to apoenzyme (control). 
 Enzyme Control 
0.1 mM 
AICAR 
0.5 mM 
AICAR 
1 mM 
AICAR 
0.5 mM 
10-f-H4F 
1 mM 
10-f-H4F 
0.1 mM 
PteGlu4 
0.5 mM 
PteGlu4 
1 M 
K
+ 
H
ig
h
 K
+
 
Human 0 4 7 9 0 1 9 9 9 
Avian 0 1 8 9 0 1 13 16 11 
L
o
w
 K
+
 
Human 0 1 4 7 0 1 5 6 10 
Avian 0 4 7 8 2 3 15 15 15 15
8
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6.3.1.2 Summary 
DSF was used to determine the melting temperature of each of the site directed mutants, 
under the same experimental conditions used for human ATIC at 25 mM KCl.  The 
effects of the mutations on stability are show in Table 6-4.  An example trace of the 
normalised DSF fluorescence output is shown in Figure 6-9 for mutant N431A. 
 
 
Figure 6-9: Normalised DSF data for N431A mutant. a) Normalised sigmoidal curves monitoring the 
change in fluorescence intensity with temperature with the incubation of various small molecules.  b) 
Differential of the sigmoidal plot.  The peak of each curve corresponds to the melting temperature of 
N431A; stabilisation in the presence of various small ligands can be seen by an increase in melting 
temperature. 
Table 6-4: The change in melting temperature (T/°C) caused by the single residue mutations in each of 
the potassium mutants.  This was calculated as the difference between the Tm of human ATIC at 25 mM 
KCl (46 °C) and the Tm of each potassium mutant at 25 mM KCl, as determined by DSF (Table 6-5). 
Enzyme S430A N431A N431D S432A D539A D539N F590A F590I 
T/°C to human 
ATIC 
-1 +5 -1 0 -3 +4 -1 -2 
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Mutations S430A, N431D and S432A have no appreciable effect on the melting 
temperature of the apoprotein.  Residue N431, which adopts a favourable position to 
hydrogen bond to the AICAR substrate in the human crystal structure, shows the largest 
stabilisation within this set of site-directed mutants when mutated to N431A, causing an 
increase in the melting temperature of 5 °C.  This mutation will neutralise any potential 
H-bonding interactions between the side chain (aspargine to alanine) and AICAR.  
Neutralising these interactions has caused an appreciable increase in stability.  This 
could be explained by the disruption of the hydrogen bonding to AICAR from the N431 
side chain, which now allows for greater flexibility of the peptide chain which could 
position the backbone carbonyl of residue 431 to interact with the potassium ion more 
strongly.  A more tightly held potassium ion would lead to a more stable dimeric 
structure and hence provide the increased Tm, as seen by DSF.  Alternatively new Van 
der Waals interactions between the alanine side chain and surrounding amino acids 
could be providing a more favourable, more stable conformation.  Mutating the 
aspargine residue to aspartate removes the ability of the side chain to function as a 
hydrogen bond donor.  N431D shows a slight destabilisation of 1 °C when compared to 
the human apoprotein. 
 
D539 interacts with the potassium ion through its negatively charged side chain.  The 
D539A mutation neutralises the side chain, and as expected, a drop in stability (3 °C) is 
seen as the side chain can no longer hold the potassium ion in place.  Unexpectedly, 
removing the negative charge by mutating to asparagine does not have the same 
destabilising effect.  Mutating the side chain to incorporate both a hydrogen bond 
acceptor and hydrogen bond donor (D539N), results in an increase in the Tm.  This is 
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most likely due to a rearrangement of the residues around the potassium binding site, 
potentially to rotate the D539N residue away from the potassium ion so that the 
backbone carbonyl interacts with the potassium ion, and/or so the aspargine side chain 
can form new favourable interactions with the surrounding residues.  Whatever 
rearrangement occurs, the resulting structure is more stable than the wild-type human 
ATIC.  Mutating F590 to remove the conjugated ring is expected to destroy the ability 
of ATIC to interact with the AICAR substrate through - stacking.  Mutations F590A 
and F590I do not dramatically reduce the stability of the enzyme. 
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Table 6-5: Tm (°C) of site-directed mutants, apo (control) and in the presence of various ligands and cofactors at specified concentrations, as measured by DSF.  All samples 
contained; 25 mM KCl and were heated from 25°C to 100°C at an increase of 1°C/s.  Tm was calculated from the peak of the differential of fluorescence intensity. 
Enzyme Control 
0.1 mM 
AICAR 
0.5 mM 
AICAR 
1 mM 
AICAR 
0.5 mM 
10-f-H4F 
1 mM 
10-f-H4F 
0.1 mM 
PteGlu4 
0.5 mM 
PteGlu4 
1 M 
K
+ 
Human 46 50 53 55 46 47 55 55 55 
S430A 45 45 45 46 45 45 48 48 56 
N431A 51 56 58 60 53 55 61 61 61 
N431D 45 45 45 45 45 46 56 56 51 
S432A 46 47 47 51 47 47 51 53 51 
D539A 43 44 45 46 44 45 51 53 48 
D539N 50 50 50 51 51 51 53 53 56 
F590A 45 45 45 44 45 45 48 50 50 
F590I 44 45 45 45 45 45 51 56 48 
1
6
2
 
 
164 
 
 
 
 
Table 6-6: Tm as compared to apoenzyme (control) calculated from Table 6-5. 
Enzyme Control 
0.1 mM 
AICAR 
0.5 mM 
AICAR 
1 mM 
AICAR 
0.5 mM 
10-f-H4F 
1 mM 
10-f-H4F 
0.5 mM 
PteGlu4 
0.5 mM 
PteGlu4 
1 M 
K
+ 
Human 0 4 7 9 0 1 9 9 9 
S430A 0 0 0 1 0 0 3 3 11 
N431A 0 5 7 9 2 4 10 10 10 
N431D 0 0 0 0 0 1 11 11 6 
S432A 0 1 1 5 1 1 5 7 5 
D539A 0 1 2 3 1 2 8 10 5 
D539N 0 0 0 1 1 1 3 3 6 
F590A 0 0 0 -1 0 0 3 5 5 
F590I 0 0 0 0 0 0 6 11 3 
1
6
3
 
 
 
1
6
3
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The site-directed mutants were also analysed by DSF under the same conditions as used 
for wild-type human ATIC, to assess what affect the mutations may have on the binding 
sites of AICAR, 10-f-H4F, PteGlu4 and K
+
.  The data obtained from DSF conducted on 
the site directed mutants is summarised in Tables 6-5, 6-6 and 6-7, and Figure 6-10.  
When comparing the DSF to that obtained for human ATIC, any mutation that causes a 
greater increase in Tm than the Tm seen for the wild-type can be considered to have 
caused an effect on the binding of the small molecule in question.  The discussion below 
focuses on the broader changes seen within the melting temperatures of the mutants 
under the different experimental conditions, a change of 1 °C is not considered 
significant. 
 
S430A and D539N show only a slight stabilisation resulting from AICAR addition.  
This behaviour differs dramatically to that seen in the wild-type protein, suggesting that 
these mutations have affected the AICAR active binding site.  Compared to the wild-
type protein, S432A and D539A show less overall stabilisation from AICAR, but they 
both still display some concentration dependence.  No appreciable change in Tm is seen 
with 10-f-H4F addition to S430A, S432A, D539A or D539N, suggesting that these 
mutations are not causing any changes to the residues surrounding the 10-f-H4F binding 
site.  A small increase in stability is seen with S430A and D539N upon the addition of 
PteGlu4, but a greater increase is measured with S432A and D539A.  S432A, D539 
mutants all show a reasonable enhancement to the stability of around 5 °C in the 
presence of 1 M potassium, and S430A has a large Tm of 11 °C.  The stability gained 
from the potassium restores the melting temperature of S430A and D539N to that of the 
wild-type ATIC.  This suggests that the destabilising effects of these mutations can be 
reversed by a high concentration of potassium. 
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Analysis of the N431 mutants shows the alanine mutation has a higher Tm compared to 
the aspartate mutation for all conditions tested.  N431A shows an increase in stability 
with an increase in AICAR concentration, which is not mimicked with N431D.  This 
suggests that whilst removing the hydrogen bonding capability of the N431 residue does 
not appear to affect AICAR binding, introducing a negative charge has abolished the 
stabilisation effects seen from the addition of AICAR.  N431A has a greater increase in 
stability with 10-f-H4F and displays a greater concentration dependence.  This mutation 
has increased the effect 10-f-H4F has on stability; potentially increasing the affinity of 
10-f-H4F for the ATIC protein.  Both mutations of residue N431 have similar large 
increases in Tm with the addition of PteGlu4, larger than is seen for PteGlu4 addition to 
the wild-type.  N431A has a large Tm of 10 °C upon addition of 1 M KCl which results 
in a Tm of 61 °C, which is the largest Tm observed for any of the proteins under any of 
the conditions assessed by DSF.  Mutating N431 to alanine increases the stability of 
ATIC under all conditions investigated.  This mutation causes a similar Tm resulting 
from the addition of potassium as the wild-type ATIC, suggesting that removing the 
charge and reducing the steric bulk of residue 431 has not adversely affected the binding 
of the small molecules to the enzyme, but actually increases the apparent stability of the 
protein. 
 
Site-directed mutants of F590 do not show any real increase in stabilisation in the 
presence of AICAR.  This is as expected, given that the F590 phenyl ring is positioned 
to interact with AICAR through a favourable - stacking arrangement.  At a 
concentration of 1 mM AICAR the F590I mutant is destabilised slightly by 1 °C, which 
could be due to the increased steric bulk of F590I side chain when compared to F590A, 
which does not show any destabilisation at this concentration. 10-f-H4F has no effect on 
the melting temperature of either mutant, but with PteGlu4 F590I is stabilised to a 
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greater extent than F590A, both mutants show an increase in Tm with increasing PteGlu4 
concentration.  Increased potassium causes some stabilisation of the F590 mutants. 
 
To summarise, S430A, N431D, D539N and both F590 mutants lose the ability for 
AICAR to increase the stability of the protein.  S430A and D539N seem to have a 
knock-on effect, from their location at the potassium binding site, through to the 
AICAR binding pocket.  The F590 mutants were hypothesised to reduce the protein’s 
ability to bind AICAR as the mutations will disrupt the favourable 
quadrupole/quadrupole interactions from the T-shaped π-π stacking formation between 
the phenylalanine ring and the imidazole ring of the AICAR substrate.  This hypothesis 
is supported by the lack of Tm resulting from AICAR addition.  S432A and D539A 
lead to a reduction in the degree of stabilisation provided by the addition of AICAR. 
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Table 6-7: Summary of the magnitude of effects different small molecule had on each enzyme, looking at 
the increase in stabilisation in the presence of the small molecule, not the final Tm.  The results have been 
scaled compared to the responses of the other mutants.  The +++ represents the highest stability increases 
from the ligand seen from the data set of all the mutants.  ++ indicates a mid-range increase compared to 
the whole data set, + represents a small stabilisation, - signifies no increase in Tm across any of the 
concentration ranges used for the ligand. 
Enzyme AICAR 10-f-H4F PteGlu4 K
+ 
Human +++ + +++ +++ 
S430A + - + +++ 
N431A +++ +++ +++ +++ 
N431D - + +++ ++ 
S432A ++ + ++ ++ 
D539A ++ ++ +++ ++ 
D539N + + + ++ 
F590A - - ++ ++ 
F590I - - +++ + 
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Figure 6-10: A graphical representation of the effects various small molecules had on the Tm of each of 
the potassium mutants of human ATIC, as measured by DSF. 
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6.3.1.3 Small molecule binding 
Isothermal titration calorimetry was used to investigate the binding of AICAR and 10-f-
H4F to the site-directed mutants of human ATIC.  These experiments were conducted to 
give an insight into if, and how, the mutations targeted at altering the potassium binding 
site (and potential interaction with AICAR) have affected the physical binding 
properties of the ligand and cofactor.  The results of the binding of AICAR and 10-f-
H4F to human ATIC are analysed in Chapter 3, with an observed Kd for AICAR of 6.14 
± 1.37 M and a Kd for 10-f-H4F of 120 ± 11.48 M  The majority of the mutants show 
a reduced number of binding sites for AICAR, the results are shown in Table 6-8. 
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Figure 6-11: the final figure analysis of the ITC experiment titrating AICAR (1.1mM) into a) N431A 
(59μM) and b) S430A (60 µM) at 25 °C. 
a) b) 
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Table 6-8:Binding affinities of ligands and small molecules to site directed mutants of human ATIC determined by ITC.  Measurements were taken using a MicroCal ITC200 at a 
constant temperature of 25 °C.  Ligand:enzyme concentrations were adjusted as required to achieve saturation.  Data were fitted using MicroCal Origin
®
 software to calculate 
number of binding sites, dissociation constant and enthalpy of binding.  
aN431D was used at 41 μM and 63 μM for the AICAR and 10-f-H4F experiments respectively. 
Mutant 
Initial 
enzyme 
conc/ μM 
AICAR 10-f-H4F 
Ligand 
conc/ mM 
Number of 
sites 
Kd/ μM H/ kcal mol
-1 
Ligand 
conc/ mM 
Number of 
sites 
Kd/ μM H/ kcal mol
-1 
S430A 60 1.1 nd 37.71 ± 7.48 -52.10 ± 164.20 2 nd nd nd 
N431A 59 1.1 1.04 ± 0.01 6.99 ± 0.45 -7.94 ± 0.12     
N431D 41/63a
 
0.5 0.20 ± 0.04 10.23 ± 1.51 -36.10 ± 7.64 2 1.35 ± 0.06 55.56 ± 4.27 -1.46 ± 0.08 
S432A 47 0.75 0.26 ± 0.01 8.62 ± 0.46 -15.90 ± 0.84 2 nm 50.76 ± 6.05 -2.91 ± 0.14 
D539A 37 0.75 0.69 ± 0.03 10.91 ± 1.04 -5.20 ± 0.87 2 0.71 ± 0.25 75.76 ± 9.79 -6.73 ± 2.53 
D539N 45 1.0 0.11 ± 0.12 32.49 ± 5.69 -12.95 ± 14.62     
F590A 55 1.0 0.36 ± 0.11 47.24 ± 7.33 -8.25 ± 2.24     
F590I 52 1.0 0.29 ± 0.12 50.99 ± 5.75 -11.60 ± 5.34 2 0.74 ± 0.08 74.63 ± 4.39 -5.26 ± 0.61 
1
6
9
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The binding affinities for the ligand and cofactor to the S430A mutant are dramatically 
reduced compared to those measured for human ATIC.  S430A binds AICAR very 
weakly with a Kd of 37.70 ± 7.48 M and less than 5% of the binding sites occupied.  
The number of binding sites of AICAR to S430A is so small, and with such a 
comparably large error that no real binding is observed.  No binding of 10-f-H4F to 
S430A was detected suggesting the mutation has also removed the ability of the enzyme 
to bind the cofactor.  N431A binds AICAR with the same affinity as human ATIC and a 
stoichiometry of 1, suggesting that AICAR binding to human ATIC has not been 
affected by the mutation.  N431D has a slightly weaker binding constant for AICAR 
than human ATIC and the occupancy of the binding site is considerably reduced.  
However, due to the unusual enthalpy of binding measured, this data is considered 
unreliable.  Unexpectedly, the N431D mutation has caused 10-f-H4F to bind with a 
higher affinity than to human ATIC.  As seen with the N431D mutant, S432A binds 
AICAR with a low number of binding sites and with a similar but slightly lower Kd 
when compared to human ATIC.  S432A binds 10-f-H4F with a Kd of 50.76 ± 6.05 M, 
but the fit was such that the binding stoichiometry could not be determined.  D539A 
binds AICAR with a Kd of 10.91 ± 1.04 M, with 0.69 ± 0.03 binding sites, and binds 
10-f-H4F twice as strongly as human ATIC.  D539N has a similar Kd as S430A which is 
32.49 ± 5.69M, and only has around 10% occupancy of the binding site.  Both F590 
mutants bind AICAR very weakly, with the lowest affinity measured of the site-directed 
mutants.  AICAR binds to F590A and F590I with a Kd of 47.24 ± 7.33 M and 50.99 ± 
5.75 M respectively.  This is the weakest dissociation constant for AICAR seen 
amongst all of the site directed mutants.  This would be as expected, if we are 
measuring AICAR binding to the AICAR transformylase site.  Destroying the - 
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interaction between F590 and the substrate would significantly reduce the ability of the 
enzymes to bind AICAR. 
6.4 AICAR KM of site-directed mutants 
The apparent KM for AICAR was determined for site directed mutants S430A, S432A, 
F590A and F590I (Table 6-9) at 25 °C and a fixed 10-f-H4F concentration of 167 µM. 
 
Figure 6-12: Effects of AICAR concentration of the activity of S430A.  KM was determined to be 4.58 ± 
0.91 M. 
Table 6-9: AICAR KM determined for selected site directed mutants. 
Enzyme AICAR KM/µM 
S430A 4.58 ± 0.91 
S432A 3.81 ± 1.27 
F590A 3.78 ± 2.30 
F590I 60 ± 16 
 
S430A, S432A and F590A all have a similar AICAR KM to the human wild-type 
enzyme, but F590I has an increased KM.  The F590 residue is expected to help bind 
AICAR through - stacking.  This suggests that the F590 residue is important for 
binding AICAR, but potentially in the F590A mutant something may bind in place of 
the missing phenylalanine, for example imidazole, to rescue activity.  With the F590I 
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mutation, the steric bulk of the isoleucine side chain blocks the site, so the activity 
cannot be recovered by whatever rescues the F590A activity. 
Mutants N431A, N431D and D539N all had a very low activity, which made kinetic 
analysis difficult.  D539A displayed no AICAR transformylase activity.  It should be 
noted that the site directed mutants lost activity upon storage (4 °C), so care was taken 
to conduct the kinetic analysis as soon as possible after the size exclusion purification of 
each of the mutants.  Residues N431 and D539 are essential for ATIC activity and, due 
their orientations in the protein crystal structure, it seems possible that D539 is essential 
for potassium binding and N431 is essential for AICAR binding. 
6.5 Discussion 
Potassium is essential for maximal activity of human ATIC, with the Ka determined to 
be 796 ± 48 μM.  This reliance on potassium cannot be reproduced with other 
monovalent metal cations, or even magnesium or calcium.  Not even partial activity can 
be recovered by supplementing with other metal ions. 
Potassium increases the thermal stability of ATIC.  DSF studies have shown a large 
increase in the melting temperature in the presence of 1 M KCl.  An increase in stability 
is also seen when conducting experiments at 25 mM KCl compared to 5 mM KCl.  The 
stability observed is in the large unfolding peak, attributed to the unfolding of the dimer 
which would expose a huge hydrophobic surface.  The addition of potassium appears to 
enhance the stability of the dimer. 
Residues suitable for site directed mutations in the proximity of the potassium ion 
binding site were identified from the crystal structure of human ATIC.  Mutants were 
created of the residues that have potential side chain interactions with the ion, 
generating S430A, S432A, D539A and D539N.  N431A and N431D were chosen as 
residue 431 sits between the previously chosen serine residues, and has potential 
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hydrogen bonding interactions with the AICAR substrate.  F590 also interacts with 
AICAR through a T-shaped π-π stacking arrangement between the phenylalanine ring of 
F590 and the imidazole ring of AICAR, hence, mutants F590A and F590I were 
analysed to investigate the effects of disrupting this interaction. 
Each mutant was analysed in terms of thermal stability, evaluating the melting 
temperature by DSF under different conditions and concentrations of small molecules, 
and the physical binding properties, measured by ITC.  Unfortunately, because of the 
confusion into the location of where the small molecules are binding, interpretation of 
the mutations in terms of alteration to AICAR binding and comparison to the 
parameters measured in Chapter 3 is difficult. 
Both S430A and D539N show similar weak binding to AICAR with a very low number 
of binding sites observed, in fact, S430A has such low occupancy it essentially does not 
bind AICAR.  This is consistent with the thermal stability data gained from DSF, as 
S430A and D539N show no significant increase in Tm in the presence of AICAR.  Each 
of these mutations of the potassium binding site has decreased the enzymes’ ability to 
bind AICAR.   
The S432A and D539A mutations have slightly weaker binding constants for AICAR, 
as compared to human ATIC.  The stability of these mutations is increased by the 
addition of AICAR, but the amount of stabilisation inferred is less than the stabilisation 
seen with human ATIC.  S432A and D539A have slightly reduced the protein’s affinity 
for AICAR.  Mutations within the potassium binding site are having an effect on the 
proteins ability to bind substrate.  This suggests the potassium ion may play a structural 
role, supporting the amino acid structure which is presented to the AICAR substrate, 
and possibly supporting the dimerisation of ATIC.  A high concentration of KCl causes 
a huge increase in thermal stability in human ATIC, increasing the temperature at which 
the dimer appears to dissociate.  This could be interpreted as the presence of potassium 
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stabilising the ATIC dimer.  As AICAR binds through interactions formed from 
residues located on both monomer chains, the strongest binding must require 
dimerisation.  If potassium plays a key role in the dimerisation of ATIC, this would 
explain the reduction in AICAR binding seen when the potassium binding site is 
altered. 
ITC and DSF results for the pair of F590 mutants supports the proposal that F590 is 
important in the binding of AICAR through a T-shaped π-π interaction.  Mutation to 
alanine and isoleucine significantly reduce AICAR binding, this pair of mutants have 
the weakest AICAR binding out of all the mutants investigated.  AICAR also provides 
no increase to the thermal stability of the mutants; suggesting the dimeric structure is no 
longer stabilised by AICAR.  The AICAR KM for F590I is increased, whilst F590A has 
a similar KM to human ATIC.  It is thought that F590I cannot bind AICAR with the 
bulky isoleucine blocking the site, with the alanine mutation activity appears to be 
rescued, potentially due to imidazole remaining bound from the metal affinity 
purification, binding in place of the phenylalanine ring. 
Unexpectedly, the N431A mutation actually produces a more stable protein, perhaps 
due to the reduction in side chain bulk, that allows the monomer chains to combine 
more tightly and effectively, increasing the Tm of the dimer.  The binding parameters 
measured for AICAR to N431D were discounted due to the uncharacteristic enthalpy of 
binding.  The increased stability of the N431A mutant could be exploited in 
crystallisation trials. 
Excluding N431D, the trends and consistency seen between ITC and DSF results for the 
effects of the mutations on AICAR binding can be summarised as shown in Table 6-10.  
A Kd of greater than 30 μM corresponds to little, or no stabilisation to the melting 
temperature of the protein, as seen for S430A, D539N, F590A and F590I.  For D539A, 
an AICAR Kd of 11 μM is accompanied by an increase in stability of 3 °C, and for 
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S432A a Kd of 8.5 μM corresponds to a Tm of 5 °C.  N431A and human ATIC have an 
AICAR Kd of 6-7 μM, and both show an increase in melting temperature of 9 °C.  
N431D is the only mutant investigated that is an exception, which following the trends 
seen with the other mutants, would be expected to have a Tm of 3 °C measured by DSF 
to correspond to the Kd observed.  As the strength of AICAR binding increases, so the 
amount of stability afforded to the enzyme by AICAR increases. 
 
Table 6-10: Comparison of AICAR Kd determined by ITC and the corresponding Tm obtained from DSF 
at 1 mM AICAR for human ATIC and the site directed mutants (excluding N431D).  The greater the 
strength of binding for AICAR the greater the increase in the Tm, and hence stability provided by 1 mM 
AICAR. 
Kd/ μM Tm/ °C 
30 1 
~11 3 
8.5 5 
6-7 9 
Kinetic studies suggest that N431 and D539 are essential for ATIC catalytic activity.  
However, N431A binds AICAR with a similar binding constant to the wild type protein.  
This suggests that AICAR may be binding to N431A in a different position, and has the 
same affinity as the wild type, but AICAR is now not correctly orientated for catalysis.  
It seems likely that D539 is essential in binding the potassium ion.  This would suggest 
that potassium is important in maintaining the structure of the active site. 
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7 Summary and conclusions 
7.1 Summary 
ATIC is a dimeric bifunctional protein, with two distinct catalytic domains located on 
each monomer, which catalyses the penultimate and final steps of the de novo purine 
biosynthetic pathway.  It has been extensively studied as a target for chemotherapeutics 
and anti-viral inhibitors, but the enzyme has not been fully characterised. 
The AICAR transformylase domain catalyses the formyl group transfer from the 10-f-
H4F cofactor to the AICAR substrate to produce FAICAR and H4F.  The catalytic 
turnover can be measured by the rate of increasing absorption at 298 nm.  A two 
dimensional, high-throughput assay was designed; this was used to measure the true 
substrate and cofactor KM as 14.1 ± 4.5 μM and 41.6 ± 11.9 μM respectively.  The data 
were fitted using an ordered binding model, assuming rapid equilibrium, which suggests 
that ATIC proceeds by an ordered binding mechanism, in which AICAR binds to the 
enzyme before the 10-f-H4F cofactor can bind.  This mechanism is supported by 
substrate and cofactor binding affinities, as measured by ITC. 
𝐸 + 𝐴𝐼𝐶𝐴𝑅
𝐾1
↔ [𝐸 − 𝐴𝐼𝐶𝐴𝑅] + 10fH4F
𝐾2
↔ [𝐸 − 𝐴𝐼𝐶𝐴𝑅 − 10fH4F]
𝑘𝑐𝑎𝑡
→  𝑃 
The binding affinities of the substrate, cofactor and various small molecules have been 
investigated by ITC for human ATIC, avian ATIC, and the IMPCH domain.  The 
IMPCH domain was isolated through the overexpression of a truncation mutant 
consisting of resides 1-200 of the full length human ATIC, to aid in identifying the 
binding location of the small molecules analysed. 
PteGlu4 was the tightest binding of the ligands analysed, and was significantly tighter 
than the in vitro cofactor, 10-f-H4F.  This suggests that the extra polyglutamated tail of 
the natural substrate is a major driving force in binding to ATIC.  Due to the lack of 
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binding seen to the IMPCH truncation mutant, PteGlu4 was confirmed to bind to the 
AICAR transformylase half of the protein, and provides evidence that it binds to the 
same site as 10-f- H4F.  XMP is observed to bind to both domains, with the tightest Kd 
of the substrate analogues investigated.  This suggests that XMP may have been co-
purified and be blocking binding to some of the sites; XMP may inhibit ATIC in vivo 
and provide a previously undiscovered regulation step.  The binding parameters 
measured for AICAR titrated into IMPCH are consistent with those obtained for the full 
length human ATIC, suggesting the measured AICAR binding to human ATIC may 
have been caused by AICAR binding to the IMPCH domain, not to the AICAR 
transformylase domain as would be expected. 
The thermal stability of ATIC was studied by DSC and DSF.  The unfolding profile as 
measured by DSF shows a large hydrophobic unfolding transition, followed by a 
smaller unfolding at a slightly higher temperature.  DSC measured an enthalpic 
unfolding event at a temperature that corresponds to the temperature of the smaller 
transition seen with DSF.  The large unfolding peak was attributed to the entropically 
driven separation of the dimer, which would expose the large 5000 Å
2
 hydrophobic 
interface.  The lack of signal seen in the ITC dilution experiments supports the 
hypothesis that the dimerisation is an entropically-driven event.  The second unfolding 
transition seen with DSF and DSC is thought to be due to the unfolding of the IMPCH 
domain, or the ATIC monomer.  DSF was also used to show the stabilisation gained by 
human and avian ATIC in the presence of AICAR and PteGlu4. 
Size exclusion chromatography shows ATIC purifies as a dimer in solution, which was 
also confirmed by AUC.  As the dimerisation constant could not be measured by ITC, 
due to the lack of an enthalpic signal as dimerisation is an entropic process, alternative 
fluorescence techniques were investigated.  Human and avian ATIC were labelled with 
fluorescein- and rhodamine-containing peptides using a newly designed vector to enable 
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the N-terminal labelling of proteins through the reaction of the terminal glycine residue 
with depsipeptides catalysed by sortase.  Unfortunately, neither FRET experiments nor 
fluorescence correlation spectroscopy could measure the monomer-dimer equilibrium of 
human or avian ATIC. 
Potassium is essential for maximal ATIC activity.  The metal dependence exhibited by 
human ATIC is unique for potassium; the presence of other monovalent cations does 
not rescue activity.  The potassium dependence was defined as Ka = 796 ± 48μM.  KCl 
was shown to increase the stability of human and avian ATIC when measured by DSF.  
Site directed mutants of residues in the proximity of the potassium ion binding site were 
characterised by DSF and ITC, and analysed for small molecule binding and increases 
to stability.  Tighter binding corresponded to a greater increase in thermal stability in 
the presence of the small molecule. 
Both S430A and D539N mutants both showed weak binding to AICAR with a very low 
number of binding sites observed. The S432A and D539A mutations have slightly 
weaker binding constants for AICAR, as compared to human ATIC.  These results 
suggest potassium may play a key role in the stabilisation of AICAR, as mutations of 
the potassium binding site have impacted on AICAR binding.  As AICAR binds 
through interactions formed from residues located on both monomer chains, the 
strongest binding must require dimerisation.  If potassium stabilises the dimerisation of 
ATIC, this would explain the reduction in AICAR binding seen when the potassium 
binding site is altered.  
ITC and DSF results for the pair of F590 mutants supports the proposal that F590 is 
important in the binding of AICAR through a T-shaped π-π interaction between the 
phenylalanine and imidazole of AICAR. 
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Unexpectedly, the N431A mutation produced a more a more stable protein as measured 
by DSF, perhaps due to the reduction in side chain bulk that allows the monomer chains 
to combine more tightly and effectively, increasing the Tm of the dimer. 
However, as there is some uncertainty that the AICAR binding is measured in the 
AICAR transformylase site, the conclusions drawn from the small molecule 
experiments require conformation of the AICAR binding location, before there can be 
full confidence in the hypothesis for the effects of the site directed mutations. 
Kinetic studies suggest that N431 and D539 are essential for ATIC catalytic activity.  
However, N431A binds AICAR with a similar binding constant to the wild type protein.  
This suggests that AICAR may be binding to N431A in a different position, and has the 
same affinity as the wild type, but AICAR is now not correctly orientated for catalysis.  
It seems likely that D539 is essential in binding the potassium ion.  This would suggest 
that potassium is important in maintaining the structure of the active site. 
 
7.2 Future work 
It is not expected that the polyglutamate tail of the PteGlu4 in vivo cofactor would 
interfere with AICAR binding.  However, it would be interesting to repeat the two 
dimensional binding order assay with AICAR and PteGlu4.  This would measure the 
true cofactor KM, and investigate if catalysis proceeds through the same binding model 
observed for AICAR and 10-f-H4F. 
The cloning of the AICAR tfase truncation mutant containing residues G360 to H592 
should be completed.  If overexpression of this construct is successful then AICAR tfase 
should be subjected to investigation by DSC, DSF and determination of small molecule 
binding constants by ITC.  Characterisation of the two separate domains should give 
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more information with which to elucidate the trends seen in the full length human 
ATIC. 
Endogenous small molecules of the de novo purine biosynthesis pathway could 
potentially be pulled through during ATIC purification.  To analyse the likelihood and 
quantities of such molecules co-purifying, two experiments could be undertaken.  A 
large concentration of E. coli containing overexpressed ATIC could be lysed, and then 
passed through a low molecular weight cut-off filter.  The filtrate could then be 
analysed by HPLC against standards for AMP, XMP, IMP and AICAR.  Subsequently, 
the same experiment could be repeated for E. coli cells which are an ATIC auxotroph. 
To determine if the IMPCH truncation mutant dissociates from monomer to dimer with 
time, a sample of purified mutant should be subjected to size exclusion chromatography 
at regular time intervals (for example, every two hours).  A change in oligomeric state 
would be indicated be a shift in the elution peak observed at 280 nm absorbance. 
To fully evaluate the ITC data measured for small molecule binding to ATIC, the 
IMPCH knock-out mutations (Y104F/D125A and/or Y104W/D125A) need to be 
incorporated into full length ATIC.  The ()IMPCH full length ATIC will be analysed 
by DSF and ITC under the same conditions used for human ATIC, to unequivocally 
determine the binding affinities to the AICAR transformylase domain.  The ()IMPCH 
could be incorporated into the IMPCH truncation mutant to provide a negative control.  
The AICAR transformylase mutant (from Gly360 to His592) cloning will be completed.  
Hopefully, without the inclusion of the -sheet, the transformylase domain will now 
overexpress in E. coli cells.  If successful, the AICAR transformylase truncation will be 
analysed by ITC and DSF to complete the set of domain binding experiments. 
It would be desirable to obtain crystal structures of the site-directed mutants to observe 
any structural rearrangements caused by the mutations.  Double and/or triple mutations 
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of S430, S432 and D539 could be designed to completely remove the ability for ATIC 
to bind the potassium ion.  These mutations could then be analysed by size exclusion 
and DSF to analyse if changes to the size and unfolding profile of the enzyme can be 
detected, determining whether potassium maintains the C-terminal structure. 
Work conducted by J Murray (unpublished) has suggested the residue His592 is 
responsible for the lack of pH dependence displayed by ATIC, by acting as a buffer to 
the AICAR transformylase active site, as the H592F mutant displays a pH dependence.  
This residue is important for enzyme stability, mutant H592F must be stored in 
imidazole-containing buffers to maintain some catalytic activity.  It is thought imidazole 
is able to bind in place of the histidine residue to stabilise the protein.  Potassium could 
also be responsible for positioning this key H592 residue.  This hypothesis can be 
investigated by studying the pH dependence of the potassium binding site directed 
mutants. 
The site-directed mutant N431A had an increased thermal stability when compared to 
wild-type human ATIC.  This increased stability could be exploited by using this 
mutant in further crystallography trials, potentially producing better quality crystals than 
were achieved for the wild-type ATIC. 
The new vector construct developed to incorporate a TEV recognition site after an N-
terminal his tag, could be applied to a wide range of systems.  For example, homo- or 
heterodimeric proteins for which the dimerisation constant may be observed using the 
same techniques applied to ATIC (FRET and fluorescence correlation spectroscopy), 
monitoring protein cleavage reactions, or the visualisation of cell penetrating proteins. 
 
183 
 
7.3 Conclusions 
The thesis has determined the ordered binding mechanism for AICAR transformylase 
using a new two-dimensional high-throughput assay.  AICAR (KM 14.1 ± 4.5 μM) binds 
the ATIC first, followed by 10-f-H4F (41.6 ± 11.9 μM).  The binding affinities for 
various ligands and small molecules have been determined by ITC, but further work is 
required to conclusively determine the location of the small molecule binding.  Initial 
observations suggest XMP may act as an inhibitor of ATIC, potentially regulating the 
enzyme in vivo.  Isolation and characterisation of the IMPCH domain was achieved to 
analyse binding to a single active site and deconvolute the binding parameters observed 
for both ATIC domains.  Residue N431 is thought to be essential in orientating AICAR 
for AICAR transformylase catalysis. 
The potassium dependence has been defined for the first time as Ka = 796 ± 48μM.  The 
maximum catalytic activity achieved with potassium cannot be replicated with any other 
metal monocation.  The presence of potassium enhances the thermal stability of ATIC.  
Residue D539 is thought to be essential in binding potassium, which may help structure 
the AICAR transformylase active site. 
The unfolding profile of ATIC proceeds initially through the separation of the dimer, 
and then the IMPCH domain or monomer unfolds at a higher temperature. 
The dimerisation of ATIC cannot be determined by ITC dilution experiments or 
fluorescent techniques.  Evidence has been provided that shows the dimerisation of 
ATIC is an entropically driven process. 
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9 Appendix 
9.1 ITC traces 
9.1.1.1 Human ATIC 
-0.4
-0.3
-0.2
-0.1
0.0
0 10 20 30 40
Time (min)
µ
c
a
l/
s
e
c
0 1 2 3 4 5
-2
0
Molar Ratio
k
c
a
l/
m
o
le
 o
f 
in
je
c
ta
n
t
-0.3
-0.2
-0.1
0.0
0 10 20 30 40
Time (min)
µ
c
a
l/
s
e
c
0.0 0.5 1.0 1.5 2.0 2.5 3.0
-2
0
Molar Ratio
k
c
a
l/
m
o
le
 o
f 
in
je
c
ta
n
t
 
Figure 9-1: ITC of IMP binding (left) and AMP (right) to human ATIC measured at 25 °C. 
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Figure 9-2: ITC of 10-f-H4F binding (left) and PteGlu4 (right) to human ATIC measured at 25 °C. 
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9.1.1.2 Avian ATIC 
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Figure 9-3: Figure 9-4: ITC of AMP binding to avian ATIC measured at 25 °C. 
9.1.1.3 IMPCH truncation mutant 
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Figure 9-5: ITC of IMP binding (left) and XMP (right) to IMPCH truncation mutant measured at 25 °C. 
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9.1.1.4 Site directed mutants 
9.1.1.5 AICAR binding 
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Figure 9-6: ITC of AICAR to S430A (left) and N431A (right) measured at 25 °C. 
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Figure 9-7: ITC of AICAR to S430A (left) and N431A (right) measured at 25 °C. 
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Figure 9-8: ITC of AICAR to D539A (left) and F590I (right) measured at 25 °C. 
9.1.1.6 10-f-H4F binding 
-0.4
-0.2
0.0
0 10 20 30
Time/min
µ
c
a
l 
s
e
c
-1
0 1 2 3 4 5 6 7
-1.0
-0.8
-0.6
-0.4
-0.2
0.0
Molar Ratio
k
c
a
l 
m
o
l-1
 o
f 
in
je
c
ta
n
t
-0.4
-0.2
0.0
0 10 20 30
Time/min
µ
c
a
l 
s
e
c
-1
0 2 4 6 8 10 12
-2
-1
0
Molar Ratio
k
c
a
l 
m
o
l-1
 o
f 
in
je
c
ta
n
t
 
Figure 9-9: ITC of 10-f-H4F into N431D (left) and D539A (right) measured at 25 °C. 
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Figure 9-10: ITC of 10-f-H4F into F590I  measured at 25 °C. 
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9.2 Sequence Alignments 
9.2.1.1 Site directed mutants 
 
10 20 30 40
. . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . |
Human ATIC M A P G Q L A L F S V S D K T G L V E F A R N L T A L G L N L V A S G G T A K A
S430A ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~
N431A ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~
N431D ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~
S432A ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~
D539A ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~
D539N ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~
F590A ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~
F590I ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~
50 60 70 80
. . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . |
Human ATIC L R D A G L A V R D V S E L T G F P E M L G G R V K T L H P A V H A G I L A R N
S430A ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~
N431A ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~
N431D ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~
S432A ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~
D539A ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~
D539N ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~
F590A ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~
F590I ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~
90 100 110 120
. . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . |
Human ATIC I P E D N A DM A R L D F N L I R V V A C N L Y P F V K T V A S P G V T V E E A
S430A ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~
N431A ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~
N431D ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~
S432A ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~
D539A ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~
D539N ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~
F590A ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~
F590I ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~
130 140 150 160
. . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . |
Human ATIC V E Q I D I G G V T L L R A A A K N H A R V T V V C E P E D Y V V V S T E MQ S
S430A ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~
N431A ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~
N431D ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~
S432A ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ X S T XM P S
D539A ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~
D539N ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~
F590A ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~
F590I ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~
170 180 190 200
. . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . |
Human ATIC S E S K D T S L E T R R Q L A L K A F T H T A Q Y D E A I S D Y F R K Q Y S K G
S430A ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ L K P L X Q R R X
N431A ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~
N431D ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~
S432A S E S K G T S L E T * R Q L P L K A F P H S A Q F D E A I S D Y F R K Q S S K G
D539A ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ X Y S K G
D539N ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~
F590A ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ X P P T X P K G E T I S G Y F R N Q S T K G
F590I ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~
198 
 
 
210 220 230 240
. . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . |
Human ATIC V S Q M P L R Y GMN P H Q T P A Q L Y T L Q P K L P I T V L N G A P G F I N L
S430A P D X X E XWX G I X ~ X Q T P A Q L Y P L Q P K L P I T V L N G A P G F I N L
N431A ~ ~ ~ ~ X L R Y GMN P H Q T P A P A Y T L Q P K L P I P V L N G A P G F I N L
N431D ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~
S432A G F Q M P L R Y GMN P H Q T P A Q L Y T X Q P K L P I T V L N G A P G F I N L
D539A V F P I A * E I G * A P T Q T P A Q L Y T L Q P K L P I P V L N G A P G F I N L
D539N ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~
F590A V F Q A P WX XWMN P L Q T L A Q L Y Q L Q P K L P I P V L N G A P G F I N L
F590I ~ ~ ~ ~ ~ ~ ~ X E MN H N Q D P G K L Y X X Q X K X X I X S L N G A X E X I N X
250 260 270 280
. . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . |
Human ATIC C D A L N AWQ L V K E L K E A L G I P A A A S F K H V S P A G A A V G I P L S
S430A C D A L N AWQ L V K E L K E A L G I P A A A S F K H V S P A G A A V G I P L S
N431A C D A L N AWQ L V K E L K E A L G I P A A A S F K H V S P A G A A V G I P L S
N431D ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~
S432A C D A L N AWQ L V K E L K E A L G I P A A A S F K H V S P A G A A V G I P L S
D539A C D A L N AWQ L V K E L K E A L G I P A A A S F K H V S P A G A A V G I P L S
D539N ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~
F590A C D A L N AWQ L V K E F K E A L G I P A A A S F K H V S P A G A A V G I P L S
F590I C D A X D A X Q A V X X L Q X A L X X P A A A X F K H V S X A X A A V X I P L S
290 300 310 320
. . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . |
Human ATIC E D E A K V C M V Y D L Y K T L T P I S A A Y A R A R G A D R M S S F G D F V A
S430A E D E A K V C M V Y D L Y K T L T P I S A A Y A R A R G A D R M S S F G D F V A
N431A E D E A K V C M V Y D L Y K T L T P I S A A Y A R A R G A D R M S S F G D F V A
N431D ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ G D L V A
S432A E D E A K V C M V Y D L Y K T L T P I S A A Y A R A R G A D R M S S F G D F V A
D539A E D E A K V C M V Y D L Y K T L T P I S A A Y A R A R G A D R M S S F G D F V A
D539N ~ ~ ~ ~ ~ ~ ~ M V Y D L Y K T L T P I S A A Y A R A R G A D R M S S F G D F V A
F590A E D E A K V C M V Y D L Y K T L T P I S A A Y A R A R G A D R M S S F G D F V A
F590I E D E A K V C M V Y D L Y K T L T P I S A A Y A R A R G A D R M S S F G D F V A
330 340 350 360
. . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . |
Human ATIC L S D V C D V P T A K I I S R E V S D G I I A P G Y E E E A L T I L S K K K N G
S430A L S D V C D V P T A K I I S R E V S D G I I A P G Y E E E A L T I L S K K K N G
N431A L S D V C D V P T A K I I S R E V S D G I I A P G Y E E E A L T I L S K K K N G
N431D Y S D VWD V P T A N I F S R E V Y D G I I A P G Y E E E A L T I L S K K K N G
S432A L S D V C D V P T A K I I S R E V S D G I I A P G Y E E E A L T I L S K K K N G
D539A L S D V C D V P T A K I I S R E V S D G I I A P G Y E E E A L T I L S K K K N G
D539N L S D V C D V P T A K I I S R E V S D G I I A P G Y E E E A L T I L S K K K N G
F590A L S D V C D V P T A K I I S R E V S D G I I A P G Y E E E A L T I L S K K K N G
F590I L S D V C D V P T A K I I S R E V S D G I I A P G Y E E E A L T I L S K K K N G
370 380 390 400
. . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . |
Human ATIC N Y C V L Q M D Q S Y K P D E N E V R T L F G L H L S Q K R N N G V V D K S L F
S430A N Y C V L Q M D Q S Y K P D E N E V R T L F G L H L S Q K R N N G V V D K S L F
N431A N Y C V L Q M D Q S Y K P D E N E V R T L F G L H L S Q K R N N G V V D K S L F
N431D N Y C V L Q M D Q S Y K P D E N E V R T L F G L H L S Q K R N N G V V D K S L F
S432A N Y C V L Q M D Q S Y K P D E N E V R T L F G L H L S Q K R N N G V V D K S L F
D539A N Y C V L Q M D Q S Y K P D E N E V R T L F G L H L S Q K R N N G V V D K S L F
D539N N Y C V L Q M D Q S Y K P D E N E V R T L F G L H L S Q K R N N G V V D K S L F
F590A N Y C V L Q M D Q S Y K P D E N E V R T L F G L H L S Q K R N N G V V D K S L F
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Figure 9-11: Sequence alignment of the site directed mutants to human ATIC. 
F590I N Y C V L Q M D Q S Y K P D E N E V R T L F G L H L S Q K R N N G V V D K S L F
410 420 430 440
. . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . |
Human ATIC S N V V T K N K D L P E S A L R D L I V A T I A V K Y T Q S N S V C Y A K N G Q
S430A S N V V T K N K D L P E S A L R D L I V A T I A V K Y T Q A N S V C Y A K N G Q
N431A S N V V T K N K D L P E S A L R D L I V A T I A V K Y T Q S A S V C Y A K N G Q
N431D S N V V T K N K D L P E S A L R D L I V A T I A V K Y T Q S D S V C Y A K N G Q
S432A S N V V T K N K D L P E S A L R D L I V A T I A V K Y T Q S N A V C Y A K N G Q
D539A S N V V T K N K D L P E S A L R D L I V A T I A V K Y T Q S N S V C Y A K N G Q
D539N S N V V T K N K D L P E S A L R D L I V A T I A V K Y T Q S N S V C Y A K N G Q
F590A S N V V T K N K D L P E S A L R D L I V A T I A V K Y T Q S N S V C Y A K N G Q
F590I S N V V T K N K D L P E S A L R D L I V A T I A V K Y T Q S N S V C Y A K N G Q
450 460 470 480
. . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . |
Human ATIC V I G I G A G Q Q S R I H C T R L A G D K A N YWW L R H H P Q V L S MK F K T
S430A V I G I G A G Q Q S R I H C T R L A G D K A N YWW L R H H P Q V L S MK F K T
N431A V I G I G A G Q Q S R I H C T R L A G D K A N YWW L R H H P Q V L S MK F K T
N431D V I G I G A G Q Q S R I H C T R L A G D K A N YWW L R H H P Q V L S MK F K T
S432A V I G I G A G Q Q S R I H C T R L A G D K A N YWW L R H H P Q V L S MK F K T
D539A V I G I G A G Q Q S R I H C T R L A G D K A N YWW L R H H P Q V L S MK F K T
D539N V I G I G A G Q Q S R I H C T R L A G D K A N YWW L R H H P Q V L S MK F K T
F590A V I G I G A G Q Q S R I H C T R L A G D K A N YWW L R H H P Q V L S MK F K T
F590I V I G I G A G Q Q S R I H C T R L A G D K A N YWW L R H H P Q V L S MK F K T
490 500 510 520
. . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . |
Human ATIC G V K R A E I S N A I D Q Y V T G T I G E D E D L I K WK A L F E E V P E L L T
S430A G V K R A E I S N A I D Q Y V T G T I G E D E D L I K WK A L F E E V P E L L T
N431A G V K R A E I S N A I D Q Y V T G T I G E D E D L I K WK A L F E E V P E L L T
N431D G V K R A E I S N A I D Q Y V T G T I G E D E D L I K WK A L F E E V P E L L T
S432A G V K R A E I S N A I D Q Y V T G T I G E D E D L I K WK A L F E E V P E L L T
D539A G V K R A E I S N A I D Q Y V T G T I G E D E D L I K WK A L F E E V P E L L T
D539N G V K R A E I S N A I D Q Y V T G T I G E D E D L I K WK A L F E E V P E L L T
F590A G V K R A E I S N A I D Q Y V T G T I G E D E D L I K WK A L F E E V P E L L T
F590I G V K R A E I S N A I D Q Y V T G T I G E D E D L I K WK A L F E E V P E L L T
530 540 550 560
. . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . |
Human ATIC E A E K K E WV E K L T E V S I S S D A F F P F R D N V D R A K R S G V A Y I A
S430A E A E K K E WV E K L T E V S I S S D A F F P F R D N V D R A K R S G V A Y I A
N431A E A E K K E WV E K L T E V S I S S D A F F P F R D N V D R A K R S G V A Y I A
N431D E A E K K E WV E K L T E V S I S S D A F F P F R D N V D R A K R S G V A Y I A
S432A E A E K K E WV E K L T E V S I S S D A F F P F R D N V D R A K R S G V A Y I A
D539A E A E K K E WV E K L T E V S I S S A A F F P F R D N V D R A K R S G V A Y I A
D539N E A E K K E WV E K L T E V S I S S N A F F P F R D N V D R A K R S G V A Y I A
F590A E A E K K E WV E K L T E V S I S S D A F F P F R D N V D R A K R S G V A Y I A
F590I E A E K K E WV E K L T E V S I S S D A F F P F R D N V D R A K R S G V A Y I A
570 580 590 600
. . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . |
Human ATIC A P S G S A A D K V V I E A C D E L G I I L A H T N L R L F H H * ~ ~ ~ ~ ~ ~ ~
S430A A P S G S A A D K V V I E A C D E L G I I L A H T N L R L F H H * G S E F E L R
N431A A P S G S A A D K V V I E A C D E L G I I L A H T N L R L F H H * G S E F E L R
N431D A P S G S A A D K V V I E A C D E L G I I L A H T N L R L F H H * G S E F E L R
S432A A P S G S A A D K V V I E A C D E L G I I L A H T N L R L F H H * G S E F E L R
D539A A P S G S A A D K V V I E A C D E L G I I L A H T N L R L F H H * G S E F E L R
D539N A P S G S A A D K V V I E A C D E L G I I L A H T N L R L F H H * G S E F E L R
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9.2.1.2 Human ATIC with TEV linker 
 
Figure 9-12: Sequence alignment of the human ATIC construct containing a TEV recognition site to 
human ATIC. 
10 20 30 40
. . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . |
hATIC TEV site ~ ~ - - - - - L R R R Y T M G S S H H H H H H S S G L V E N L Y F Q G HM A P G
hATIC C E F P Q N I L F T L R R R Y T M G S S H H H H H H S S G L V P R G S HM A P G
50 60 70 80
. . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . |
hATIC TEV site Q L A L F S V S D K T G L V E F A R N L T A L G L N L V A S G G T A K A L R D A
hATIC Q L A L F S V S D K T G L V E F A R N L T A L G L N L V A S G G T A K A L R D A
90 100 110 120
. . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . |
hATIC TEV site G L A V R D V S E L T G F P E M L G G R V K T L H P A V H A G I L A R N I P E D
hATIC G L A V R D V S E L T G F P E M L G G R V K T L H P A V H A G I L A R N I P E D
130 140 150 160
. . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . |
hATIC TEV site N A DM A R L D F N L I R V V A C N L Y P F V K T V A S P G V T V E E A V E Q I
hATIC N A DM A R L D F N L I R V V A C N L Y P F V K T V A S P G V T V E E A V E Q I
170 180 190 200
. . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . |
hATIC TEV site D I G G V T L L R A A A K N H A R V T V V C E P E D Y V V V S T E MQ S S E S K
hATIC D I G G V T L L R A A A K N H A R V T V V C E P E D Y V V V S T E MQ S S E S K
210 220 230 240
. . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . |
hATIC TEV site D T S L E T R R Q L A L K A F T H T A Q Y D E A I S D Y F R K Q Y S X G V S Q M
hATIC D T S L E T R R Q L A L K A F T H T A Q Y D E A I S D Y F R K Q Y S K G V S Q M
250 260 270 280
. . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . |
hATIC TEV site P L R Y GMN P H S D P C P                           
hATIC P L R Y GMN P H Q T P A Q L Y T L Q P K L P I T V L N G A P G F I N L C D A L
290 300 310 320
. . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . |
hATIC TEV site                                         
hATIC N AWQ L V K E L K E A L G I P A A A S F K H V S P A G A A V G I P L S E D E A
330 340 350 360
. . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . |
hATIC TEV site                                         
hATIC K V C M V Y D L Y K T L T P I S A A Y A R A R G A D R M S S F G D F V A L S D V
370 380 390 400
. . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . |
hATIC TEV site                                         
hATIC C D V P T A K I I S R E V S D G I I A P G Y E E E A L T I L S K K K N G N YWV
410 420 430 440
. . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . |
hATIC TEV site                                         
hATIC L Q M D Q S Y K P D E N E V R T L F G L H L S Q K R N N G V L D K S L F S N G V
450 460 470 480
. . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . |
hATIC TEV site                                         
hATIC T K N K D L P E S A L R N L T E A T I G G R Y T E S N S V X N T K ~ X E V X ~ X
201 
 
9.2.1.3 Avian ATIC with TEV linker 
 
Figure 9-13: Sequence alignment of the avian ATIC construct containing a TEV recognition site to avian 
ATIC. 
10 20 30 40
. . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . |
aATIC TEV site R R R Y T M G S S H H H H H H S S G L V E N L Y F Q G HM A A R Q Q L A L L S V
aATIC ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ M A A R Q Q L A L L S V
50 60 70 80
. . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . |
aATIC TEV site S E K A G L V E F A R S L N A L G L G L I A S G G T A T A L R D A G L P V R D V
aATIC S E K A G L V E F A R S L N A L G L G L I A S G G T A T A L R D A G L P V R D V
90 100 110 120
. . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . |
aATIC TEV site S D L T G F P E M L G G R V K T L H P A V H A G I L A R N I P E D N A DMN K Q
aATIC S D L T G F P E M L G G R V K T L H P A V H A G I L A R N I P E D N A DMN K Q
130 140 150 160
. . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . |
aATIC TEV site D F S L V R V V V C N L Y P F V K T V S S P G V T V P E A V E K I D I G G V A L
aATIC D F S L V R V V V C N L Y P F V K T V S S P G V T V P E A V E K I D I G G V A L
170 180 190 200
. . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . |
aATIC TEV site L R A A A K N H A R V T V V C D P A D Y S S V A K E M A A S K D K D T S V E T R
aATIC L R A A A K N H A R V T V V C D P A D Y S S V A K E M A A S K D K D T S V E T R
210 220 230 240
. . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . |
aATIC TEV site R H L A L K A F T H T A Q Y D A A I S D Y F R K E Y S K G V S Q L P L R Y GMN
aATIC R H L A L K A F T H T A Q Y D A A I S D Y F R K E Y S K G V S Q L P L R Y GMN
250 260 270 280
. . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . |
aATIC TEV site P H Q S P A Q L Y T T R P K L P L T V V N G S P G F I N L C D A L N AWQ L V K
aATIC P H Q S P A Q L Y T T R P K L P L T V V N G S P G F I N L C D A L N AWQ L V K
290 300 310 320
. . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . |
aATIC TEV site E L K Q A L G I P A A A S F K H V S P A G A A V G I P L S E E E A Q V C M V H D
aATIC E L K Q A L G I P A A A S F K H V S P A G A A V G I P L S E E E A Q V C M V H D
330 340 350 360
. . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . |
aATIC TEV site L H K T L T X L A S A Y A R S K                         
aATIC L H K T L T P L A S A Y A R S R G A D R M S S F G D F I A L S D I C D V P T A K
370 380 390 400
. . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . |
aATIC TEV site                                         
aATIC I I S R E V S D G V V A P G Y E E E A L K I L S K K K N G G Y C V L Q M D P N Y
410 420 430 440
. . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . |
aATIC TEV site                                         
aATIC E P D D N E I R T L Y G L Q L MQ K R N N A V I D R S L F K N I V T K N K T L P
450 460 470 480
. . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . |
aATIC TEV site                                         
aATIC E S A V R D L I V A S I A V K Y T Q S N S V C Y A K D G Q V I G I G A G Q Q S R
202 
 
9.2.1.4 IMPCH truncation mutant 
 
Figure 9-14: Sequence alignment of the IMPCH truncation mutant to human ATIC showing a stop codon 
at Gly200. 
 
 
10 20 30 40
. . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . |
Human ATIC ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ M A P G Q L A L F S V S D K T G L
IMPCH mutant R Y T M G S S H P H H H H S S G L V P R G S HM A P G Q L A L F S V S D K T G L
50 60 70 80
. . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . |
Human ATIC V E F A R N L T A L G L N L V A S G G T A K A L R D A G L A V R D V S E L T G F
IMPCH mutant V E F A R N L T A L G L N L V A S G G T A K A L R D A G L A V R D V S E L T G F
90 100 110 120
. . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . |
Human ATIC P E M L G G R V K T L H P A V H A G I L A R N I P E D N A DM A R L D F N L I R
IMPCH mutant P E M L G G R V K T L H P A V H A G I L A R N I P E D N A DM A R L D F N L I R
130 140 150 160
. . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . |
Human ATIC V V A C N L Y P F V K T V A S P G V T V E E A V E Q I D I G G V T L L R A A A K
IMPCH mutant V V A C N L Y P F V K T V A S P G V T V E E A V E Q I D I G G V T L L R A A A K
170 180 190 200
. . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . |
Human ATIC N H A R V T V V C E P E D Y V V V S T E MQ S S E S K D T S L E T R R Q L A L K
IMPCH mutant N H A R V T V V C E P E D Y V V V S T E MQ S S E S K D T S L E T R R Q L A L K
210 220 230
. . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | .
Human ATIC A F T H T A Q Y D E A I S D Y F R K Q Y S K G V S Q M P L R Y GMN P H
IMPCH mutant A F T H T A Q Y D E A I S D Y F R K Q Y S K * G S E F E L R R Q A C G R
